[	0	1	O
Histopathologic	1	16	O
examination	17	28	O
of	29	31	O
rectal	32	38	B-Pathological_formation
carcinoma	39	48	I-Pathological_formation
]	48	49	O
.	49	50	O

In	51	53	O
patients	54	62	O
with	63	67	O
rectal	68	74	B-Pathological_formation
carcinoma	75	84	I-Pathological_formation
,	84	85	O
the	86	89	O
histopathological	90	107	O
evaluation	108	118	O
of	119	121	O
the	122	125	O
surgical	126	134	B-Pathological_formation
specimen	135	143	I-Pathological_formation
provides	144	152	O
pivotal	153	160	O
prognostic	161	171	O
and	172	175	O
therapeutic	176	187	O
information	188	199	O
.	199	200	O

Important	201	210	O
parameters	211	221	O
are	222	225	O
tumor	226	231	B-Pathological_formation
site	232	236	O
,	236	237	O
depth	238	243	O
of	244	246	O
invasion	247	255	O
,	255	256	O
histological	257	269	O
type	270	274	O
and	275	278	O
grade	279	284	O
,	284	285	O
pattern	286	293	O
of	294	296	O
invasion	297	305	O
(	306	307	O
diffusely	307	316	O
infiltrating	317	329	O
versus	330	336	O
expanding	337	346	O
margin	347	353	O
)	353	354	O
,	354	355	O
degree	356	362	O
of	363	365	O
peritumoral	366	377	B-Cell
lymphocytic	378	389	I-Cell
infiltration	390	402	O
,	402	403	O
and	404	407	O
tumor	408	413	B-Pathological_formation
involvement	414	425	O
of	426	428	O
surgical	429	437	B-Tissue
margins	438	445	I-Tissue
and	446	449	O
lymph	450	455	B-Multi-tissue_structure
nodes	456	461	I-Multi-tissue_structure
.	461	462	O

Evaluation	463	473	O
of	474	476	O
the	477	480	O
circumferential	481	496	B-Tissue
(	497	498	I-Tissue
deep	498	502	I-Tissue
,	502	503	I-Tissue
lateral	504	511	I-Tissue
)	511	512	I-Tissue
margin	513	519	I-Tissue
is	520	522	O
of	523	525	O
utmost	526	532	O
importance	533	543	O
.	543	544	O

It	545	547	O
should	548	554	O
be	555	557	O
labeled	558	565	O
with	566	570	O
ink	571	574	O
in	575	577	O
the	578	581	O
gross	582	587	O
specimen	588	596	B-Pathological_formation
and	597	600	O
should	601	607	O
be	608	610	O
examined	611	619	O
histologically	620	634	O
using	635	640	O
several	641	648	O
tissue	649	655	B-Tissue
blocks	656	662	O
.	662	663	O

The	664	667	O
number	668	674	O
of	675	677	O
lymph	678	683	B-Pathological_formation
node	684	688	I-Pathological_formation
metastases	689	699	I-Pathological_formation
and	700	703	O
the	704	707	O
total	708	713	O
number	714	720	O
of	721	723	O
lymph	724	729	B-Multi-tissue_structure
nodes	730	735	I-Multi-tissue_structure
examined	736	744	O
should	745	751	O
be	752	754	O
reported	755	763	O
.	763	764	O

A	765	766	O
histological	767	779	O
evaluation	780	790	O
of	791	793	O
the	794	797	O
distal	798	804	B-Multi-tissue_structure
mesorectum	805	815	I-Multi-tissue_structure
in	816	818	O
its	819	822	O
entirety	823	831	O
is	832	834	O
recommended	835	846	O
to	847	849	O
detect	850	856	O
discontinuous	857	870	O
distal	871	877	B-Pathological_formation
mesorectal	878	888	I-Pathological_formation
tumor	889	894	I-Pathological_formation
spread	895	901	O
.	901	902	O

The	903	906	O
histopathological	907	924	O
findings	925	933	O
should	934	940	O
be	941	943	O
summarized	944	954	O
using	955	960	O
the	961	964	O
TNM	965	968	O
-	968	969	O
classification	969	983	O
.	983	984	O

Antisense	0	9	O
technologies	10	22	O
have	23	27	O
a	28	29	O
future	30	36	O
fighting	37	45	O
neurodegenerative	46	63	O
diseases	64	72	O
.	72	73	O

Our	74	77	O
growing	78	85	O
understanding	86	99	O
of	100	102	O
the	103	106	O
role	107	111	O
that	112	116	O
unfavorable	117	128	O
patterns	129	137	O
of	138	140	O
gene	141	145	O
expression	146	156	O
play	157	161	O
in	162	164	O
the	165	168	O
etiology	169	177	O
of	178	180	O
neurodegenerative	181	198	O
disease	199	206	O
emphasizes	207	217	O
the	218	221	O
need	222	226	O
for	227	230	O
strategies	231	241	O
to	242	244	O
selectively	245	256	O
block	257	262	O
the	263	266	O
biosynthesis	267	279	O
of	280	282	O
harmful	283	290	O
proteins	291	299	O
in	300	302	O
the	303	306	O
brain	307	312	B-Organ
.	312	313	O

Antisense	314	323	O
technologies	324	336	O
are	337	340	O
ideally	341	348	O
suited	349	355	O
to	356	358	O
this	359	363	O
purpose	364	371	O
.	371	372	O

Tailor	373	379	O
-	379	380	O
designed	380	388	O
to	389	391	O
target	392	398	O
specific	399	407	O
RNA	408	411	O
,	411	412	O
antisense	413	422	O
oligonucleotides	423	439	O
and	440	443	O
ribozymes	444	453	O
offer	454	459	O
tools	460	465	O
to	466	468	O
suppress	469	477	O
the	478	481	O
production	482	492	O
of	493	495	O
proteins	496	504	O
mediating	505	514	O
neurodegeneration	515	532	O
.	532	533	O

Although	534	542	O
technical	543	552	O
limitations	553	564	O
must	565	569	O
still	570	575	O
be	576	578	O
overcome	579	587	O
,	587	588	O
the	589	592	O
antisense	593	602	O
approach	603	611	O
represents	612	622	O
a	623	624	O
novel	625	630	O
and	631	634	O
exciting	635	643	O
strategy	644	652	O
for	653	656	O
intervention	657	669	O
in	670	672	O
diseases	673	681	O
of	682	684	O
the	685	688	O
central	689	696	B-Anatomical_system
nervous	697	704	I-Anatomical_system
system	705	711	I-Anatomical_system
.	711	712	O

Spacing	0	7	O
effects	8	15	O
on	16	18	O
the	19	22	O
memory	23	29	O
for	30	33	O
faces	34	39	B-Organism_subdivision
.	39	40	O

25	41	43	O
undergraduate	44	57	O
women	58	63	O
studied	64	71	O
12	72	74	O
stimulus	75	83	O
pictures	84	92	O
of	93	95	O
female	96	102	O
faces	103	108	B-Organism_subdivision
successively	109	121	O
presented	122	131	O
in	132	134	O
spaced	135	141	O
or	142	144	O
massed	145	151	O
conditions	152	162	O
and	163	166	O
made	167	171	O
affective	172	181	O
judgments	182	191	O
for	192	195	O
the	196	199	O
pictures	200	208	O
along	209	214	O
a	215	216	O
dimension	217	226	O
of	227	229	O
like	230	234	O
to	235	237	O
dislike	238	245	O
.	245	246	O

One	247	250	O
week	251	255	O
after	256	261	O
the	262	265	O
exposure	266	274	O
(	275	276	O
study	276	281	O
)	281	282	O
period	283	289	O
,	289	290	O
subjects	291	299	O
were	300	304	O
given	305	310	O
an	311	313	O
identification	314	328	O
test	329	333	O
comprised	334	343	O
of	344	346	O
photographs	347	358	O
of	359	361	O
the	362	365	O
same	366	370	O
female	371	377	O
faces	378	383	B-Organism_subdivision
with	384	388	O
different	389	398	O
expressions	399	410	O
.	410	411	O

Analysis	412	420	O
showed	421	427	O
that	428	432	O
the	433	436	O
pictures	437	445	O
presented	446	455	O
in	456	458	O
the	459	462	O
spaced	463	469	O
condition	470	479	O
were	480	484	O
more	485	489	O
frequently	490	500	O
and	501	504	O
accurately	505	515	O
identified	516	526	O
than	527	531	O
those	532	537	O
presented	538	547	O
under	548	553	O
the	554	557	O
massed	558	564	O
condition	565	574	O
and	575	578	O
that	579	583	O
affective	584	593	O
judgment	594	602	O
was	603	606	O
unrelated	607	616	O
to	617	619	O
conditions	620	630	O
of	631	633	O
presentation	634	646	O
.	646	647	O

Abdominal	0	9	B-Organism_subdivision
approach	10	18	O
for	19	22	O
the	23	26	O
ligation	27	35	O
of	36	38	O
bleeding	39	47	O
oesophageal	48	59	B-Multi-tissue_structure
varices	60	67	I-Multi-tissue_structure
.	67	68	O

The	69	72	O
conventional	73	85	O
surgical	86	94	O
treatment	95	104	O
of	105	107	O
bleeding	108	116	O
oesophageal	117	128	B-Multi-tissue_structure
varices	129	136	I-Multi-tissue_structure
in	137	139	O
the	140	143	O
emergency	144	153	O
situation	154	163	O
is	164	166	O
based	167	172	O
upon	173	177	O
the	178	181	O
Boerema	182	189	O
-	189	190	O
Crile	190	195	O
operation	196	205	O
of	206	208	O
transthoracic	209	222	B-Organism_subdivision
oesophagotomy	223	236	O
and	237	240	O
ligation	241	249	O
of	250	252	O
the	253	256	O
varices	257	264	B-Multi-tissue_structure
.	264	265	O

This	266	270	O
and	271	274	O
the	275	278	O
other	279	284	O
methods	285	292	O
of	293	295	O
treatment	296	305	O
of	306	308	O
this	309	313	O
condition	314	323	O
in	324	326	O
current	327	334	O
practice	335	343	O
are	344	347	O
discussed	348	357	O
.	357	358	O

Two	359	362	O
cases	363	368	O
are	369	372	O
reported	373	381	O
in	382	384	O
which	385	390	O
a	391	392	O
transabdominal	393	407	B-Organism_subdivision
oesophagogastrotomy	408	427	O
was	428	431	O
used	432	436	O
to	437	439	O
approach	440	448	O
the	449	452	O
site	453	457	O
of	458	460	O
bleeding	461	469	O
.	469	470	O

This	471	475	O
operation	476	485	O
is	486	488	O
described	489	498	O
and	499	502	O
the	503	506	O
theoretical	507	518	O
and	519	522	O
practical	523	532	O
advantages	533	543	O
it	544	546	O
appears	547	554	O
to	555	557	O
offer	558	563	O
over	564	568	O
the	569	572	O
standard	573	581	O
approach	582	590	O
are	591	594	O
considered	595	605	O
.	605	606	O

Stimulation	0	11	O
of	12	14	O
the	15	18	O
sodium	19	25	O
pump	26	30	O
by	31	33	O
azide	34	39	O
and	40	43	O
high	44	48	O
internal	49	57	O
sodium	58	64	O
:	64	65	O
changes	66	73	O
in	74	76	O
the	77	80	O
number	81	87	O
of	88	90	O
pumping	91	98	O
sites	99	104	O
and	105	108	O
turnover	109	117	O
rate	118	122	O
.	122	123	O

1	124	125	O
.	125	126	O

The	127	130	O
effects	131	138	O
of	139	141	O
5	142	143	O
mM	144	146	O
azide	147	152	O
on	153	155	O
[	156	157	O
3H	157	159	O
]	159	160	O
ouabain	160	167	O
uptake	168	174	O
and	175	178	O
22Na	179	183	O
efflux	184	190	O
were	191	195	O
determined	196	206	O
.	206	207	O

Both	208	212	O
glycoside	213	222	O
uptake	223	229	O
and	230	233	O
22Na	234	238	O
efflux	239	245	O
were	246	250	O
enhanced	251	259	O
by	260	262	O
azide	263	268	O
.	268	269	O

2	270	271	O
.	271	272	O

Azide	273	278	O
stimulated	279	289	O
the	290	293	O
Na	294	296	O
pump	297	301	O
in	302	304	O
muscles	305	312	B-Tissue
whose	313	318	O
pumping	319	326	O
sites	327	332	O
had	333	336	O
been	337	341	O
inhibited	342	351	O
by	352	354	O
ouabain	355	362	O
and	363	366	O
then	367	371	O
transferred	372	383	O
to	384	386	O
a	387	388	O
glycoside	389	398	O
-	398	399	O
free	399	403	O
solution	404	412	O
.	412	413	O

This	414	418	O
stimulation	419	430	O
was	431	434	O
observed	435	443	O
before	444	450	O
detecting	451	460	O
any	461	464	O
recovery	465	473	O
of	474	476	O
the	477	480	O
initial	481	488	O
pumping	489	496	O
activity	497	505	O
.	505	506	O

3	507	508	O
.	508	509	O

When	510	514	O
both	515	519	O
the	520	523	O
resting	524	531	O
and	532	535	O
the	536	539	O
azide	540	545	O
-	545	546	O
stimulated	546	556	O
22Na	557	561	O
efflux	562	568	O
had	569	572	O
been	573	577	O
blocked	578	585	O
by	586	588	O
ouabain	589	596	O
,	596	597	O
an	598	600	O
additional	601	611	O
exposure	612	620	O
to	621	623	O
azide	624	629	O
,	629	630	O
in	631	633	O
a	634	635	O
ouabain	636	643	O
-	643	644	O
free	644	648	O
solution	649	657	O
,	657	658	O
had	659	662	O
no	663	665	O
further	666	673	O
effects	674	681	O
on	682	684	O
22Na	685	689	O
efflux	690	696	O
.	696	697	O

4	698	699	O
.	699	700	O

It	701	703	O
is	704	706	O
concluded	707	716	O
that	717	721	O
the	722	725	O
increase	726	734	O
in	735	737	O
Na	738	740	O
pumping	741	748	O
caused	749	755	O
by	756	758	O
azide	759	764	O
is	765	767	O
due	768	771	O
in	772	774	O
part	775	779	O
to	780	782	O
an	783	785	O
increase	786	794	O
in	795	797	O
the	798	801	O
number	802	808	O
of	809	811	O
pumping	812	819	O
sites	820	825	O
.	825	826	O

5	827	828	O
.	828	829	O

[	830	831	O
3H	831	833	O
]	833	834	O
ouabain	834	841	O
binding	842	849	O
was	850	853	O
measured	854	862	O
in	863	865	O
muscles	866	873	B-Tissue
with	874	878	O
different	879	888	O
intracellular	889	902	B-Immaterial_anatomical_entity
alkali	903	909	O
cation	910	916	O
concentrations	917	931	O
.	931	932	O

Variations	933	943	O
in	944	946	O
[	947	948	O
Na	948	950	O
]	950	951	O
i	951	952	O
from	953	957	O
15	958	960	O
up	961	963	O
to	964	966	O
50	967	969	O
mM	970	972	O
did	973	976	O
not	977	980	O
significantly	981	994	O
affect	995	1001	O
the	1002	1005	O
amount	1006	1012	O
of	1013	1015	O
glycoside	1016	1025	O
bound	1026	1031	O
.	1031	1032	O

A	1033	1034	O
substantial	1035	1046	O
increase	1047	1055	O
in	1056	1058	O
binding	1059	1066	O
occurred	1067	1075	O
when	1076	1080	O
[	1081	1082	O
Na	1082	1084	O
]	1084	1085	O
i	1085	1086	O
reached	1087	1094	O
70	1095	1097	O
mM	1098	1100	O
.	1100	1101	O

6	1102	1103	O
.	1103	1104	O

It	1105	1107	O
is	1108	1110	O
proposed	1111	1119	O
that	1120	1124	O
the	1125	1128	O
increase	1129	1137	O
in	1138	1140	O
Na	1141	1143	O
extrusion	1144	1153	O
that	1154	1158	O
occurs	1159	1165	O
during	1166	1172	O
the	1173	1176	O
recovery	1177	1185	O
of	1186	1188	O
Na	1189	1191	O
loaded	1192	1198	O
muscles	1199	1206	B-Tissue
mostly	1207	1213	O
results	1214	1221	O
from	1222	1226	O
an	1227	1229	O
increased	1230	1239	O
turnover	1240	1248	O
rate	1249	1253	O
of	1254	1256	O
the	1257	1260	O
pump	1261	1265	O
rather	1266	1272	O
than	1273	1277	O
from	1278	1282	O
an	1283	1285	O
increase	1286	1294	O
in	1295	1297	O
number	1298	1304	O
of	1305	1307	O
pumping	1308	1315	O
sites	1316	1321	O
.	1321	1322	O

Focal	0	5	O
congenital	6	16	O
alveolar	17	25	B-Multi-tissue_structure
proteinosis	26	37	O
associated	38	48	O
with	49	53	O
abnormal	54	62	O
surfactant	63	73	O
protein	74	81	O
B	82	83	O
messenger	84	93	O
RNA	94	97	O
.	97	98	O

Two	99	102	O
siblings	103	111	O
presented	112	121	O
with	122	126	O
typical	127	134	O
clinical	135	143	O
features	144	152	O
of	153	155	O
congenital	156	166	O
pulmonary	167	176	B-Multi-tissue_structure
alveolar	177	185	I-Multi-tissue_structure
proteinosis	186	197	O
(	198	199	O
PAP	199	202	O
)	202	203	O
.	203	204	O

Necropsy	205	213	O
of	214	216	O
one	217	220	O
sibling	221	228	O
revealed	229	237	O
scattered	238	247	O
foci	248	252	B-Pathological_formation
of	253	255	O
the	256	259	O
diagnostic	260	270	O
histologic	271	281	O
changes	282	289	O
in	290	292	O
the	293	296	O
lung	297	301	B-Tissue
tissue	302	308	I-Tissue
.	308	309	O

In	310	312	O
contrast	313	321	O
to	322	324	O
infantile	325	334	O
and	335	338	O
adult	339	344	O
PAP	345	348	O
,	348	349	O
focal	350	355	B-Pathological_formation
distribution	356	368	O
is	369	371	O
uncommon	372	380	O
in	381	383	O
congenital	384	394	O
PAP	395	398	O
.	398	399	O

Defective	400	409	O
expression	410	420	O
of	421	423	O
the	424	427	O
granulocyte	428	439	O
-	439	440	O
macrophage	440	450	O
colony	451	457	O
-	457	458	O
stimulating	458	469	O
factor	470	476	O
receptor	477	485	O
was	486	489	O
ruled	490	495	O
out	496	499	O
.	499	500	O

The	501	504	O
surfactant	505	515	O
protein	516	523	O
B	524	525	O
(	526	527	O
SP	527	529	O
-	529	530	O
B	530	531	O
)	531	532	O
content	533	540	O
in	541	543	O
the	544	547	O
lung	548	552	B-Tissue
tissue	553	559	I-Tissue
of	560	562	O
the	563	566	O
autopsied	567	576	O
patient	577	584	O
was	585	588	O
low	589	592	O
,	592	593	O
and	594	597	O
a	598	599	O
deletion	600	608	O
in	609	611	O
the	612	615	O
SP	616	618	O
-	618	619	O
B	619	620	O
messenger	621	630	O
RNA	631	634	O
was	635	638	O
detected	639	647	O
.	647	648	O

We	649	651	O
speculate	652	661	O
that	662	666	O
the	667	670	O
PAP	671	674	O
in	675	677	O
our	678	681	O
patients	682	690	O
was	691	694	O
related	695	702	O
to	703	705	O
the	706	709	O
reduced	710	717	O
quantity	718	726	O
and	727	730	O
/	730	731	O
or	731	733	O
to	734	736	O
the	737	740	O
altered	741	748	O
quality	749	756	O
of	757	759	O
SP	760	762	O
-	762	763	O
B	763	764	O
.	764	765	O

Tonometry	0	9	O
in	10	12	O
normal	13	19	O
and	20	23	O
scarred	24	31	O
corneas	32	39	B-Multi-tissue_structure
,	39	40	O
and	41	44	O
in	45	47	O
postkeratoplasty	48	64	O
eyes	65	69	B-Organ
:	69	70	O
a	71	72	O
comparative	73	84	O
study	85	90	O
of	91	93	O
the	94	97	O
Goldmann	98	106	O
,	106	107	O
the	108	111	O
ProTon	112	118	O
and	119	122	O
the	123	126	O
Schiotz	127	134	O
tonometers	135	145	O
.	145	146	O

PURPOSE	147	154	O
:	154	155	O

Clinical	156	164	O
comparison	165	175	O
of	176	178	O
intraocular	179	190	B-Immaterial_anatomical_entity
pressure	191	199	O
(	200	201	O
IOP	201	204	O
)	204	205	O
measured	206	214	O
with	215	219	O
the	220	223	O
Goldmann	224	232	O
applanation	233	244	O
tonometer	245	254	O
(	255	256	O
GAT	256	259	O
)	259	260	O
,	260	261	O
the	262	265	O
ProTon	266	272	O
tonometer	273	282	O
(	283	284	O
PT	284	286	O
)	286	287	O
,	287	288	O
and	289	292	O
the	293	296	O
Schiotz	297	304	O
tonometer	305	314	O
(	315	316	O
ST	316	318	O
)	318	319	O
,	319	320	O
in	321	323	O
normal	324	330	O
eyes	331	335	B-Organ
,	335	336	O
eyes	337	341	B-Organ
with	342	346	O
scarred	347	354	O
corneas	355	362	B-Multi-tissue_structure
and	363	366	O
postkeratoplasty	367	383	O
eyes	384	388	B-Organ
.	388	389	O

MATERIAL	390	398	O
AND	399	402	O
METHODS	403	410	O
:	410	411	O

The	412	415	O
IOP	416	419	O
readings	420	428	O
with	429	433	O
GAT	434	437	O
,	437	438	O
PT	439	441	O
,	441	442	O
and	443	446	O
ST	447	449	O
were	450	454	O
compared	455	463	O
in	464	466	O
125	467	470	O
eyes	471	475	B-Organ
with	476	480	O
normal	481	487	O
corneas	488	495	B-Multi-tissue_structure
(	496	497	O
Group	497	502	O
A	503	504	O
)	504	505	O
,	505	506	O
17	507	509	O
eyes	510	514	B-Organ
with	515	519	O
scarred	520	527	O
corneas	528	535	B-Multi-tissue_structure
(	536	537	O
Group	537	542	O
B	543	544	O
)	544	545	O
,	545	546	O
and	547	550	O
in	551	553	O
21	554	556	O
postkeratoplasty	557	573	O
eyes	574	578	B-Organ
(	579	580	O
Group	580	585	O
C	586	587	O
)	587	588	O
.	588	589	O

The	590	593	O
data	594	598	O
were	599	603	O
statistically	604	617	O
analysed	618	626	O
at	627	629	O
95	630	632	O
%	632	633	O
confidence	634	644	O
interval	645	653	O
;	653	654	O
linear	655	661	O
regression	662	672	O
analysis	673	681	O
and	682	685	O
paired	686	692	O
t	693	694	O
-	694	695	O
test	695	699	O
were	700	704	O
done	705	709	O
.	709	710	O

RESULTS	711	718	O
:	718	719	O

The	720	723	O
mean	724	728	O
differences	729	740	O
and	741	744	O
their	745	750	O
standard	751	759	O
deviation	760	769	O
[	770	771	O
SD	771	773	O
]	773	774	O
between	775	782	O
GAT	783	786	O
and	787	790	O
PT	791	793	O
readings	794	802	O
,	802	803	O
and	804	807	O
GAT	808	811	O
and	812	815	O
ST	816	818	O
readings	819	827	O
respectively	828	840	O
were	841	845	O
:	845	846	O
[	847	848	O
1	848	849	O
]	849	850	O
in	851	853	O
Group	854	859	O
A	860	861	O
:	861	862	O
-	863	864	O
0	864	865	O
.	865	866	O
23	866	868	O
[	869	870	O
SD	870	872	O
2	873	874	O
.	874	875	O
75	875	877	O
]	877	878	O
mmHg	879	883	O
and	884	887	O
+	888	889	O
0	889	890	O
.	890	891	O
24	891	893	O
[	894	895	O
SD	895	897	O
3	898	899	O
.	899	900	O
18	900	902	O
]	902	903	O
mmHg	904	908	O
respectively	909	921	O
;	921	922	O
[	923	924	O
2	924	925	O
]	925	926	O
in	927	929	O
Group	930	935	O
B	936	937	O
:	937	938	O
-	939	940	O
1	940	941	O
.	941	942	O
8	942	943	O
[	944	945	O
SD	945	947	O
12	948	950	O
.	950	951	O
67	951	953	O
]	953	954	O
mmHg	955	959	O
and	960	963	O
-	964	965	O
4	965	966	O
.	966	967	O
5	967	968	O
[	969	970	O
SD	970	972	O
9	973	974	O
.	974	975	O
95	975	977	O
mmHg	978	982	O
;	982	983	O
and	984	987	O
[	988	989	O
3	989	990	O
]	990	991	O
in	992	994	O
Group	995	1000	O
C	1001	1002	O
:	1002	1003	O
+	1004	1005	O
0	1005	1006	O
.	1006	1007	O
24	1007	1009	O
[	1010	1011	O
SD	1011	1013	O
8	1014	1015	O
.	1015	1016	O
72	1016	1018	O
]	1018	1019	O
mmHg	1020	1024	O
and	1025	1028	O
-	1029	1030	O
0	1030	1031	O
.	1031	1032	O
12	1032	1034	O
[	1035	1036	O
SD	1036	1038	O
8	1039	1040	O
.	1040	1041	O
7	1041	1042	O
]	1042	1043	O
mmHg	1044	1048	O
.	1048	1049	O

They	1050	1054	O
were	1055	1059	O
not	1060	1063	O
statistically	1064	1077	O
significant	1078	1089	O
.	1089	1090	O

In	1091	1093	O
Group	1094	1099	O
A	1100	1101	O
the	1102	1105	O
95	1106	1108	O
%	1108	1109	O
confidence	1110	1120	O
interval	1121	1129	O
between	1130	1137	O
GAT	1138	1141	O
and	1142	1145	O
PT	1146	1148	O
readings	1149	1157	O
was	1158	1161	O
-	1162	1163	O
5	1163	1164	O
.	1164	1165	O
27	1165	1167	O
mmHg	1168	1172	O
to	1173	1175	O
5	1176	1177	O
.	1177	1178	O
73	1178	1180	O
mmHg	1181	1185	O
,	1185	1186	O
and	1187	1190	O
between	1191	1198	O
GAT	1199	1202	O
and	1203	1206	O
ST	1207	1209	O
readings	1210	1218	O
,	1218	1219	O
-	1220	1221	O
6	1221	1222	O
.	1222	1223	O
12	1223	1225	O
mmHg	1226	1230	O
to	1231	1233	O
6	1234	1235	O
.	1235	1236	O
59	1236	1238	O
mmHg	1239	1243	O
.	1243	1244	O

Ninety	1245	1251	O
six	1252	1255	O
[	1256	1257	O
77	1257	1259	O
%	1259	1260	O
]	1260	1261	O
eyes	1262	1266	B-Organ
with	1267	1271	O
the	1272	1275	O
PT	1276	1278	O
and	1279	1282	O
84	1283	1285	O
[	1286	1287	O
69	1287	1289	O
%	1289	1290	O
]	1290	1291	O
eyes	1292	1296	B-Organ
with	1297	1301	O
ST	1302	1304	O
measurements	1305	1317	O
were	1318	1322	O
within	1323	1329	O
3	1330	1331	O
mmHg	1332	1336	O
of	1337	1339	O
GAT	1340	1343	O
pressure	1344	1352	O
.	1352	1353	O

The	1354	1357	O
correlation	1358	1369	O
coefficients	1370	1382	O
[	1383	1384	O
r	1384	1385	O
]	1385	1386	O
for	1387	1390	O
PT	1391	1393	O
and	1394	1397	O
ST	1398	1400	O
were	1401	1405	O
0	1406	1407	O
.	1407	1408	O
93	1408	1410	O
[	1411	1412	O
P	1412	1413	O
=	1414	1415	O
0	1416	1417	O
.	1417	1418	O
0000	1418	1422	O
]	1422	1423	O
and	1424	1427	O
0	1428	1429	O
.	1429	1430	O
88	1430	1432	O
[	1433	1434	O
P	1434	1435	O
=	1436	1437	O
0	1438	1439	O
.	1439	1440	O
0000	1440	1444	O
]	1444	1445	O
respectively	1446	1458	O
.	1458	1459	O

In	1460	1462	O
Group	1463	1468	O
B	1469	1470	O
95	1471	1473	O
%	1473	1474	O
confidence	1475	1485	O
interval	1486	1494	O
between	1495	1502	O
GAT	1503	1506	O
and	1507	1510	O
PT	1511	1513	O
readings	1514	1522	O
was	1523	1526	O
-	1527	1528	O
27	1528	1530	O
.	1530	1531	O
17	1531	1533	O
mmHg	1534	1538	O
to	1539	1541	O
23	1542	1544	O
.	1544	1545	O
51	1545	1547	O
mmHg	1548	1552	O
,	1552	1553	O
and	1554	1557	O
between	1558	1565	O
GAT	1566	1569	O
and	1570	1573	O
ST	1574	1576	O
measurement	1577	1588	O
,	1588	1589	O
-	1590	1591	O
24	1591	1593	O
.	1593	1594	O
37	1594	1596	O
mmHg	1597	1601	O
to	1602	1604	O
15	1605	1607	O
.	1607	1608	O
44	1608	1610	O
mmHg	1611	1615	O
.	1615	1616	O

The	1617	1620	O
correlation	1621	1632	O
coefficients	1633	1645	O
[	1646	1647	O
r	1647	1648	O
]	1648	1649	O
for	1650	1653	O
the	1654	1657	O
PT	1658	1660	O
and	1661	1664	O
ST	1665	1667	O
were	1668	1672	O
0	1673	1674	O
.	1674	1675	O
112	1675	1678	O
[	1679	1680	O
P	1680	1681	O
=	1682	1683	O
0	1684	1685	O
.	1685	1686	O
660	1686	1689	O
]	1689	1690	O
and	1691	1694	O
0	1695	1696	O
.	1696	1697	O
630	1697	1700	O
[	1701	1702	O
P	1702	1703	O
=	1704	1705	O
0	1706	1707	O
.	1707	1708	O
006	1708	1711	O
]	1711	1712	O
respectively	1713	1725	O
.	1725	1726	O

In	1727	1729	O
group	1730	1735	O
C	1736	1737	O
,	1737	1738	O
the	1739	1742	O
95	1743	1745	O
%	1745	1746	O
confidence	1747	1757	O
interval	1758	1766	O
between	1767	1774	O
GAT	1775	1778	O
and	1779	1782	O
PT	1783	1785	O
measurements	1786	1798	O
was	1799	1802	O
-	1803	1804	O
17	1804	1806	O
.	1806	1807	O
20	1807	1809	O
mmHg	1810	1814	O
to	1815	1817	O
17	1818	1820	O
.	1820	1821	O
67	1821	1823	O
mmHg	1824	1828	O
,	1828	1829	O
and	1830	1833	O
between	1834	1841	O
GAT	1842	1845	O
and	1846	1849	O
ST	1850	1852	O
measurements	1853	1865	O
,	1865	1866	O
-	1867	1868	O
17	1868	1870	O
.	1870	1871	O
51	1871	1873	O
mmHg	1874	1878	O
to	1879	1881	O
17	1882	1884	O
.	1884	1885	O
27	1885	1887	O
mmHg	1888	1892	O
.	1892	1893	O

The	1894	1897	O
correlation	1898	1909	O
coefficients	1910	1922	O
[	1923	1924	O
r	1924	1925	O
]	1925	1926	O
for	1927	1930	O
the	1931	1934	O
PT	1935	1937	O
and	1938	1941	O
the	1942	1945	O
ST	1946	1948	O
were	1949	1953	O
0	1954	1955	O
.	1955	1956	O
780	1956	1959	O
[	1960	1961	O
P	1961	1962	O
=	1963	1964	O
0	1965	1966	O
.	1966	1967	O
0000	1967	1971	O
]	1971	1972	O
and	1973	1976	O
0	1977	1978	O
.	1978	1979	O
740	1979	1982	O
[	1983	1984	O
P	1984	1985	O
=	1986	1987	O
0	1988	1989	O
.	1989	1990	O
0001	1990	1994	O
]	1994	1995	O
respectively	1996	2008	O
.	2008	2009	O

CONCLUSIONS	2010	2021	O
:	2021	2022	O

In	2023	2025	O
clinical	2026	2034	O
practice	2035	2043	O
PT	2044	2046	O
appears	2047	2054	O
to	2055	2057	O
have	2058	2062	O
a	2063	2064	O
higher	2065	2071	O
level	2072	2077	O
of	2078	2080	O
accuracy	2081	2089	O
than	2090	2094	O
ST	2095	2097	O
in	2098	2100	O
normal	2101	2107	O
corneas	2108	2115	B-Multi-tissue_structure
.	2115	2116	O

In	2117	2119	O
scarred	2120	2127	O
corneas	2128	2135	B-Multi-tissue_structure
and	2136	2139	O
post	2140	2144	O
-	2144	2145	O
penetrating	2145	2156	O
keratoplasty	2157	2169	O
eyes	2170	2174	B-Organ
,	2174	2175	O
because	2176	2183	O
of	2184	2186	O
high	2187	2191	O
SD	2192	2194	O
for	2195	2198	O
mean	2199	2203	O
differences	2204	2215	O
and	2216	2219	O
wide	2220	2224	O
confidence	2225	2235	O
interval	2236	2244	O
of	2245	2247	O
95	2248	2250	O
%	2250	2251	O
,	2251	2252	O
both	2253	2257	O
PT	2258	2260	O
and	2261	2264	O
ST	2265	2267	O
are	2268	2271	O
inaccurate	2272	2282	O
in	2283	2285	O
measuring	2286	2295	O
IOP	2296	2299	O
as	2300	2302	O
compared	2303	2311	O
to	2312	2314	O
GAT	2315	2318	O
in	2319	2321	O
such	2322	2326	O
eyes	2327	2331	B-Organ
.	2331	2332	O

[	0	1	O
H	1	2	O
.	2	3	O
pylori	4	10	O
infection	11	20	O
.	20	21	O
Our	22	25	O
experience	26	36	O
with	37	41	O
the	42	45	O
quadruple	46	55	O
and	56	59	O
triple	60	66	O
therapy	67	74	O
as	75	77	O
first	78	83	O
pharmacologic	84	97	O
approach	98	106	O
]	106	107	O
.	107	108	O

For	109	112	O
now	113	116	O
the	117	120	O
most	121	125	O
used	126	130	O
pharmacological	131	146	O
treatment	147	156	O
of	157	159	O
first	160	165	O
instance	166	174	O
to	175	177	O
eradication	178	189	O
of	190	192	O
Hp	193	195	O
foresees	196	204	O
utilization	205	216	O
of	217	219	O
triple	220	226	O
therapy	227	234	O
(	235	236	O
PPI	236	239	O
+	240	241	O
two	242	245	O
antibiotics	246	257	O
)	257	258	O
.	258	259	O

In	260	262	O
our	263	266	O
study	267	272	O
we	273	275	O
have	276	280	O
compared	281	289	O
this	290	294	O
kind	295	299	O
of	300	302	O
treatment	303	312	O
with	313	317	O
the	318	321	O
quadruple	322	331	O
therapy	332	339	O
(	340	341	O
PPI	341	344	O
+	345	346	O
three	347	352	O
antibiotics	353	364	O
)	364	365	O
,	365	366	O
that	367	371	O
have	372	376	O
showed	377	383	O
a	384	385	O
taller	386	392	O
percentage	393	403	O
of	404	406	O
eradication	407	418	O
at	419	421	O
the	422	425	O
end	426	429	O
of	430	432	O
first	433	438	O
therapeutical	439	452	O
cycle	453	458	O
with	459	463	O
a	464	465	O
shorter	466	473	O
time	474	478	O
and	479	482	O
lower	483	488	O
price	489	494	O
of	495	497	O
treatment	498	507	O
.	507	508	O

Renormalization	0	15	O
group	16	21	O
analysis	22	30	O
of	31	33	O
autoregressive	34	48	O
processes	49	58	O
and	59	62	O
fractional	63	73	O
noise	74	79	O
.	79	80	O

A	81	82	O
renormalization	83	98	O
group	99	104	O
analysis	105	113	O
is	114	116	O
applied	117	124	O
to	125	127	O
autoregressive	128	142	O
processes	143	152	O
with	153	157	O
an	158	160	O
infinite	161	169	O
series	170	176	O
of	177	179	O
coefficients	180	192	O
.	192	193	O

A	194	195	O
simple	196	202	O
fixed	203	208	O
point	209	214	O
is	215	217	O
given	218	223	O
by	224	226	O
a	227	228	O
random	229	235	O
walk	236	240	O
,	240	241	O
and	242	245	O
a	246	247	O
second	248	254	O
class	255	260	O
is	261	263	O
found	264	269	O
that	270	274	O
is	275	277	O
proportional	278	290	O
to	291	293	O
the	294	297	O
high	298	302	O
order	303	308	O
coefficients	309	321	O
of	322	324	O
fractional	325	335	O
autoregressive	336	350	O
integrated	351	361	O
moving	362	368	O
average	369	376	O
(	377	378	O
ARIMA	378	383	O
)	383	384	O
processes	385	394	O
.	394	395	O

The	396	399	O
approach	400	408	O
might	409	414	O
be	415	417	O
useful	418	424	O
to	425	427	O
detect	428	434	O
nonstationarity	435	450	O
in	451	453	O
autoregressive	454	468	O
processes	469	478	O
.	478	479	O

In	0	2	O
vitro	3	8	O
cytotoxic	9	18	O
potential	19	28	O
and	29	32	O
mechanism	33	42	O
of	43	45	O
action	46	52	O
of	53	55	O
selected	56	64	O
coumarins	65	74	O
,	74	75	O
using	76	81	O
human	82	87	O
renal	88	93	B-Cell
cell	94	98	I-Cell
lines	99	104	I-Cell
.	104	105	O

This	106	110	O
study	111	116	O
determined	117	127	O
the	128	131	O
selective	132	141	O
cytotoxicity	142	154	O
of	155	157	O
eight	158	163	O
coumarin	164	172	O
compounds	173	182	O
to	183	185	O
human	186	191	O
renal	192	197	B-Cell
carcinoma	198	207	I-Cell
cells	208	213	I-Cell
,	213	214	O
relative	215	223	O
to	224	226	O
non	227	230	B-Cell
-	230	231	I-Cell
carcinoma	231	240	I-Cell
proximal	241	249	I-Cell
tubular	250	257	I-Cell
cells	258	263	I-Cell
.	263	264	O

Selectivity	265	276	O
cytotoxicity	277	289	O
was	290	293	O
observed	294	302	O
following	303	312	O
exposure	313	321	O
to	322	324	O
6	325	326	O
-	326	327	O
nitro	327	332	O
-	332	333	O
7	333	334	O
-	334	335	O
hydroxycoumarin	335	350	O
(	351	352	O
6	352	353	O
-	353	354	O
NO	354	356	O
(	356	357	O
2	357	358	O
)	358	359	O
-	359	360	O
7	360	361	O
-	361	362	O
OHC	362	365	O
)	365	366	O
and	367	370	O
7	371	372	O
,	372	373	O
8	373	374	O
-	374	375	O
dihydroxycoumarin	375	392	O
(	393	394	O
7	394	395	O
,	395	396	O
8	396	397	O
-	397	398	O
OHC	398	401	O
)	401	402	O
.	402	403	O

6	404	405	O
-	405	406	O
NO	406	408	O
(	408	409	O
2	409	410	O
)	410	411	O
-	411	412	O
7	412	413	O
-	413	414	O
OHC	414	417	O
induced	418	425	O
cytotoxicity	426	438	O
was	439	442	O
irreversible	443	455	O
in	456	458	O
both	459	463	O
cell	464	468	B-Cell
lines	469	474	I-Cell
,	474	475	O
unlike	476	482	O
7	483	484	O
,	484	485	O
8	485	486	O
-	486	487	O
OHC	487	490	O
,	490	491	O
which	492	497	O
was	498	501	O
reversible	502	512	O
in	513	515	O
the	516	519	O
carcinoma	520	529	B-Cell
cells	530	535	I-Cell
only	536	540	O
.	540	541	O

Mobility	542	550	O
shift	551	556	O
and	557	560	O
BrdU	561	565	O
incorporation	566	579	O
assays	580	586	O
showed	587	593	O
that	594	598	O
both	599	603	O
compounds	604	613	O
did	614	617	O
not	618	621	O
intercalate	622	633	O
DNA	634	637	O
but	638	641	O
had	642	645	O
a	646	647	O
concentration	648	661	O
-	661	662	O
dependent	662	671	O
inhibitory	672	682	O
effect	683	689	O
on	690	692	O
its	693	696	O
synthesis	697	706	O
.	706	707	O

All	708	711	O
coumarins	712	721	O
studied	722	729	O
were	730	734	O
found	735	740	O
to	741	743	O
be	744	746	O
non	747	750	O
-	750	751	O
mutagenic	751	760	O
using	761	766	O
the	767	770	O
standard	771	779	O
Ames	780	784	O
test	785	789	O
.	789	790	O

These	791	796	O
results	797	804	O
would	805	810	O
suggest	811	818	O
that	819	823	O
6	824	825	O
-	825	826	O
NO	826	828	O
(	828	829	O
2	829	830	O
)	830	831	O
-	831	832	O
7	832	833	O
-	833	834	O
OHC	834	837	O
and	838	841	O
7	842	843	O
,	843	844	O
8	844	845	O
-	845	846	O
OHC	846	849	O
might	850	855	O
have	856	860	O
a	861	862	O
therapeutic	863	874	O
role	875	879	O
to	880	882	O
play	883	887	O
in	888	890	O
the	891	894	O
treatment	895	904	O
of	905	907	O
renal	908	913	B-Pathological_formation
cell	914	918	I-Pathological_formation
carcinoma	919	928	I-Pathological_formation
.	928	929	O

On	0	2	O
the	3	6	O
relationship	7	19	O
between	20	27	O
the	28	31	O
population	32	42	O
structure	43	52	O
and	53	56	O
national	57	65	O
economic	66	74	O
development	75	86	O
in	87	89	O
China	90	95	O
.	95	96	O

The	97	100	O
authors	101	108	O
examine	109	116	O
the	117	120	O
relationship	121	133	O
between	134	141	O
population	142	152	O
reproduction	153	165	O
and	166	169	O
the	170	173	O
production	174	184	O
of	185	187	O
material	188	196	O
goods	197	202	O
,	202	203	O
with	204	208	O
particular	209	219	O
reference	220	229	O
to	230	232	O
the	233	236	O
effect	237	243	O
of	244	246	O
changes	247	254	O
in	255	257	O
the	258	261	O
age	262	265	O
composition	266	277	O
of	278	280	O
the	281	284	O
population	285	295	O
on	296	298	O
the	299	302	O
national	303	311	O
economy	312	319	O
and	320	323	O
national	324	332	O
income	333	339	O
.	339	340	O

An	342	344	O
analysis	345	353	O
of	354	356	O
the	357	360	O
population	361	371	O
structure	372	381	O
of	382	384	O
China	385	390	O
is	391	393	O
presented	394	403	O
,	403	404	O
with	405	409	O
consideration	410	423	O
given	424	429	O
to	430	432	O
age	433	436	O
characteristics	437	452	O
,	452	453	O
occupation	454	464	O
,	464	465	O
and	466	469	O
urban	470	475	O
and	476	479	O
rural	480	485	O
population	486	496	O
.	496	497	O

Suggestions	499	510	O
for	511	514	O
improving	515	524	O
the	525	528	O
population	529	539	O
structure	540	549	O
to	550	552	O
achieve	553	560	O
maximum	561	568	O
rates	569	574	O
of	575	577	O
economic	578	586	O
development	587	598	O
are	599	602	O
presented	603	612	O
.	612	613	O

Regional	615	623	O
differences	624	635	O
in	636	638	O
population	639	649	O
structure	650	659	O
are	660	663	O
also	664	668	O
discussed	669	678	O
.	678	679	O

No	0	2	O
evidence	3	11	O
for	12	15	O
an	16	18	O
influence	19	28	O
of	29	31	O
the	32	35	O
human	36	41	O
platelet	42	50	O
antigen	51	58	O
-	58	59	O
1	59	60	O
polymorphism	61	73	O
on	74	76	O
the	77	80	O
antiplatelet	81	93	O
effects	94	101	O
of	102	104	O
glycoprotein	105	117	O
IIb	118	121	O
/	121	122	O
IIIa	122	126	O
inhibitors	127	137	O
.	137	138	O

This	139	143	O
study	144	149	O
investigated	150	162	O
the	163	166	O
hypothesis	167	177	O
that	178	182	O
the	183	186	O
human	187	192	O
platelet	193	201	O
antigen	202	209	O
-	209	210	O
1	210	211	O
(	212	213	O
HPA	213	216	O
-	216	217	O
1	217	218	O
)	218	219	O
polymorphism	220	232	O
may	233	236	O
influence	237	246	O
the	247	250	O
antiplatelet	251	263	O
effects	264	271	O
of	272	274	O
glycoprotein	275	287	O
(	288	289	O
GP	289	291	O
)	291	292	O
IIb	292	295	O
/	295	296	O
IIIa	296	300	O
inhibitors	301	311	O
.	311	312	O

Adenosine	313	322	O
diphosphate	323	334	O
(	335	336	O
30	336	338	O
micro	339	344	O
mol	345	348	O
)	348	349	O
-	349	350	O
induced	350	357	O
fibrinogen	358	368	O
binding	369	376	O
was	377	380	O
measured	381	389	O
by	390	392	O
flow	393	397	O
cytometry	398	407	O
.	407	408	O

Abciximab	409	418	O
(	419	420	O
0	420	421	O
.	421	422	O
03	422	424	O
-	424	425	O
3	425	426	O
micro	427	432	O
g	433	434	O
/	434	435	O
ml	435	437	O
)	437	438	O
,	438	439	O
tirofiban	440	449	O
(	450	451	O
0	451	452	O
.	452	453	O
3	453	454	O
-	454	455	O
30	455	457	O
nmol	458	462	O
/	462	463	O
l	463	464	O
)	464	465	O
or	466	468	O
eptifibatide	469	481	O
(	482	483	O
0	483	484	O
.	484	485	O
01	485	487	O
-	487	488	O
1	488	489	O
micro	490	495	O
g	496	497	O
/	497	498	O
ml	498	500	O
)	500	501	O
were	502	506	O
incubated	507	516	O
for	517	520	O
15	521	523	O
min	524	527	O
with	528	532	O
the	533	536	O
samples	537	544	O
prior	545	550	O
to	551	553	O
stimulation	554	565	O
.	565	566	O

IC	567	569	O
(	569	570	O
50	570	572	O
)	572	573	O
values	574	580	O
for	581	584	O
the	585	588	O
inhibition	589	599	O
of	600	602	O
fibrinogen	603	613	O
binding	614	621	O
were	622	626	O
determined	627	637	O
from	638	642	O
each	643	647	O
experiment	648	658	O
.	658	659	O

All	660	663	O
subjects	664	672	O
were	673	677	O
genotyped	678	687	O
by	688	690	O
GALIOS	691	697	O
and	698	701	O
automated	702	711	O
fluorescence	712	724	O
correlation	725	736	O
spectroscopy	737	749	O
.	749	750	O

Although	751	759	O
a	760	761	O
marked	762	768	O
variability	769	780	O
in	781	783	O
the	784	787	O
inhibitory	788	798	O
effects	799	806	O
of	807	809	O
all	810	813	O
three	814	819	O
GPIIb	820	825	O
/	825	826	O
IIIa	826	830	O
inhibitors	831	841	O
was	842	845	O
confirmed	846	855	O
,	855	856	O
there	857	862	O
were	863	867	O
no	868	870	O
significant	871	882	O
differences	883	894	O
between	895	902	O
the	903	906	O
genotypes	907	916	O
with	917	921	O
respect	922	929	O
to	930	932	O
the	933	936	O
inhibition	937	947	O
of	948	950	O
fibrinogen	951	961	O
binding	962	969	O
.	969	970	O

Thus	971	975	O
,	975	976	O
the	977	980	O
present	981	988	O
study	989	994	O
does	995	999	O
not	1000	1003	O
provide	1004	1011	O
evidence	1012	1020	O
for	1021	1024	O
an	1025	1027	O
effect	1028	1034	O
of	1035	1037	O
HPA	1038	1041	O
-	1041	1042	O
1	1042	1043	O
polymorphism	1044	1056	O
on	1057	1059	O
the	1060	1063	O
inter	1064	1069	O
-	1069	1070	O
individual	1070	1080	O
variability	1081	1092	O
in	1093	1095	O
the	1096	1099	O
platelet	1100	1108	B-Cell
inhibitory	1109	1119	O
effects	1120	1127	O
of	1128	1130	O
the	1131	1134	O
three	1135	1140	O
GPIIb	1141	1146	O
/	1146	1147	O
IIIa	1147	1151	O
inhibitors	1152	1162	O
approved	1163	1171	O
for	1172	1175	O
clinical	1176	1184	O
use	1185	1188	O
.	1188	1189	O

The	0	3	O
Acute	4	9	O
Dialysis	10	18	O
Quality	19	26	O
Initiative	27	37	O
-	37	38	O
-	38	39	O
part	39	43	O
IV	44	46	O
:	46	47	O
membranes	48	57	B-Multi-tissue_structure
for	58	61	O
CRRT	62	66	O
.	66	67	O

The	68	71	O
extracorporeal	72	86	B-Multi-tissue_structure
membrane	87	95	I-Multi-tissue_structure
used	96	100	O
in	101	103	O
a	104	105	O
continuous	106	116	O
renal	117	122	B-Organ
replacement	123	134	O
therapy	135	142	O
(	143	144	O
CRRT	144	148	O
)	148	149	O
for	150	153	O
the	154	157	O
treatment	158	167	O
of	168	170	O
a	171	172	O
critically	173	183	O
ill	184	187	O
patient	188	195	O
with	196	200	O
acute	201	206	O
renal	207	212	B-Organ
failure	213	220	O
(	221	222	O
ARF	222	225	O
)	225	226	O
is	227	229	O
vitally	230	237	O
important	238	247	O
for	248	251	O
several	252	259	O
reasons	260	267	O
,	267	268	O
including	269	278	O
its	279	282	O
influence	283	292	O
on	293	295	O
biocompatibility	296	312	O
and	313	316	O
filter	317	323	O
performance	324	335	O
.	335	336	O

The	337	340	O
clinical	341	349	O
relevance	350	359	O
of	360	362	O
membrane	363	371	B-Multi-tissue_structure
-	371	372	O
related	372	379	O
biocompatibility	380	396	O
markers	397	404	O
traditionally	405	418	O
used	419	423	O
in	424	426	O
chronic	427	434	O
hemodialysis	435	447	O
remains	448	455	O
unclear	456	463	O
in	464	466	O
CRRT	467	471	O
.	471	472	O

Numerous	473	481	O
approaches	482	492	O
may	493	496	O
be	497	499	O
used	500	504	O
to	505	507	O
assess	508	514	O
membrane	515	523	B-Multi-tissue_structure
and	524	527	O
filter	528	534	O
performance	535	546	O
in	547	549	O
CRRT	550	554	O
,	554	555	O
but	556	559	O
no	560	562	O
specific	563	571	O
methodology	572	583	O
is	584	586	O
accepted	587	595	O
widely	596	602	O
at	603	605	O
present	606	613	O
.	613	614	O

Although	615	623	O
a	624	625	O
potential	626	635	O
benefit	636	643	O
of	644	646	O
certain	647	654	O
membranes	655	664	B-Multi-tissue_structure
used	665	669	O
for	670	673	O
CRRT	674	678	O
is	679	681	O
adsorptive	682	692	O
removal	693	700	O
of	701	703	O
inflammatory	704	716	O
mediators	717	726	O
,	726	727	O
this	728	732	O
issue	733	738	O
has	739	742	O
not	743	746	O
been	747	751	O
assessed	752	760	O
carefully	761	770	O
in	771	773	O
well	774	778	O
-	778	779	O
designed	779	787	O
clinical	788	796	O
trials	797	803	O
.	803	804	O

These	805	810	O
and	811	814	O
other	815	820	O
issues	821	827	O
should	828	834	O
be	835	837	O
the	838	841	O
subject	842	849	O
of	850	852	O
future	853	859	O
clinical	860	868	O
research	869	877	O
efforts	878	885	O
.	885	886	O

Sickle	0	6	B-Cell
cell	7	11	I-Cell
disease	12	19	O
:	19	20	O
continuous	21	31	O
arterial	32	40	B-Multi-tissue_structure
spin	41	45	O
-	45	46	O
labeling	46	54	O
perfusion	55	64	O
MR	65	67	O
imaging	68	75	O
in	76	78	O
children	79	87	O
.	87	88	O

Cerebral	89	97	B-Organ
blood	98	103	B-Organism_substance
flow	104	108	O
(	109	110	O
CBF	110	113	O
)	113	114	O
was	115	118	O
measured	119	127	O
with	128	132	O
continuous	133	143	O
arterial	144	152	B-Multi-tissue_structure
spin	153	157	O
-	157	158	O
labeling	158	166	O
perfusion	167	176	O
magnetic	177	185	O
resonance	186	195	O
(	196	197	O
MR	197	199	O
)	199	200	O
imaging	201	208	O
in	209	211	O
14	212	214	O
children	215	223	O
with	224	228	O
sickle	229	235	B-Cell
cell	236	240	I-Cell
disease	241	248	O
and	249	252	O
seven	253	258	O
control	259	266	O
subjects	267	275	O
.	275	276	O

Mean	277	281	O
CBF	282	285	O
values	286	292	O
were	293	297	O
higher	298	304	O
in	305	307	O
patients	308	316	O
(	317	318	O
P	318	319	O
<	320	321	O
.	321	322	O
005	322	325	O
)	325	326	O
than	327	331	O
in	332	334	O
control	335	342	O
subjects	343	351	O
in	352	354	O
all	355	358	O
cerebral	359	367	B-Multi-tissue_structure
artery	368	374	I-Multi-tissue_structure
territories	375	386	O
.	386	387	O

Three	388	393	O
patients	394	402	O
had	403	406	O
decreased	407	416	O
CBF	417	420	O
in	421	423	O
right	424	429	B-Multi-tissue_structure
anterior	430	438	I-Multi-tissue_structure
and	439	442	O
middle	443	449	O
cerebral	450	458	B-Multi-tissue_structure
artery	459	465	I-Multi-tissue_structure
territories	466	477	O
compared	478	486	O
with	487	491	O
CBF	492	495	O
on	496	498	O
the	499	502	O
left	503	507	O
,	507	508	O
and	509	512	O
one	513	516	O
patient	517	524	O
had	525	528	O
a	529	530	O
profound	531	539	O
decrease	540	548	O
in	549	551	O
CBF	552	555	O
in	556	558	O
all	559	562	O
three	563	568	O
territories	569	580	O
in	581	583	O
the	584	587	O
right	588	593	B-Organism_subdivision
hemisphere	594	604	I-Organism_subdivision
.	604	605	O

Baseline	606	614	O
CBF	615	618	O
was	619	622	O
significantly	623	636	O
decreased	637	646	O
in	647	649	O
territories	650	661	O
seen	662	666	O
as	667	669	O
unaffected	670	680	O
on	681	683	O
conventional	684	696	O
MR	697	699	O
images	700	706	O
and	707	710	O
MR	711	713	O
angiograms	714	724	O
in	725	727	O
four	728	732	O
children	733	741	O
with	742	746	O
sickle	747	753	B-Cell
cell	754	758	I-Cell
disease	759	766	O
.	766	767	O

The	0	3	O
septic	4	10	B-Multi-tissue_structure
abscess	11	18	I-Multi-tissue_structure
wall	19	23	I-Multi-tissue_structure
:	23	24	O
a	25	26	O
cytokine	27	35	O
-	35	36	O
generating	36	46	O
organ	47	52	B-Organ
associated	53	63	O
with	64	68	O
portal	69	75	B-Multi-tissue_structure
venous	76	82	I-Multi-tissue_structure
cytokinemia	83	94	O
,	94	95	O
hepatic	96	103	B-Organ
outflow	104	111	O
fibrosis	112	120	O
,	120	121	O
sinusoidal	122	132	B-Tissue
congestion	133	143	O
,	143	144	O
inflammatory	145	157	B-Cell
cell	158	162	I-Cell
sequestration	163	176	O
,	176	177	O
hepatocellular	178	192	B-Cell
lipid	193	198	O
deposition	199	209	O
,	209	210	O
and	211	214	O
focal	215	220	O
cell	221	225	B-Cell
death	226	231	O
.	231	232	O

An	233	235	O
acute	236	241	O
septic	242	248	O
inflammatory	249	261	O
response	262	270	O
with	271	275	O
access	276	282	O
to	283	285	O
the	286	289	O
portal	290	296	O
circulation	297	308	O
was	309	312	O
created	313	320	O
in	321	323	O
a	324	325	O
rat	326	329	O
model	330	335	O
using	336	341	O
an	342	344	O
intra	345	350	O
-	350	351	O
abdominal	351	360	B-Pathological_formation
abscess	361	368	I-Pathological_formation
composed	369	377	O
of	378	380	O
a	381	382	O
sterile	383	390	O
agar	391	395	O
pellet	396	402	O
,	402	403	O
or	404	406	O
one	407	410	O
contaminated	411	423	O
with	424	428	O
102	429	432	O
Escherichia	433	444	O
coli	445	449	O
(	450	451	O
E	451	452	O
.	452	453	O
coli	454	458	O
)	458	459	O
and	460	463	O
109	464	467	O
Bacteriodes	468	479	O
fragilis	480	488	O
(	489	490	O
B	490	491	O
.	491	492	O
fragilis	493	501	O
)	501	502	O
.	502	503	O

After	504	509	O
3	510	511	O
days	512	516	O
postimplantation	517	533	O
,	533	534	O
a	535	536	O
well	537	541	O
-	541	542	O
formed	542	548	O
intra	549	554	O
-	554	555	O
abdominal	555	564	B-Pathological_formation
abscess	565	572	I-Pathological_formation
occurred	573	581	O
whose	582	587	O
wall	588	592	B-Tissue
showed	593	599	O
IL	600	602	O
-	602	603	O
6	603	604	O
DNA	605	608	O
by	609	611	O
PCR	612	615	O
and	616	619	O
IL	620	622	O
-	622	623	O
6	623	624	O
mRNA	625	629	O
by	630	632	O
in	633	635	O
situ	636	640	O
hybridization	641	654	O
.	654	655	O

Portal	656	662	B-Organism_substance
venous	663	669	I-Organism_substance
blood	670	675	I-Organism_substance
draining	676	684	O
into	685	689	O
the	690	693	O
liver	694	699	B-Organ
from	700	704	O
the	705	708	O
intra	709	714	O
-	714	715	O
abdominal	715	724	B-Pathological_formation
abscess	725	732	I-Pathological_formation
had	733	736	O
increased	737	746	O
levels	747	753	O
of	754	756	O
TNF	757	760	O
-	760	761	O
alpha	761	766	O
,	766	767	O
IL	768	770	O
-	770	771	O
1beta	771	776	O
,	776	777	O
and	778	781	O
IL	782	784	O
-	784	785	O
6	785	786	O
in	787	789	O
both	790	794	O
sterile	795	802	O
and	803	806	O
septic	807	813	O
groups	814	820	O
compared	821	829	O
with	830	834	O
a	835	836	O
control	837	844	O
normal	845	851	O
animal	852	858	O
group	859	864	O
.	864	865	O

Increased	866	875	O
levels	876	882	O
of	883	885	O
these	886	891	O
cytokines	892	901	O
were	902	906	O
also	907	911	O
found	912	917	O
in	918	920	O
suprahepatic	921	933	B-Organism_substance
inferior	934	942	I-Organism_substance
vena	943	947	I-Organism_substance
caval	948	953	I-Organism_substance
blood	954	959	I-Organism_substance
,	959	960	O
but	961	964	O
were	965	969	O
correlated	970	980	O
with	981	985	O
the	986	989	O
higher	990	996	O
portal	997	1003	B-Multi-tissue_structure
vein	1004	1008	I-Multi-tissue_structure
levels	1009	1015	O
,	1015	1016	O
suggesting	1017	1027	O
a	1028	1029	O
gradient	1030	1038	O
from	1039	1043	O
abscess	1044	1051	B-Multi-tissue_structure
wall	1052	1056	I-Multi-tissue_structure
to	1057	1059	O
portal	1060	1066	B-Multi-tissue_structure
vein	1067	1071	I-Multi-tissue_structure
into	1072	1076	O
the	1077	1080	O
systemic	1081	1089	O
circulation	1090	1101	O
via	1102	1105	O
the	1106	1109	O
liver	1110	1115	B-Organ
.	1115	1116	O

Liver	1117	1122	B-Organ
histology	1123	1132	O
demonstrated	1133	1145	O
sinusoidal	1146	1156	B-Tissue
congestion	1157	1167	O
centering	1168	1177	O
on	1178	1180	O
the	1181	1184	O
central	1185	1192	B-Multi-tissue_structure
vein	1193	1197	I-Multi-tissue_structure
,	1197	1198	O
growing	1199	1206	O
worse	1207	1212	O
with	1213	1217	O
progression	1218	1229	O
from	1230	1234	O
normal	1235	1241	O
in	1242	1244	O
control	1245	1252	O
,	1252	1253	O
to	1254	1256	O
sterile	1257	1264	O
,	1264	1265	O
to	1266	1268	O
septic	1269	1275	O
.	1275	1276	O

Similarly	1277	1286	O
,	1286	1287	O
the	1288	1291	O
degree	1292	1298	O
of	1299	1301	O
intrahepatic	1302	1314	O
myeloperoxidase	1315	1330	O
-	1330	1331	O
positive	1331	1339	O
inflammatory	1340	1352	B-Cell
cell	1353	1357	I-Cell
infiltration	1358	1370	O
and	1371	1374	O
hepatocellular	1375	1389	B-Cell
lipid	1390	1395	O
deposition	1396	1406	O
and	1407	1410	O
apoptosis	1411	1420	O
also	1421	1425	O
increased	1426	1435	O
from	1436	1440	O
control	1441	1448	O
,	1448	1449	O
to	1450	1452	O
sterile	1453	1460	O
,	1460	1461	O
to	1462	1464	O
septic	1465	1471	O
.	1471	1472	O

Gene	1473	1477	O
expression	1478	1488	O
by	1489	1491	O
in	1492	1494	O
situ	1495	1499	O
hybridization	1500	1513	O
demonstrated	1514	1526	O
a	1527	1528	O
significant	1529	1540	O
increase	1541	1549	O
in	1550	1552	O
IL	1553	1555	O
-	1555	1556	O
6	1556	1557	O
and	1558	1561	O
fibrinogen	1562	1572	O
mRNAs	1573	1578	O
in	1579	1581	O
cells	1582	1587	B-Cell
surrounding	1588	1599	O
the	1600	1603	O
central	1604	1611	B-Multi-tissue_structure
vein	1612	1616	I-Multi-tissue_structure
in	1617	1619	O
sterile	1620	1627	O
and	1628	1631	O
septic	1632	1638	O
animals	1639	1646	O
,	1646	1647	O
being	1648	1653	O
greatest	1654	1662	O
in	1663	1665	O
animals	1666	1673	O
with	1674	1678	O
sepsis	1679	1685	O
,	1685	1686	O
associated	1687	1697	O
with	1698	1702	O
an	1703	1705	O
increased	1706	1715	O
deposition	1716	1726	O
of	1727	1729	O
collagen	1730	1738	O
in	1739	1741	O
the	1742	1745	O
central	1746	1753	B-Multi-tissue_structure
vein	1754	1758	I-Multi-tissue_structure
area	1759	1763	O
,	1763	1764	O
most	1765	1769	O
prominent	1770	1779	O
in	1780	1782	O
the	1783	1786	O
septic	1787	1793	B-Organ
liver	1794	1799	I-Organ
.	1799	1800	O

The	1801	1804	O
pericentral	1805	1816	B-Cell
vein	1817	1821	I-Cell
cells	1822	1827	I-Cell
with	1828	1832	O
IL	1833	1835	O
-	1835	1836	O
6	1836	1837	O
and	1838	1841	O
fibrinogen	1842	1852	O
mRNA	1853	1857	O
increases	1858	1867	O
paralleled	1868	1878	O
the	1879	1882	O
increases	1883	1892	O
in	1893	1895	O
cells	1896	1901	B-Cell
containing	1902	1912	O
IL	1913	1915	O
-	1915	1916	O
6	1916	1917	O
and	1918	1921	O
fibrinogen	1922	1932	O
mRNAs	1933	1938	O
in	1939	1941	O
the	1942	1945	O
abscess	1946	1953	B-Multi-tissue_structure
walls	1954	1959	I-Multi-tissue_structure
of	1960	1962	O
sterile	1963	1970	O
and	1971	1974	O
septic	1975	1981	O
animals	1982	1989	O
,	1989	1990	O
respectively	1991	2003	O
.	2003	2004	O

The	2005	2008	O
data	2009	2013	O
suggest	2014	2021	O
that	2022	2026	O
an	2027	2029	O
intra	2030	2035	O
-	2035	2036	O
abdominal	2036	2045	B-Pathological_formation
abscess	2046	2053	I-Pathological_formation
,	2053	2054	O
especially	2055	2065	O
when	2066	2070	O
contaminated	2071	2083	O
with	2084	2088	O
gram	2089	2093	O
-	2093	2094	O
negative	2094	2102	O
bacteria	2103	2111	O
,	2111	2112	O
induces	2113	2120	O
mRNA	2121	2125	O
-	2125	2126	O
generated	2126	2135	O
cytokine	2136	2144	O
responses	2145	2154	O
in	2155	2157	O
the	2158	2161	O
abscess	2162	2169	B-Multi-tissue_structure
wall	2170	2174	I-Multi-tissue_structure
that	2175	2179	O
are	2180	2183	O
related	2184	2191	O
to	2192	2194	O
increased	2195	2204	O
portal	2205	2211	B-Multi-tissue_structure
venous	2212	2218	I-Multi-tissue_structure
levels	2219	2225	O
of	2226	2228	O
the	2229	2232	O
inflammatory	2233	2245	O
cytokines	2246	2255	O
TNF	2256	2259	O
-	2259	2260	O
alpha	2260	2265	O
,	2265	2266	O
IL	2267	2269	O
-	2269	2270	O
1beta	2270	2275	O
,	2275	2276	O
and	2277	2280	O
IL	2281	2283	O
-	2283	2284	O
6	2284	2285	O
perfusing	2286	2295	O
the	2296	2299	O
liver	2300	2305	B-Organ
.	2305	2306	O

These	2307	2312	O
,	2312	2313	O
in	2314	2316	O
turn	2317	2321	O
,	2321	2322	O
induce	2323	2329	O
localized	2330	2339	O
production	2340	2350	O
of	2351	2353	O
IL	2354	2356	O
-	2356	2357	O
6	2357	2358	O
and	2359	2362	O
fibrinogen	2363	2373	O
mRNAs	2374	2379	O
in	2380	2382	O
cells	2383	2388	B-Cell
at	2389	2391	O
the	2392	2395	O
central	2396	2403	B-Multi-tissue_structure
vein	2404	2408	I-Multi-tissue_structure
area	2409	2413	O
with	2414	2418	O
resultant	2419	2428	O
outflow	2429	2436	O
fibrosis	2437	2445	O
and	2446	2449	O
increased	2450	2459	O
inflammatory	2460	2472	B-Cell
cell	2473	2477	I-Cell
sequestration	2478	2491	O
within	2492	2498	O
the	2499	2502	O
liver	2503	2508	B-Multi-tissue_structure
lobular	2509	2516	I-Multi-tissue_structure
sinuses	2517	2524	I-Multi-tissue_structure
.	2524	2525	O

This	2526	2530	O
is	2531	2533	O
associated	2534	2544	O
with	2545	2549	O
a	2550	2551	O
generalized	2552	2563	O
inflammatory	2564	2576	O
response	2577	2585	O
and	2586	2589	O
intrahepatic	2590	2602	O
portal	2603	2609	O
sinusoid	2610	2618	O
congestion	2619	2629	O
.	2629	2630	O

There	2631	2636	O
is	2637	2639	O
also	2640	2644	O
increased	2645	2654	O
hepatocellular	2655	2669	B-Cell
lipid	2670	2675	O
deposition	2676	2686	O
and	2687	2690	O
apoptosis	2691	2700	O
.	2700	2701	O

Thus	2702	2706	O
,	2706	2707	O
the	2708	2711	O
cytokine	2712	2720	O
production	2721	2731	O
of	2732	2734	O
the	2735	2738	O
abscess	2739	2746	B-Multi-tissue_structure
wall	2747	2751	I-Multi-tissue_structure
itself	2752	2758	O
appears	2759	2766	O
to	2767	2769	O
be	2770	2772	O
a	2773	2774	O
major	2775	2780	O
mediator	2781	2789	O
of	2790	2792	O
the	2793	2796	O
septic	2797	2803	B-Organ
hepatic	2804	2811	I-Organ
response	2812	2820	O
.	2820	2821	O

Treatment	0	9	O
effects	10	17	O
on	18	20	O
nigrostriatal	21	34	B-Multi-tissue_structure
projection	35	45	O
integrity	46	55	O
in	56	58	O
partial	59	66	O
6	67	68	O
-	68	69	O
OHDA	69	73	O
lesions	74	81	B-Pathological_formation
:	81	82	O
comparison	83	93	O
of	94	96	O
L	97	98	O
-	98	99	O
DOPA	99	103	O
and	104	107	O
pramipexole	108	119	O
.	119	120	O

There	121	126	O
is	127	129	O
controversy	130	141	O
over	142	146	O
potential	147	156	O
effects	157	164	O
of	165	167	O
dopaminergic	168	180	O
replacement	181	192	O
therapies	193	202	O
on	203	205	O
the	206	209	O
partially	210	219	O
lesioned	220	228	B-Multi-tissue_structure
nigrostriatal	229	242	I-Multi-tissue_structure
dopaminergic	243	255	O
projection	256	266	O
.	266	267	O

We	268	270	O
evaluated	271	280	O
indirect	281	289	O
(	290	291	O
levodopa	291	299	O
,	299	300	O
L	301	302	O
-	302	303	O
DOPA	303	307	O
)	307	308	O
versus	309	315	O
direct	316	322	O
(	323	324	O
pramipexole	324	335	O
,	335	336	O
PRA	337	340	O
)	340	341	O
dopaminergic	342	354	O
treatment	355	364	O
effects	365	372	O
on	373	375	O
nigrostriatal	376	389	B-Pathological_formation
lesion	390	396	I-Pathological_formation
severity	397	405	O
as	406	408	O
measured	409	417	O
with	418	422	O
vesicular	423	432	O
monoamine	433	442	O
transporter	443	454	O
type	455	459	O
-	459	460	O
2	460	461	O
(	462	463	O
VMAT2	463	468	O
)	468	469	O
binding	470	477	O
.	477	478	O

Prior	479	484	O
studies	485	492	O
have	493	497	O
shown	498	503	O
that	504	508	O
striatal	509	517	B-Multi-tissue_structure
VMAT2	518	523	O
density	524	531	O
provides	532	540	O
an	541	543	O
objective	544	553	O
estimate	554	562	O
of	563	565	O
dopaminergic	566	578	O
neuronal	579	587	B-Cell
integrity	588	597	O
,	597	598	O
without	599	606	O
confounding	607	618	O
effects	619	626	O
of	627	629	O
compensatory	630	642	O
regulation	643	653	O
.	653	654	O

Partial	655	662	O
unilateral	663	673	B-Multi-tissue_structure
median	674	680	I-Multi-tissue_structure
forebrain	681	690	I-Multi-tissue_structure
bundle	691	697	I-Multi-tissue_structure
lesions	698	705	I-Multi-tissue_structure
were	706	710	O
made	711	715	O
by	716	718	O
injection	719	728	O
of	729	731	O
6	732	733	O
-	733	734	O
hydroxydopamine	734	749	O
in	750	752	O
adult	753	758	O
male	759	763	O
Sprague	764	771	O
-	771	772	O
Dawley	772	778	O
rats	779	783	O
.	783	784	O

Lesion	785	791	B-Pathological_formation
severity	792	800	O
was	801	804	O
estimated	805	814	O
using	815	820	O
rotational	821	831	O
behavior	832	840	O
after	841	846	O
injections	847	857	O
of	858	860	O
apomorphine	861	872	O
and	873	876	O
amphetamine	877	888	O
.	888	889	O

Rats	890	894	O
were	895	899	O
ranked	900	906	O
and	907	910	O
matched	911	918	O
in	919	921	O
pairs	922	927	O
by	928	930	O
rotation	931	939	O
and	940	943	O
assigned	944	952	O
to	953	955	O
receive	956	963	O
either	964	970	O
PRA	971	974	O
(	975	976	O
1	976	977	O
mg	978	980	O
/	980	981	O
kg	981	983	O
/	983	984	O
day	984	987	O
)	987	988	O
or	989	991	O
L	992	993	O
-	993	994	O
DOPA	994	998	O
/	998	999	O
benserazide	999	1010	O
(	1011	1012	O
100	1012	1015	O
/	1015	1016	O
25	1016	1018	O
mg	1019	1021	O
/	1021	1022	O
kg	1022	1024	O
/	1024	1025	O
day	1025	1028	O
)	1028	1029	O
ip	1030	1032	O
via	1033	1036	O
osmotic	1037	1044	O
pump	1045	1049	O
.	1049	1050	O

After	1051	1056	O
4	1057	1058	O
weeks	1059	1064	O
of	1065	1067	O
drug	1068	1072	O
treatment	1073	1082	O
,	1082	1083	O
in	1084	1086	O
vitro	1087	1092	O
autoradiography	1093	1108	O
was	1109	1112	O
performed	1113	1122	O
with	1123	1127	O
[	1128	1129	O
(	1129	1130	O
3	1130	1131	O
)	1131	1132	O
H	1132	1133	O
]	1133	1134	O
methoxytetrabenazine	1134	1154	O
to	1155	1157	O
measure	1158	1165	O
striatal	1166	1174	B-Multi-tissue_structure
VMAT2	1175	1180	O
binding	1181	1188	O
density	1189	1196	O
.	1196	1197	O

Lesion	1198	1204	B-Pathological_formation
-	1204	1205	O
to	1205	1207	O
-	1207	1208	O
intact	1208	1214	O
VMAT2	1215	1220	O
density	1221	1228	O
correlated	1229	1239	O
with	1240	1244	O
rotation	1245	1253	O
in	1254	1256	O
both	1257	1261	O
treatment	1262	1271	O
groups	1272	1278	O
.	1278	1279	O

There	1280	1285	O
was	1286	1289	O
no	1290	1292	O
treatment	1293	1302	O
effect	1303	1309	O
on	1310	1312	O
VMAT2	1313	1318	O
expression	1319	1329	O
in	1330	1332	O
the	1333	1336	O
partially	1337	1346	O
lesioned	1347	1355	B-Multi-tissue_structure
striatum	1356	1364	I-Multi-tissue_structure
and	1365	1368	O
thus	1369	1373	O
no	1374	1376	O
differential	1377	1389	O
effect	1390	1396	O
of	1397	1399	O
indirect	1400	1408	O
versus	1409	1415	O
direct	1416	1422	O
dopamimetic	1423	1434	O
treatment	1435	1444	O
on	1445	1447	O
nigrostriatal	1448	1461	B-Multi-tissue_structure
integrity	1462	1471	O
.	1471	1472	O

Neutrophil	0	10	B-Cell
function	11	19	O
in	20	22	O
chronic	23	30	O
neutrophilic	31	43	B-Cell
leukemia	44	52	O
:	52	53	O
defective	54	63	O
respiratory	64	75	B-Anatomical_system
burst	76	81	O
in	82	84	O
response	85	93	O
to	94	96	O
phorbol	97	104	O
esters	105	111	O
.	111	112	O

Functional	113	123	O
analyses	124	132	O
were	133	137	O
performed	138	147	O
on	148	150	O
neutrophils	151	162	B-Cell
isolated	163	171	O
from	172	176	O
6	177	178	O
patients	179	187	O
from	188	192	O
two	193	196	O
institutions	197	209	O
who	210	213	O
displayed	214	223	O
features	224	232	O
of	233	235	O
chronic	236	243	O
neutrophilic	244	256	B-Cell
leukemia	257	265	O
(	266	267	O
CNL	267	270	O
)	270	271	O
.	271	272	O

These	273	278	O
neutrophils	279	290	B-Cell
demonstrated	291	303	O
a	304	305	O
consistent	306	316	O
deficiency	317	327	O
(	328	329	O
44	329	331	O
+	332	333	O
/	333	334	O
-	334	335	O
8	336	337	O
%	337	338	O
of	339	341	O
control	342	349	O
values	350	356	O
)	356	357	O
in	358	360	O
superoxide	361	371	O
anion	372	377	O
(	378	379	O
O2	379	381	O
-	381	382	O
)	382	383	O
production	384	394	O
in	395	397	O
response	398	406	O
to	407	409	O
the	410	413	O
phorbol	414	421	O
ester	422	427	O
,	427	428	O
phorbol	429	436	O
myristate	437	446	O
acetate	447	454	O
(	455	456	O
PMA	456	459	O
)	459	460	O
.	460	461	O

O2	462	464	O
-	464	465	O
production	466	476	O
in	477	479	O
response	480	488	O
to	489	491	O
chemotactic	492	503	O
peptides	504	512	O
was	513	516	O
near	517	521	O
normal	522	528	O
(	529	530	O
82	530	532	O
.	532	533	O
3	533	534	O
+	535	536	O
/	536	537	O
-	537	538	O
10	539	541	O
.	541	542	O
7	542	543	O
%	543	544	O
of	545	547	O
control	548	555	O
values	556	562	O
)	562	563	O
.	563	564	O

Bacterial	565	574	O
killing	575	582	O
was	583	586	O
normal	587	593	O
in	594	596	O
the	597	600	O
two	601	604	O
patients	605	613	O
studied	614	621	O
,	621	622	O
and	623	626	O
chemotaxis	627	637	O
was	638	641	O
diminished	642	652	O
in	653	655	O
response	656	664	O
to	665	667	O
zymosan	668	675	O
-	675	676	O
activated	676	685	O
plasma	686	692	B-Organism_substance
and	693	696	O
to	697	699	O
high	700	704	O
concentrations	705	719	O
of	720	722	O
chemotactic	723	734	O
peptides	735	743	O
in	744	746	O
the	747	750	O
patients	751	759	O
studied	760	767	O
.	767	768	O

Cytosolic	769	778	O
C	779	780	O
kinase	781	787	O
activity	788	796	O
was	797	800	O
decreased	801	810	O
in	811	813	O
one	814	817	O
of	818	820	O
the	821	824	O
two	825	828	O
patients	829	837	O
studied	838	845	O
.	845	846	O

These	847	852	O
results	853	860	O
suggest	861	868	O
that	869	873	O
a	874	875	O
deficient	876	885	O
O2	886	888	O
-	888	889	O
release	890	897	O
in	898	900	O
response	901	909	O
to	910	912	O
PMA	913	916	O
is	917	919	O
a	920	921	O
hallmark	922	930	O
of	931	933	O
neutrophils	934	945	B-Cell
in	946	948	O
CNL	949	952	O
and	953	956	O
may	957	960	O
provide	961	968	O
a	969	970	O
diagnostic	971	981	O
indicator	982	991	O
of	992	994	O
this	995	999	O
condition	1000	1009	O
.	1009	1010	O

In	0	2	O
situ	3	7	O
alkylation	8	18	O
of	19	21	O
cysteine	22	30	O
residues	31	39	O
in	40	42	O
a	43	44	O
hydrophobic	45	56	O
membrane	57	65	B-Cellular_component
protein	66	73	O
immobilized	74	85	O
on	86	88	O
polyvinylidene	89	103	O
difluoride	104	114	O
membranes	115	124	O
by	125	127	O
electroblotting	128	143	O
prior	144	149	O
to	150	152	O
microsequence	153	166	O
and	167	170	O
amino	171	176	O
acid	177	181	O
analysis	182	190	O
.	190	191	O

For	192	195	O
identification	196	210	O
of	211	213	O
cysteine	214	222	O
residues	223	231	O
on	232	234	O
microsequence	235	248	O
analysis	249	257	O
it	258	260	O
is	261	263	O
crucial	264	271	O
to	272	274	O
derivatize	275	285	O
the	286	289	O
sulfhydryl	290	300	O
groups	301	307	O
.	307	308	O

This	309	313	O
reaction	314	322	O
requires	323	331	O
a	332	333	O
desalting	334	343	O
step	344	348	O
which	349	354	O
often	355	360	O
represents	361	371	O
a	372	373	O
major	374	379	O
obstacle	380	388	O
,	388	389	O
especially	390	400	O
if	401	403	O
the	404	407	O
sample	408	414	O
consists	415	423	O
of	424	426	O
limited	427	434	O
amounts	435	442	O
of	443	445	O
a	446	447	O
hydrophobic	448	459	O
membrane	460	468	B-Cellular_component
protein	469	476	O
.	476	477	O

An	478	480	O
alkylation	481	491	O
procedure	492	501	O
is	502	504	O
described	505	514	O
,	514	515	O
allowing	516	524	O
efficient	525	534	O
derivatization	535	549	O
(	550	551	O
greater	551	558	O
than	559	563	O
90	564	566	O
%	566	567	O
)	567	568	O
of	569	571	O
cysteines	572	581	O
and	582	585	O
cystines	586	594	O
even	595	599	O
in	600	602	O
low	603	606	O
microgram	607	616	O
quantities	617	627	O
,	627	628	O
as	629	631	O
revealed	632	640	O
by	641	643	O
test	644	648	O
analyses	649	657	O
with	658	662	O
lysozyme	663	671	O
and	672	675	O
a	676	677	O
hydrophobic	678	689	O
membrane	690	698	B-Cellular_component
protein	699	706	O
.	706	707	O

The	708	711	O
modified	712	720	O
protein	721	728	O
is	729	731	O
recovered	732	741	O
in	742	744	O
high	745	749	O
yields	750	756	O
in	757	759	O
a	760	761	O
form	762	766	O
suitable	767	775	O
for	776	779	O
both	780	784	O
microsequence	785	798	O
analysis	799	807	O
and	808	811	O
amino	812	817	O
acid	818	822	O
analysis	823	831	O
.	831	832	O

The	833	836	O
method	837	843	O
involves	844	852	O
electrophoretic	853	868	O
desalting	869	878	O
by	879	881	O
miniaturized	882	894	O
Tricine	895	902	O
-	902	903	O
sodium	903	909	O
dodecyl	910	917	O
sulfate	918	925	O
-	925	926	O
polyacrylamide	926	940	O
gel	941	944	O
electrophoresis	945	960	O
and	961	964	O
in	965	967	O
situ	968	972	O
alkylation	973	983	O
after	984	989	O
electro	990	997	O
-	997	998	O
transfer	998	1006	O
onto	1007	1011	O
polyvinylidene	1012	1026	O
difluoride	1027	1037	O
membranes	1038	1047	O
.	1047	1048	O

Precautions	1049	1060	O
against	1061	1068	O
NH2	1069	1072	O
-	1072	1073	O
terminal	1073	1081	O
blocking	1082	1090	O
during	1091	1097	O
sample	1098	1104	O
preparations	1105	1117	O
are	1118	1121	O
provided	1122	1130	O
.	1130	1131	O

The	1132	1135	O
general	1136	1143	O
applicability	1144	1157	O
of	1158	1160	O
the	1161	1164	O
method	1165	1171	O
is	1172	1174	O
illustrated	1175	1186	O
by	1187	1189	O
the	1190	1193	O
structural	1194	1204	O
characterization	1205	1221	O
of	1222	1224	O
the	1225	1228	O
low	1229	1232	O
abundance	1233	1242	O
membrane	1243	1251	B-Cellular_component
receptor	1252	1260	O
for	1261	1264	O
human	1265	1270	O
urokinase	1271	1280	O
plasminogen	1281	1292	O
activator	1293	1302	O
.	1302	1303	O

The	0	3	O
effect	4	10	O
of	11	13	O
p	14	15	O
-	15	16	O
chlorophenylalanine	16	35	O
on	36	38	O
the	39	42	O
pethidine	43	52	O
-	52	53	O
or	54	56	O
methadone	57	66	O
-	66	67	O
induced	67	74	O
decrease	75	83	O
in	84	86	O
locomotor	87	96	O
activity	97	105	O
of	106	108	O
rats	109	113	O
.	113	114	O

Either	115	121	O
pethidine	122	131	O
HCl	132	135	O
(	136	137	O
50	137	139	O
mg	140	142	O
/	142	143	O
kg	143	145	O
s	146	147	O
.	147	148	O
c	148	149	O
.	149	150	O
)	150	151	O
or	152	154	O
methadone	155	164	O
HCl	165	168	O
(	169	170	O
8	170	171	O
mg	172	174	O
/	174	175	O
kg	175	177	O
s	178	179	O
.	179	180	O
c	180	181	O
.	181	182	O
)	182	183	O
produced	184	192	O
a	193	194	O
prominent	195	204	O
decrease	205	213	O
in	214	216	O
locomotor	217	226	O
activity	227	235	O
of	236	238	O
rats	239	243	O
.	243	244	O

Pretreatment	245	257	O
of	258	260	O
rats	261	265	O
with	266	270	O
p	271	272	O
-	272	273	O
chlorophenylalanine	273	292	O
(	293	294	O
p	294	295	O
-	295	296	O
CPA	296	299	O
,	299	300	O
320	301	304	O
mg	305	307	O
/	307	308	O
kg	308	310	O
i	311	312	O
.	312	313	O
p	313	314	O
.	314	315	O
)	315	316	O
48	317	319	O
h	320	321	O
before	322	328	O
the	329	332	O
narcotic	333	341	O
injection	342	351	O
significantly	352	365	O
antagonized	366	377	O
the	378	381	O
activity	382	390	O
-	390	391	O
decreasing	391	401	O
effects	402	409	O
of	410	412	O
narcotics	413	422	O
.	422	423	O

When	424	428	O
rats	429	433	O
pretreated	434	444	O
with	445	449	O
p	450	451	O
-	451	452	O
CPA	452	455	O
were	456	460	O
given	461	466	O
5	467	468	O
-	468	469	O
hydroxytryptophan	469	486	O
(	487	488	O
75	488	490	O
mg	491	493	O
/	493	494	O
kg	494	496	O
s	497	498	O
.	498	499	O
c	499	500	O
.	500	501	O
)	501	502	O
30	503	505	O
min	506	509	O
before	510	516	O
narcotic	517	525	O
administration	526	540	O
,	540	541	O
the	542	545	O
activity	546	554	O
-	554	555	O
decreasing	555	565	O
response	566	574	O
to	575	577	O
narcotics	578	587	O
was	588	591	O
restored	592	600	O
.	600	601	O

Thus	602	606	O
,	606	607	O
a	608	609	O
decrease	610	618	O
in	619	621	O
locomotor	622	631	O
activity	632	640	O
induced	641	648	O
in	649	651	O
rats	652	656	O
by	657	659	O
either	660	666	O
pethidine	667	676	O
or	677	679	O
methadone	680	689	O
is	690	692	O
probably	693	701	O
mediated	702	710	O
by	711	713	O
serotonergic	714	726	O
mechanisms	727	737	O
.	737	738	O

The	0	3	O
presence	4	12	O
of	13	15	O
nitrite	16	23	O
during	24	30	O
UVA	31	34	O
irradiation	35	46	O
protects	47	55	O
from	56	60	O
apoptosis	61	70	O
.	70	71	O

Nitrite	72	79	O
occurs	80	86	O
ubiquitously	87	99	O
in	100	102	O
biological	103	113	B-Organism_substance
fluids	114	120	I-Organism_substance
such	121	125	O
as	126	128	O
blood	129	134	B-Organism_substance
and	135	138	O
sweat	139	144	B-Organism_substance
,	144	145	O
representing	146	158	O
an	159	161	O
oxidation	162	171	O
product	172	179	O
of	180	182	O
nitric	183	189	O
oxide	190	195	O
.	195	196	O

Nitrite	197	204	O
has	205	208	O
been	209	213	O
associated	214	224	O
with	225	229	O
a	230	231	O
variety	232	239	O
of	240	242	O
adverse	243	250	O
effects	251	258	O
such	259	263	O
as	264	266	O
mutagenicity	267	279	O
,	279	280	O
carcinogenesis	281	295	O
,	295	296	O
and	297	300	O
toxicity	301	309	O
.	309	310	O

In	311	313	O
contrast	314	322	O
,	322	323	O
here	324	328	O
we	329	331	O
demonstrate	332	343	O
that	344	348	O
the	349	352	O
presence	353	361	O
of	362	364	O
nitrite	365	372	O
,	372	373	O
but	374	377	O
not	378	381	O
nitrate	382	389	O
,	389	390	O
during	391	397	O
irradiation	398	409	O
of	410	412	O
endothelial	413	424	B-Cell
cells	425	430	I-Cell
in	431	433	O
culture	434	441	O
exerts	442	448	O
a	449	450	O
potent	451	457	O
and	458	461	O
concentration	462	475	O
-	475	476	O
dependent	476	485	O
protection	486	496	O
against	497	504	O
UVA	505	508	O
-	508	509	O
induced	509	516	O
apoptotic	517	526	O
cell	527	531	B-Cell
death	532	537	O
.	537	538	O

Protection	539	549	O
is	550	552	O
half	553	557	O
-	557	558	O
maximal	558	565	O
at	566	568	O
a	569	570	O
concentration	571	584	O
of	585	587	O
3	588	589	O
mM	590	592	O
,	592	593	O
and	594	597	O
complete	598	606	O
rescue	607	613	O
is	614	616	O
observed	617	625	O
at	626	628	O
10	629	631	O
mM	632	634	O
.	634	635	O

Nitrite	636	643	O
-	643	644	O
mediated	644	652	O
protection	653	663	O
is	664	666	O
mediated	667	675	O
via	676	679	O
inhibition	680	690	O
of	691	693	O
lipid	694	699	O
peroxidation	700	712	O
in	713	715	O
a	716	717	O
similar	718	725	O
manner	726	732	O
as	733	735	O
seen	736	740	O
with	741	745	O
butylated	746	755	O
hydroxytoluene	756	770	O
,	770	771	O
a	772	773	O
known	774	779	O
inhibitor	780	789	O
of	790	792	O
lipid	793	798	O
peroxidation	799	811	O
.	811	812	O

Interestingly	813	826	O
,	826	827	O
nitrite	828	835	O
-	835	836	O
mediated	836	844	O
protection	845	855	O
is	856	858	O
completely	859	869	O
abolished	870	879	O
by	880	882	O
coincubation	883	895	O
with	896	900	O
the	901	904	O
NO	905	907	O
scavenger	908	917	O
cPTIO	918	923	O
.	923	924	O

Using	925	930	O
electron	931	939	O
paramagnetic	940	952	O
resonance	953	962	O
(	963	964	O
EPR	964	967	O
)	967	968	O
spectroscopy	969	981	O
or	982	984	O
Faraday	985	992	O
modulation	993	1003	O
spectroscopy	1004	1016	O
,	1016	1017	O
we	1018	1020	O
directly	1021	1029	O
prove	1030	1035	O
UVA	1036	1039	O
-	1039	1040	O
induced	1040	1047	O
NO	1048	1050	O
formation	1051	1060	O
in	1061	1063	O
solutions	1064	1073	O
containing	1074	1084	O
nitrite	1085	1092	O
.	1092	1093	O

In	1094	1096	O
conclusion	1097	1107	O
,	1107	1108	O
evidence	1109	1117	O
is	1118	1120	O
presented	1121	1130	O
that	1131	1135	O
nitrite	1136	1143	O
represents	1144	1154	O
a	1155	1156	O
protective	1157	1167	O
agent	1168	1173	O
against	1174	1181	O
UVA	1182	1185	O
-	1185	1186	O
induced	1186	1193	O
apoptosis	1194	1203	O
due	1204	1207	O
to	1208	1210	O
photodecomposition	1211	1229	O
of	1230	1232	O
nitrite	1233	1240	O
and	1241	1244	O
subsequent	1245	1255	O
formation	1256	1265	O
of	1266	1268	O
NO	1269	1271	O
.	1271	1272	O

Induction	0	9	O
of	10	12	O
apoptosis	13	22	O
in	23	25	O
skeletal	26	34	B-Tissue
tissues	35	42	I-Tissue
:	42	43	O
phosphate	44	53	O
-	53	54	O
mediated	54	62	O
chick	63	68	O
chondrocyte	69	80	B-Cell
apoptosis	81	90	O
is	91	93	O
calcium	94	101	O
dependent	102	111	O
.	111	112	O

In	113	115	O
an	116	118	O
earlier	119	126	O
study	127	132	O
,	132	133	O
we	134	136	O
have	137	141	O
shown	142	147	O
that	148	152	O
Pi	153	155	O
induced	156	163	O
apoptosis	164	173	O
of	174	176	O
terminally	177	187	O
differentiated	188	202	O
hypertrophic	203	215	O
chondrocytes	216	228	B-Cell
.	228	229	O

To	230	232	O
ascertain	233	242	O
whether	243	250	O
Ca2	251	254	O
+	254	255	O
modulates	256	265	O
Pi	266	268	O
-	268	269	O
induced	269	276	O
cell	277	281	B-Cell
death	282	287	O
,	287	288	O
we	289	291	O
asked	292	297	O
the	298	301	O
following	302	311	O
two	312	315	O
questions	316	325	O
:	325	326	O
First	327	332	O
,	332	333	O
can	334	337	O
we	338	340	O
prevent	341	348	O
Pi	349	351	O
-	351	352	O
induced	352	359	O
apoptosis	360	369	O
by	370	372	O
removing	373	381	O
Ca2	382	385	O
+	385	386	O
from	387	391	O
the	392	395	O
culture	396	403	O
medium	404	410	O
;	410	411	O
alternatively	412	425	O
,	425	426	O
can	427	430	O
we	431	433	O
potentiate	434	444	O
cell	445	449	B-Cell
death	450	455	O
by	456	458	O
increasing	459	469	O
the	470	473	O
Ca2	474	477	O
+	477	478	O
concentration	479	492	O
?	492	493	O

Second	494	500	O
,	500	501	O
can	502	505	O
we	506	508	O
inhibit	509	516	O
chondrocyte	517	528	B-Cell
apoptosis	529	538	O
by	539	541	O
blocking	542	550	O
Pi	551	553	O
transport	554	563	O
?	563	564	O

We	565	567	O
also	568	572	O
explored	573	581	O
the	582	585	O
mechanism	586	595	O
of	596	598	O
apoptosis	599	608	O
by	609	611	O
evaluating	612	622	O
mitochondrial	623	636	B-Cellular_component
activity	637	645	O
and	646	649	O
reactive	650	658	O
oxygen	659	665	O
species	666	673	O
(	674	675	O
ROS	675	678	O
)	678	679	O
generation	680	690	O
in	691	693	O
cells	694	699	B-Cell
treated	700	707	O
with	708	712	O
the	713	716	O
ion	717	720	O
pair	721	725	O
.	725	726	O

We	727	729	O
noted	730	735	O
that	736	740	O
EDTA	741	745	O
and	746	749	O
EGTA	750	754	O
blocked	755	762	O
Pi	763	765	O
-	765	766	O
induced	766	773	O
apoptosis	774	783	O
in	784	786	O
a	787	788	O
dose	789	793	O
-	793	794	O
dependent	794	803	O
manner	804	810	O
.	810	811	O

While	812	817	O
high	818	822	O
levels	823	829	O
of	830	832	O
Ca2	833	836	O
+	836	837	O
alone	838	843	O
had	844	847	O
little	848	854	O
effect	855	861	O
on	862	864	O
chondrocyte	865	876	B-Cell
viability	877	886	O
,	886	887	O
the	888	891	O
cation	892	898	O
enhanced	899	907	O
Pi	908	910	O
-	910	911	O
dependent	911	920	O
cell	921	925	B-Cell
death	926	931	O
and	932	935	O
greatly	936	943	O
increased	944	953	O
Pi	954	956	O
uptake	957	963	O
.	963	964	O

When	965	969	O
Pi	970	972	O
transport	973	982	O
was	983	986	O
blocked	987	994	O
,	994	995	O
there	996	1001	O
was	1002	1005	O
complete	1006	1014	O
inhibition	1015	1025	O
of	1026	1028	O
cell	1029	1033	B-Cell
killing	1034	1041	O
.	1041	1042	O

The	1043	1046	O
process	1047	1054	O
of	1055	1057	O
cell	1058	1062	B-Cell
death	1063	1068	O
was	1069	1072	O
characterized	1073	1086	O
by	1087	1089	O
mitochondrial	1090	1103	B-Cellular_component
hyperpolarization	1104	1121	O
;	1121	1122	O
two	1123	1126	O
hours	1127	1132	O
following	1133	1142	O
apoptogen	1143	1152	O
treatment	1153	1162	O
,	1162	1163	O
there	1164	1169	O
was	1170	1173	O
a	1174	1175	O
significant	1176	1187	O
decrease	1188	1196	O
in	1197	1199	O
the	1200	1203	O
mitochondrial	1204	1217	B-Cellular_component
membrane	1218	1226	I-Cellular_component
potential	1227	1236	O
.	1236	1237	O

Coincident	1238	1248	O
with	1249	1253	O
the	1254	1257	O
changes	1258	1265	O
in	1266	1268	O
mitochondrial	1269	1282	B-Cellular_component
function	1283	1291	O
,	1291	1292	O
there	1293	1298	O
was	1299	1302	O
an	1303	1305	O
increase	1306	1314	O
in	1315	1317	O
intracellular	1318	1331	B-Immaterial_anatomical_entity
Ca2	1332	1335	O
+	1335	1336	O
that	1337	1341	O
was	1342	1345	O
maintained	1346	1356	O
throughout	1357	1367	O
the	1368	1371	O
experimental	1372	1384	O
period	1385	1391	O
.	1391	1392	O

A	1393	1394	O
raised	1395	1401	O
Ca2	1402	1405	O
+	1405	1406	O
signal	1407	1413	O
was	1414	1417	O
observed	1418	1426	O
in	1427	1429	O
blebs	1430	1435	O
at	1436	1438	O
the	1439	1442	O
cell	1443	1447	B-Cellular_component
membrane	1448	1456	I-Cellular_component
.	1456	1457	O

Finally	1458	1465	O
,	1465	1466	O
we	1467	1469	O
noted	1470	1475	O
that	1476	1480	O
,	1480	1481	O
75	1482	1484	O
minutes	1485	1492	O
after	1493	1498	O
treatment	1499	1508	O
with	1509	1513	O
the	1514	1517	O
ion	1518	1521	O
pair	1522	1526	O
,	1526	1527	O
there	1528	1533	O
was	1534	1537	O
a	1538	1539	O
six	1540	1543	O
-	1543	1544	O
fold	1544	1548	O
elevation	1549	1558	O
in	1559	1561	O
ROS	1562	1565	O
levels	1566	1572	O
.	1572	1573	O

This	1574	1578	O
increase	1579	1587	O
declined	1588	1596	O
to	1597	1599	O
baseline	1600	1608	O
values	1609	1615	O
after	1616	1621	O
three	1622	1627	O
hours	1628	1633	O
.	1633	1634	O

Based	1635	1640	O
on	1641	1643	O
these	1644	1649	O
observations	1650	1662	O
,	1662	1663	O
we	1664	1666	O
suggest	1667	1674	O
that	1675	1679	O
,	1679	1680	O
at	1681	1683	O
the	1684	1687	O
cartilage	1688	1697	B-Tissue
mineralization	1698	1712	O
front	1713	1718	O
,	1718	1719	O
an	1720	1722	O
elevation	1723	1732	O
in	1733	1735	O
local	1736	1741	O
environmental	1742	1755	O
Ca2	1756	1759	O
+	1759	1760	O
and	1761	1764	O
Pi	1765	1767	O
concentrations	1768	1782	O
modulates	1783	1792	O
oxidative	1793	1802	O
metabolism	1803	1813	O
,	1813	1814	O
and	1815	1818	O
triggers	1819	1827	O
apoptosis	1828	1837	O
of	1838	1840	O
terminally	1841	1851	O
differentiated	1852	1866	O
chondrocytes	1867	1879	B-Cell
.	1879	1880	O

Outcomes	0	8	O
of	9	11	O
cefazolin	12	21	O
versus	22	28	O
ceftriaxone	29	40	O
therapy	41	48	O
in	49	51	O
treating	52	60	O
lower	61	66	B-Multi-tissue_structure
respiratory	67	78	I-Multi-tissue_structure
tract	79	84	I-Multi-tissue_structure
infections	85	95	O
in	96	98	O
adults	99	105	O
.	105	106	O

OBJECTIVE	107	116	O
:	116	117	O

To	118	120	O
determine	121	130	O
whether	131	138	O
choice	139	145	O
of	146	148	O
a	149	150	O
first	151	156	O
-	156	157	O
versus	158	164	O
third	165	170	O
-	170	171	O
generation	171	181	O
cephalosporin	182	195	O
as	196	198	O
initial	199	206	O
therapy	207	214	O
for	215	218	O
lower	219	224	B-Multi-tissue_structure
respiratory	225	236	I-Multi-tissue_structure
tract	237	242	I-Multi-tissue_structure
infections	243	253	O
in	254	256	O
hospitalized	257	269	O
adults	270	276	O
affects	277	284	O
the	285	288	O
course	289	295	O
and	296	299	O
duration	300	308	O
of	309	311	O
care	312	316	O
,	316	317	O
both	318	322	O
of	323	325	O
which	326	331	O
may	332	335	O
influence	336	345	O
antimicrobial	346	359	O
treatment	360	369	O
cost	370	374	O
.	374	375	O

DESIGN	376	382	O
:	382	383	O

Retrospective	384	397	O
analysis	398	406	O
of	407	409	O
discharge	410	419	O
abstracts	420	429	O
and	430	433	O
hospital	434	442	O
pharmacy	443	451	O
records	452	459	O
.	459	460	O

SETTING	461	468	O
:	468	469	O

Forty	470	475	O
-	475	476	O
eight	476	481	O
US	482	484	O
acute	485	490	O
-	490	491	O
care	491	495	O
hospitals	496	505	O
.	505	506	O

PATIENTS	507	515	O
:	515	516	O

One	517	520	O
thousand	521	529	O
ninety	530	536	O
-	536	537	O
two	537	540	O
hospitalized	541	553	O
adults	554	560	O
(	561	562	O
aged	562	566	O
>	567	568	O
17	569	571	O
y	572	573	O
)	573	574	O
with	575	579	O
principal	580	589	O
diagnoses	590	599	O
of	600	602	O
lower	603	608	B-Multi-tissue_structure
respiratory	609	620	I-Multi-tissue_structure
tract	621	626	I-Multi-tissue_structure
infections	627	637	O
(	638	639	O
DRGs	639	643	O
79	644	646	O
-	646	647	O
80	647	649	O
,	649	650	O
89	651	653	O
-	653	654	O
90	654	656	O
)	656	657	O
.	657	658	O

INTERVENTIONS	659	672	O
:	672	673	O

Cefazolin	674	683	O
or	684	686	O
ceftriaxone	687	698	O
,	698	699	O
given	700	705	O
as	706	708	O
sole	709	713	O
antimicrobial	714	727	O
therapy	728	735	O
for	736	739	O
at	740	742	O
least	743	748	O
one	749	752	O
day	753	756	O
.	756	757	O

MAIN	758	762	O
OUTCOME	763	770	O
MEASURES	771	779	O
:	779	780	O

(	781	782	O
1	782	783	O
)	783	784	O
The	785	788	O
number	789	795	O
of	796	798	O
patients	799	807	O
who	808	811	O
received	812	820	O
another	821	828	O
parenteral	829	839	O
antibiotic	840	850	O
anytime	851	858	O
prior	859	864	O
to	865	867	O
hospital	868	876	O
discharge	877	886	O
;	886	887	O
(	888	889	O
2	889	890	O
)	890	891	O
the	892	895	O
number	896	902	O
of	903	905	O
days	906	910	O
during	911	917	O
which	918	923	O
patients	924	932	O
received	933	941	O
any	942	945	O
parenteral	946	956	O
antibiotic	957	967	O
while	968	973	O
in	974	976	O
the	977	980	O
hospital	981	989	O
;	989	990	O
and	991	994	O
(	995	996	O
3	996	997	O
)	997	998	O
the	999	1002	O
number	1003	1009	O
of	1010	1012	O
days	1013	1017	O
patients	1018	1026	O
remained	1027	1035	O
hospitalized	1036	1048	O
following	1049	1058	O
the	1059	1062	O
start	1063	1068	O
of	1069	1071	O
antibiotic	1072	1082	O
therapy	1083	1090	O
.	1090	1091	O

RESULTS	1092	1099	O
:	1099	1100	O

Patients	1101	1109	O
treated	1110	1117	O
with	1118	1122	O
cefazolin	1123	1132	O
(	1133	1134	O
n	1134	1135	O
=	1136	1137	O
763	1138	1141	O
)	1141	1142	O
were	1143	1147	O
more	1148	1152	O
likely	1153	1159	O
to	1160	1162	O
receive	1163	1170	O
another	1171	1178	O
parenteral	1179	1189	O
antibiotic	1190	1200	O
while	1201	1206	O
in	1207	1209	O
the	1210	1213	O
hospital	1214	1222	O
(	1223	1224	O
30	1224	1226	O
.	1226	1227	O
3	1227	1228	O
vs	1229	1231	O
.	1231	1232	O
20	1233	1235	O
.	1235	1236	O
7	1236	1237	O
percent	1238	1245	O
;	1245	1246	O
p	1247	1248	O
<	1249	1250	O
0	1251	1252	O
.	1252	1253	O
001	1253	1256	O
)	1256	1257	O
and	1258	1261	O
received	1262	1270	O
more	1271	1275	O
total	1276	1281	O
days	1282	1286	O
of	1287	1289	O
therapy	1290	1297	O
(	1298	1299	O
7	1299	1300	O
.	1300	1301	O
2	1301	1302	O
vs	1303	1305	O
.	1305	1306	O
6	1307	1308	O
.	1308	1309	O
7	1309	1310	O
d	1311	1312	O
;	1312	1313	O
p	1314	1315	O
<	1316	1317	O
0	1318	1319	O
.	1319	1320	O
05	1320	1322	O
)	1322	1323	O
than	1324	1328	O
those	1329	1334	O
treated	1335	1342	O
with	1343	1347	O
ceftriaxone	1348	1359	O
(	1360	1361	O
n	1361	1362	O
=	1363	1364	O
329	1365	1368	O
)	1368	1369	O
.	1369	1370	O

Although	1371	1379	O
the	1380	1383	O
time	1384	1388	O
to	1389	1391	O
hospital	1392	1400	O
discharge	1401	1410	O
did	1411	1414	O
not	1415	1418	O
differ	1419	1425	O
in	1426	1428	O
the	1429	1432	O
full	1433	1437	O
sample	1438	1444	O
(	1445	1446	O
9	1446	1447	O
.	1447	1448	O
2	1448	1449	O
d	1450	1451	O
for	1452	1455	O
both	1456	1460	O
groups	1461	1467	O
)	1467	1468	O
,	1468	1469	O
it	1470	1472	O
was	1473	1476	O
greater	1477	1484	O
among	1485	1490	O
those	1491	1496	O
receiving	1497	1506	O
cefazolin	1507	1516	O
(	1517	1518	O
8	1518	1519	O
.	1519	1520	O
6	1520	1521	O
vs	1522	1524	O
.	1524	1525	O
8	1526	1527	O
.	1527	1528	O
0	1528	1529	O
d	1530	1531	O
;	1531	1532	O
p	1533	1534	O
<	1535	1536	O
0	1537	1538	O
.	1538	1539	O
05	1539	1541	O
)	1541	1542	O
when	1543	1547	O
patients	1548	1556	O
with	1557	1561	O
lengths	1562	1569	O
of	1570	1572	O
stay	1573	1577	O
exceeding	1578	1587	O
24	1588	1590	O
days	1591	1595	O
were	1596	1600	O
excluded	1601	1609	O
from	1610	1614	O
both	1615	1619	O
groups	1620	1626	O
.	1626	1627	O

CONCLUSIONS	1628	1639	O
:	1639	1640	O

In	1641	1643	O
addition	1644	1652	O
to	1653	1655	O
acquisition	1656	1667	O
cost	1668	1672	O
,	1672	1673	O
differences	1674	1685	O
in	1686	1688	O
course	1689	1695	O
and	1696	1699	O
duration	1700	1708	O
of	1709	1711	O
care	1712	1716	O
should	1717	1723	O
be	1724	1726	O
considered	1727	1737	O
when	1738	1742	O
determining	1743	1754	O
the	1755	1758	O
most	1759	1763	O
cost	1764	1768	O
-	1768	1769	O
effective	1769	1778	O
choice	1779	1785	O
for	1786	1789	O
antimicrobial	1790	1803	O
therapy	1804	1811	O
.	1811	1812	O

Is	0	2	O
there	3	8	O
an	9	11	O
upper	12	17	O
limit	18	23	O
of	24	26	O
intracranial	27	39	B-Immaterial_anatomical_entity
pressure	40	48	O
in	49	51	O
patients	52	60	O
with	61	65	O
severe	66	72	O
head	73	77	B-Organism_subdivision
injury	78	84	O
if	85	87	O
cerebral	88	96	B-Organ
perfusion	97	106	O
pressure	107	115	O
is	116	118	O
maintained	119	129	O
?	129	130	O

Authors	131	138	O
of	139	141	O
recent	142	148	O
studies	149	156	O
have	157	161	O
championed	162	172	O
the	173	176	O
importance	177	187	O
of	188	190	O
maintaining	191	202	O
cerebral	203	211	B-Organ
perfusion	212	221	O
pressure	222	230	O
(	231	232	O
CPP	232	235	O
)	235	236	O
to	237	239	O
prevent	240	247	O
secondary	248	257	O
brain	258	263	B-Organ
injury	264	270	O
following	271	280	O
traumatic	281	290	O
head	291	295	B-Organism_subdivision
injury	296	302	O
.	302	303	O

Data	304	308	O
from	309	313	O
these	314	319	O
studies	320	327	O
have	328	332	O
provided	333	341	O
little	342	348	O
information	349	360	O
regarding	361	370	O
outcome	371	378	O
following	379	388	O
severe	389	395	O
head	396	400	B-Organism_subdivision
injury	401	407	O
in	408	410	O
patients	411	419	O
with	420	424	O
an	425	427	O
intracranial	428	440	B-Immaterial_anatomical_entity
pressure	441	449	O
(	450	451	O
ICP	451	454	O
)	454	455	O
greater	456	463	O
than	464	468	O
40	469	471	O
mm	472	474	O
Hg	475	477	O
,	477	478	O
however	479	486	O
,	486	487	O
in	488	490	O
July	491	495	O
1997	496	500	O
the	501	504	O
authors	505	512	O
instituted	513	523	O
a	524	525	O
protocol	526	534	O
for	535	538	O
the	539	542	O
management	543	553	O
of	554	556	O
severe	557	563	O
head	564	568	B-Organism_subdivision
injury	569	575	O
in	576	578	O
patients	579	587	O
with	588	592	O
a	593	594	O
Glasgow	595	602	O
Coma	603	607	O
Scale	608	613	O
score	614	619	O
lower	620	625	O
than	626	630	O
9	631	632	O
.	632	633	O

The	634	637	O
protocol	638	646	O
was	647	650	O
focused	651	658	O
on	659	661	O
resuscitation	662	675	O
from	676	680	O
acidosis	681	689	O
,	689	690	O
maintenance	691	702	O
of	703	705	O
a	706	707	O
CPP	708	711	O
greater	712	719	O
than	720	724	O
60	725	727	O
mm	728	730	O
Hg	731	733	O
through	734	741	O
whatever	742	750	O
means	751	756	O
necessary	757	766	O
as	767	769	O
well	770	774	O
as	775	777	O
elevation	778	787	O
of	788	790	O
the	791	794	O
head	795	799	O
of	800	802	O
the	803	806	O
bed	807	810	O
,	810	811	O
mannitol	812	820	O
infusion	821	829	O
,	829	830	O
and	831	834	O
ventriculostomy	835	850	O
with	851	855	O
cerebrospinal	856	869	B-Organism_substance
fluid	870	875	I-Organism_substance
drainage	876	884	O
for	885	888	O
control	889	896	O
of	897	899	O
ICP	900	903	O
.	903	904	O

Since	905	910	O
the	911	914	O
institution	915	926	O
of	927	929	O
this	930	934	O
protocol	935	943	O
,	943	944	O
nine	945	949	O
patients	950	958	O
had	959	962	O
a	963	964	O
sustained	965	974	O
ICP	975	978	O
greater	979	986	O
than	987	991	O
40	992	994	O
mm	995	997	O
Hg	998	1000	O
for	1001	1004	O
2	1005	1006	O
or	1007	1009	O
more	1010	1014	O
hours	1015	1020	O
,	1020	1021	O
and	1022	1025	O
five	1026	1030	O
of	1031	1033	O
these	1034	1039	O
had	1040	1043	O
an	1044	1046	O
ICP	1047	1050	O
greater	1051	1058	O
than	1059	1063	O
75	1064	1066	O
mm	1067	1069	O
Hg	1070	1072	O
on	1073	1075	O
insertion	1076	1085	O
of	1086	1088	O
the	1089	1092	O
ICP	1093	1096	O
monitor	1097	1104	O
and	1105	1108	O
later	1109	1114	O
experienced	1115	1126	O
herniation	1127	1137	O
and	1138	1141	O
expired	1142	1149	O
within	1150	1156	O
24	1157	1159	O
hours	1160	1165	O
.	1165	1166	O

Because	1167	1174	O
of	1175	1177	O
the	1178	1181	O
severe	1182	1188	O
nature	1189	1195	O
of	1196	1198	O
the	1199	1202	O
injuries	1203	1211	O
demonstrated	1212	1224	O
on	1225	1227	O
computerized	1228	1240	O
tomography	1241	1251	O
scans	1252	1257	O
and	1258	1261	O
their	1262	1267	O
physical	1268	1276	O
examinations	1277	1289	O
,	1289	1290	O
these	1291	1296	O
patients	1297	1305	O
were	1306	1310	O
not	1311	1314	O
aggressively	1315	1327	O
treated	1328	1335	O
under	1336	1341	O
this	1342	1346	O
protocol	1347	1355	O
.	1355	1356	O

The	1357	1360	O
authors	1361	1368	O
vigorously	1369	1379	O
attempted	1380	1389	O
to	1390	1392	O
maintain	1393	1401	O
a	1402	1403	O
CPP	1404	1407	O
greater	1408	1415	O
than	1416	1420	O
60	1421	1423	O
mm	1424	1426	O
Hg	1427	1429	O
with	1430	1434	O
intensive	1435	1444	O
fluid	1445	1450	B-Organism_substance
resuscitation	1451	1464	O
and	1465	1468	O
the	1469	1472	O
administration	1473	1487	O
of	1488	1490	O
pressor	1491	1498	O
agents	1499	1505	O
in	1506	1508	O
the	1509	1512	O
four	1513	1517	O
remaining	1518	1527	O
patients	1528	1536	O
who	1537	1540	O
had	1541	1544	O
developed	1545	1554	O
an	1555	1557	O
ICP	1558	1561	O
higher	1562	1568	O
than	1569	1573	O
40	1574	1576	O
mm	1577	1579	O
Hg	1580	1582	O
after	1583	1588	O
placement	1589	1598	O
of	1599	1601	O
the	1602	1605	O
ICP	1606	1609	O
monitor	1610	1617	O
.	1617	1618	O

Two	1619	1622	O
patients	1623	1631	O
had	1632	1635	O
an	1636	1638	O
episodic	1639	1647	O
ICP	1648	1651	O
greater	1652	1659	O
than	1660	1664	O
40	1665	1667	O
mm	1668	1670	O
Hg	1671	1673	O
for	1674	1677	O
more	1678	1682	O
than	1683	1687	O
36	1688	1690	O
hours	1691	1696	O
,	1696	1697	O
the	1698	1701	O
third	1702	1707	O
patient	1708	1715	O
had	1716	1719	O
an	1720	1722	O
episodic	1723	1731	O
ICP	1732	1735	O
greater	1736	1743	O
than	1744	1748	O
of	1749	1751	O
50	1752	1754	O
mm	1755	1757	O
Hg	1758	1760	O
for	1761	1764	O
more	1765	1769	O
than	1770	1774	O
36	1775	1777	O
hours	1778	1783	O
,	1783	1784	O
and	1785	1788	O
the	1789	1792	O
fourth	1793	1799	O
patient	1800	1807	O
had	1808	1811	O
an	1812	1814	O
episodic	1815	1823	O
ICP	1824	1827	O
greater	1828	1835	O
than	1836	1840	O
50	1841	1843	O
mm	1844	1846	O
Hg	1847	1849	O
for	1850	1853	O
more	1854	1858	O
than	1859	1863	O
48	1864	1866	O
hours	1867	1872	O
.	1872	1873	O

On	1874	1876	O
discharge	1877	1886	O
,	1886	1887	O
all	1888	1891	O
four	1892	1896	O
patients	1897	1905	O
were	1906	1910	O
able	1911	1915	O
to	1916	1918	O
perform	1919	1926	O
normal	1927	1933	O
activities	1934	1944	O
of	1945	1947	O
daily	1948	1953	O
living	1954	1960	O
with	1961	1965	O
minimal	1966	1973	O
assistance	1974	1984	O
and	1985	1988	O
experience	1989	1999	O
ongoing	2000	2007	O
improvement	2008	2019	O
.	2019	2020	O

Data	2021	2025	O
from	2026	2030	O
this	2031	2035	O
preliminary	2036	2047	O
study	2048	2053	O
indicate	2054	2062	O
that	2063	2067	O
intense	2068	2075	O
,	2075	2076	O
aggressive	2077	2087	O
management	2088	2098	O
of	2099	2101	O
CPP	2102	2105	O
can	2106	2109	O
lead	2110	2114	O
to	2115	2117	O
good	2118	2122	O
neurological	2123	2135	B-Anatomical_system
outcomes	2136	2144	O
despite	2145	2152	O
extremely	2153	2162	O
high	2163	2167	O
ICP	2168	2171	O
.	2171	2172	O

Aggressive	2173	2183	O
CPP	2184	2187	O
therapy	2188	2195	O
should	2196	2202	O
be	2203	2205	O
performed	2206	2215	O
and	2216	2219	O
maintained	2220	2230	O
even	2231	2235	O
though	2236	2242	O
apparently	2243	2253	O
lethal	2254	2260	O
ICP	2261	2264	O
levels	2265	2271	O
may	2272	2275	O
be	2276	2278	O
present	2279	2286	O
.	2286	2287	O

Further	2288	2295	O
study	2296	2301	O
is	2302	2304	O
needed	2305	2311	O
to	2312	2314	O
support	2315	2322	O
these	2323	2328	O
encouraging	2329	2340	O
results	2341	2348	O
.	2348	2349	O

Newly	0	5	O
recognized	6	16	O
syndrome	17	25	O
with	26	30	O
heminasal	31	40	O
aplasia	41	48	O
and	49	52	O
ocular	53	59	B-Organ
anomalies	60	69	O
or	70	72	O
wider	73	78	O
spectrum	79	87	O
of	88	90	O
heminasal	91	100	O
aplasia	101	108	O
/	108	109	O
atypical	109	117	O
clefting	118	126	O
syndrome	127	135	O
?	135	136	O

We	137	139	O
report	140	146	O
on	147	149	O
five	150	154	O
unrelated	155	164	O
Brazilian	165	174	O
patients	175	183	O
with	184	188	O
heminasal	189	198	O
aplasia	199	206	O
associated	207	217	O
with	218	222	O
diverses	223	231	O
anomalies	232	241	O
,	241	242	O
including	243	252	O
lateral	253	260	O
proboscis	261	270	O
,	270	271	O
and	272	275	O
anomalies	276	285	O
of	286	288	O
the	289	292	O
eye	293	296	B-Organ
and	297	300	O
first	301	306	O
branchial	307	316	B-Multi-tissue_structure
arch	317	321	I-Multi-tissue_structure
.	321	322	O

We	323	325	O
suggest	326	333	O
that	334	338	O
these	339	344	O
patients	345	353	O
represent	354	363	O
different	364	373	O
conditions	374	384	O
within	385	391	O
the	392	395	O
spectrum	396	404	O
of	405	407	O
the	408	411	O
heminasal	412	421	O
aplasia	422	429	O
malformation	430	442	O
.	442	443	O

Clinical	444	452	O
,	452	453	O
genetic	454	461	O
,	461	462	O
and	463	466	O
differential	467	479	O
diagnosis	480	489	O
are	490	493	O
discussed	494	503	O
.	503	504	O

Neurologic	0	10	O
diagnosis	11	20	O
and	21	24	O
treatment	25	34	O
in	35	37	O
patients	38	46	O
with	47	51	O
computed	52	60	O
tomography	61	71	O
and	72	75	O
nasal	76	81	B-Organism_subdivision
endoscopy	82	91	O
negative	92	100	O
facial	101	107	B-Organism_subdivision
pain	108	112	O
.	112	113	O

OBJECTIVE	114	123	O
:	123	124	O

To	125	127	O
determine	128	137	O
the	138	141	O
helpfulness	142	153	O
of	154	156	O
specialist	157	167	O
neurology	168	177	O
referral	178	186	O
for	187	190	O
patients	191	199	O
with	200	204	O
facial	205	211	B-Organism_subdivision
pain	212	216	O
,	216	217	O
a	218	219	O
normal	220	226	O
sinus	227	232	B-Immaterial_anatomical_entity
computed	233	241	O
tomography	242	252	O
(	253	254	O
CT	254	256	O
)	256	257	O
scan	258	262	O
,	262	263	O
and	264	267	O
normal	268	274	O
nasal	275	280	B-Organism_subdivision
endoscopy	281	290	O
findings	291	299	O
.	299	300	O

STUDY	301	306	O
DESIGN	307	313	O
:	313	314	O

Prospective	315	326	O
identification	327	341	O
of	342	344	O
patients	345	353	O
and	354	357	O
analysis	358	366	O
of	367	369	O
data	370	374	O
approved	375	383	O
by	384	386	O
the	387	390	O
Institutional	391	404	O
Review	405	411	O
Board	412	417	O
.	417	418	O

METHODS	419	426	O
:	426	427	O

The	428	431	O
data	432	436	O
of	437	439	O
104	440	443	O
consecutive	444	455	O
patients	456	464	O
presenting	465	475	O
with	476	480	O
facial	481	487	B-Organism_subdivision
pain	488	492	O
,	492	493	O
a	494	495	O
normal	496	502	O
sinus	503	508	B-Immaterial_anatomical_entity
CT	509	511	O
scan	512	516	O
,	516	517	O
and	518	521	O
normal	522	528	O
nasal	529	534	B-Organism_subdivision
endoscopy	535	544	O
findings	545	553	O
were	554	558	O
reviewed	559	567	O
.	567	568	O

The	569	572	O
patients	573	581	O
presented	582	591	O
to	592	594	O
a	595	596	O
single	597	603	O
rhinologist	604	615	O
in	616	618	O
a	619	620	O
tertiary	621	629	O
care	630	634	O
institution	635	646	O
.	646	647	O

All	648	651	O
patients	652	660	O
were	661	665	O
referred	666	674	O
for	675	678	O
specialist	679	689	O
neurologic	690	700	O
evaluation	701	711	O
and	712	715	O
potential	716	725	O
treatment	726	735	O
.	735	736	O

Further	737	744	O
information	745	756	O
was	757	760	O
obtained	761	769	O
from	770	774	O
a	775	776	O
patient	777	784	O
survey	785	791	O
.	791	792	O

RESULTS	793	800	O
:	800	801	O

Of	802	804	O
the	805	808	O
104	809	812	O
patients	813	821	O
,	821	822	O
81	823	825	O
were	826	830	O
women	831	836	O
and	837	840	O
23	841	843	O
were	844	848	O
men	849	852	O
.	852	853	O

The	854	857	O
average	858	865	O
age	866	869	O
was	870	873	O
46	874	876	O
years	877	882	O
(	883	884	O
range	884	889	O
,	889	890	O
22	891	893	O
-	893	894	O
85	894	896	O
)	896	897	O
.	897	898	O

Fifty	899	904	O
-	904	905	O
six	905	908	O
had	909	912	O
clear	913	918	O
CT	919	921	O
scans	922	927	O
,	927	928	O
48	929	931	O
had	932	935	O
minimal	936	943	O
change	944	950	O
,	950	951	O
and	952	955	O
all	956	959	O
had	960	963	O
negative	964	972	O
endoscopies	973	984	O
.	984	985	O

Twenty	986	992	O
-	992	993	O
nine	993	997	O
had	998	1001	O
previous	1002	1010	O
unsuccessful	1011	1023	O
sinus	1024	1029	B-Immaterial_anatomical_entity
surgery	1030	1037	O
.	1037	1038	O

The	1039	1042	O
average	1043	1050	O
follow	1051	1057	O
-	1057	1058	O
up	1058	1060	O
period	1061	1067	O
was	1068	1071	O
10	1072	1074	O
.	1074	1075	O
5	1075	1076	O
months	1077	1083	O
.	1083	1084	O

Forty	1085	1090	O
of	1091	1093	O
75	1094	1096	O
patients	1097	1105	O
seeing	1106	1112	O
a	1113	1114	O
neurologist	1115	1126	O
were	1127	1131	O
seen	1132	1136	O
on	1137	1139	O
multiple	1140	1148	O
occasions	1149	1158	O
.	1158	1159	O

Four	1160	1164	O
percent	1165	1172	O
of	1173	1175	O
patients	1176	1184	O
seen	1185	1189	O
by	1190	1192	O
a	1193	1194	O
neurologist	1195	1206	O
had	1207	1210	O
an	1211	1213	O
unsuspected	1214	1225	O
serious	1226	1233	O
intracranial	1234	1246	B-Immaterial_anatomical_entity
diagnosis	1247	1256	O
.	1256	1257	O

The	1258	1261	O
most	1262	1266	O
common	1267	1273	O
diagnoses	1274	1283	O
were	1284	1288	O
migraine	1289	1297	O
(	1298	1299	O
37	1299	1301	O
%	1301	1302	O
)	1302	1303	O
,	1303	1304	O
rebound	1305	1312	O
headache	1313	1321	O
(	1322	1323	O
17	1323	1325	O
%	1325	1326	O
)	1326	1327	O
,	1327	1328	O
chronic	1329	1336	O
daily	1337	1342	O
headache	1343	1351	O
(	1352	1353	O
17	1353	1355	O
%	1355	1356	O
)	1356	1357	O
,	1357	1358	O
and	1359	1362	O
obstructive	1363	1374	O
sleep	1375	1380	O
apnea	1381	1386	O
(	1387	1388	O
16	1388	1390	O
%	1390	1391	O
)	1391	1392	O
.	1392	1393	O

Overall	1394	1401	O
,	1401	1402	O
58	1403	1405	O
%	1405	1406	O
improved	1407	1415	O
on	1416	1418	O
medical	1419	1426	O
therapy	1427	1434	O
;	1434	1435	O
60	1436	1438	O
%	1438	1439	O
of	1440	1442	O
those	1443	1448	O
with	1449	1453	O
a	1454	1455	O
clear	1456	1461	O
CT	1462	1464	O
scan	1465	1469	O
improved	1470	1478	O
,	1478	1479	O
and	1480	1483	O
53	1484	1486	O
%	1486	1487	O
of	1488	1490	O
those	1491	1496	O
with	1497	1501	O
minimal	1502	1509	O
change	1510	1516	O
on	1517	1519	O
CT	1520	1522	O
scan	1523	1527	O
improved	1528	1536	O
(	1537	1538	O
P	1538	1539	O
=	1540	1541	O
.	1542	1543	O
749	1543	1546	O
)	1546	1547	O
.	1547	1548	O

CONCLUSIONS	1549	1560	O
:	1560	1561	O

Facial	1562	1568	B-Organism_subdivision
pain	1569	1573	O
remains	1574	1581	O
a	1582	1583	O
difficult	1584	1593	O
symptom	1594	1601	O
to	1602	1604	O
diagnose	1605	1613	O
and	1614	1617	O
treat	1618	1623	O
in	1624	1626	O
rhinologic	1627	1637	O
practice	1638	1646	O
.	1646	1647	O

Patients	1648	1656	O
often	1657	1662	O
undergo	1663	1670	O
surgery	1671	1678	O
without	1679	1686	O
help	1687	1691	O
.	1691	1692	O

Most	1693	1697	O
patients	1698	1706	O
with	1707	1711	O
facial	1712	1718	B-Organism_subdivision
pain	1719	1723	O
,	1723	1724	O
a	1725	1726	O
normal	1727	1733	O
sinus	1734	1739	B-Immaterial_anatomical_entity
CT	1740	1742	O
scan	1743	1747	O
,	1747	1748	O
and	1749	1752	O
normal	1753	1759	O
endoscopy	1760	1769	O
findings	1770	1778	O
benefit	1779	1786	O
from	1787	1791	O
neurologic	1792	1802	O
consultation	1803	1815	O
.	1815	1816	O

Serious	1817	1824	O
intracranial	1825	1837	B-Immaterial_anatomical_entity
pathologic	1838	1848	O
conditions	1849	1859	O
can	1860	1863	O
be	1864	1866	O
excluded	1867	1875	O
and	1876	1879	O
diagnosis	1880	1889	O
-	1889	1890	O
specific	1890	1898	O
pharmacogenetic	1899	1914	O
therapy	1915	1922	O
instituted	1923	1933	O
with	1934	1938	O
improvement	1939	1950	O
in	1951	1953	O
more	1954	1958	O
than	1959	1963	O
50	1964	1966	O
%	1966	1967	O
.	1967	1968	O

TBX21	0	5	O
:	5	6	O
a	7	8	O
functional	9	19	O
variant	20	27	O
predicts	28	36	O
improvement	37	48	O
in	49	51	O
asthma	52	58	O
with	59	63	O
the	64	67	O
use	68	71	O
of	72	74	O
inhaled	75	82	O
corticosteroids	83	98	O
.	98	99	O

TBX21	100	105	O
encodes	106	113	O
for	114	117	O
the	118	121	O
transcription	122	135	O
factor	136	142	O
T	143	144	O
-	144	145	O
bet	145	148	O
(	149	150	O
T	150	151	O
-	151	152	O
box	152	155	O
expressed	156	165	O
in	166	168	O
T	169	170	B-Cell
cells	171	176	I-Cell
)	176	177	O
,	177	178	O
which	179	184	O
influences	185	195	O
naive	196	201	O
T	202	203	B-Cell
lymphocyte	204	214	I-Cell
development	215	226	O
and	227	230	O
has	231	234	O
been	235	239	O
implicated	240	250	O
in	251	253	O
asthma	254	260	O
pathogenesis	261	273	O
.	273	274	O

Specifically	275	287	O
,	287	288	O
the	289	292	O
T	293	294	O
-	294	295	O
bet	295	298	O
knockout	299	307	O
mouse	308	313	O
spontaneously	314	327	O
develops	328	336	O
airway	337	343	B-Multi-tissue_structure
hyperresponsiveness	344	363	O
and	364	367	O
other	368	373	O
changes	374	381	O
consistent	382	392	O
with	393	397	O
asthma	398	404	O
.	404	405	O

Because	406	413	O
airway	414	420	B-Multi-tissue_structure
responsiveness	421	435	O
is	436	438	O
moderated	439	448	O
by	449	451	O
the	452	455	O
use	456	459	O
of	460	462	O
inhaled	463	470	O
corticosteroids	471	486	O
in	487	489	O
asthma	490	496	O
,	496	497	O
it	498	500	O
is	501	503	O
conceivable	504	515	O
that	516	520	O
genetic	521	528	O
variation	529	538	O
in	539	541	O
TBX21	542	547	O
may	548	551	O
alter	552	557	O
asthma	558	564	O
phenotypes	565	575	O
in	576	578	O
a	579	580	O
treatment	581	590	O
-	590	591	O
specific	591	599	O
fashion	600	607	O
.	607	608	O

Here	609	613	O
we	614	616	O
demonstrate	617	628	O
that	629	633	O
the	634	637	O
nonsynonymous	638	651	O
variation	652	661	O
in	662	664	O
TBX21	665	670	O
coding	671	677	O
for	678	681	O
replacement	682	693	O
of	694	696	O
histidine	697	706	O
33	707	709	O
with	710	714	O
glutamine	715	724	O
is	725	727	O
associated	728	738	O
with	739	743	O
significant	744	755	O
improvement	756	767	O
in	768	770	O
the	771	774	O
PC	775	777	O
(	777	778	O
20	778	780	O
)	780	781	O
(	782	783	O
a	783	784	O
measure	785	792	O
of	793	795	O
airway	796	802	B-Multi-tissue_structure
responsiveness	803	817	O
)	817	818	O
of	819	821	O
asthmatic	822	831	O
children	832	840	O
in	841	843	O
a	844	845	O
large	846	851	O
clinical	852	860	O
trial	861	866	O
spanning	867	875	O
4	876	877	O
years	878	883	O
.	883	884	O

We	885	887	O
note	888	892	O
that	893	897	O
this	898	902	O
increase	903	911	O
occurs	912	918	O
only	919	923	O
in	924	926	O
the	927	930	O
children	931	939	O
randomized	940	950	O
to	951	953	O
inhaled	954	961	O
corticosteroids	962	977	O
and	978	981	O
that	982	986	O
it	987	989	O
dramatically	990	1002	O
enhances	1003	1011	O
the	1012	1015	O
overall	1016	1023	O
improvement	1024	1035	O
in	1036	1038	O
PC	1039	1041	O
(	1041	1042	O
20	1042	1044	O
)	1044	1045	O
associated	1046	1056	O
with	1057	1061	O
inhaled	1062	1069	O
corticosteroid	1070	1084	O
usage	1085	1090	O
.	1090	1091	O

The	1092	1095	O
average	1096	1103	O
PC	1104	1106	O
(	1106	1107	O
20	1107	1109	O
)	1109	1110	O
at	1111	1113	O
trial	1114	1119	O
end	1120	1123	O
for	1124	1127	O
subjects	1128	1136	O
on	1137	1139	O
inhaled	1140	1147	O
corticosteroids	1148	1163	O
possessing	1164	1174	O
a	1175	1176	O
variant	1177	1184	O
allele	1185	1191	O
was	1192	1195	O
in	1196	1198	O
the	1199	1202	O
normal	1203	1209	O
range	1210	1215	O
for	1216	1219	O
nonasthmatics	1220	1233	O
.	1233	1234	O

In	1235	1237	O
cellular	1238	1246	O
models	1247	1253	O
,	1253	1254	O
we	1255	1257	O
show	1258	1262	O
that	1263	1267	O
the	1268	1271	O
TBX21	1272	1277	O
variant	1278	1285	O
increases	1286	1295	O
T	1296	1297	B-Cell
helper	1298	1304	I-Cell
1	1305	1306	I-Cell
and	1307	1310	O
decreases	1311	1320	O
T	1321	1322	B-Cell
helper	1323	1329	I-Cell
2	1330	1331	I-Cell
cytokine	1332	1340	O
expression	1341	1351	O
comparably	1352	1362	O
with	1363	1367	O
wild	1368	1372	O
type	1373	1377	O
.	1377	1378	O

TBX21	1379	1384	O
may	1385	1388	O
thus	1389	1393	O
be	1394	1396	O
an	1397	1399	O
important	1400	1409	O
determinant	1410	1421	O
pharmacogenetic	1422	1437	O
response	1438	1446	O
to	1447	1449	O
the	1450	1453	O
therapy	1454	1461	O
of	1462	1464	O
asthma	1465	1471	O
with	1472	1476	O
inhaled	1477	1484	O
corticosteroids	1485	1500	O
.	1500	1501	O

Sox9	0	4	O
neural	5	11	B-Tissue
crest	12	17	I-Tissue
determinant	18	29	O
gene	30	34	O
controls	35	43	O
patterning	44	54	O
and	55	58	O
closure	59	66	O
of	67	69	O
the	70	73	O
posterior	74	83	B-Multi-tissue_structure
frontal	84	91	I-Multi-tissue_structure
cranial	92	99	I-Multi-tissue_structure
suture	100	106	I-Multi-tissue_structure
.	106	107	O

Cranial	108	115	B-Multi-tissue_structure
suture	116	122	I-Multi-tissue_structure
development	123	134	O
involves	135	143	O
a	144	145	O
complex	146	153	O
interaction	154	165	O
of	166	168	O
genes	169	174	O
and	175	178	O
tissues	179	186	B-Tissue
derived	187	194	O
from	195	199	O
neural	200	206	B-Cell
crest	207	212	I-Cell
cells	213	218	I-Cell
(	219	220	O
NCC	220	223	B-Cell
)	223	224	O
and	225	228	O
paraxial	229	237	B-Multi-tissue_structure
mesoderm	238	246	I-Multi-tissue_structure
.	246	247	O

In	248	250	O
mice	251	255	O
,	255	256	O
the	257	260	O
posterior	261	270	B-Multi-tissue_structure
frontal	271	278	I-Multi-tissue_structure
(	279	280	I-Multi-tissue_structure
PF	280	282	I-Multi-tissue_structure
)	282	283	I-Multi-tissue_structure
suture	284	290	I-Multi-tissue_structure
closes	291	297	O
during	298	304	O
the	305	308	O
first	309	314	O
month	315	320	O
of	321	323	O
life	324	328	O
while	329	334	O
other	335	340	O
sutures	341	348	B-Multi-tissue_structure
remain	349	355	O
patent	356	362	O
throughout	363	373	O
the	374	377	O
life	378	382	O
of	383	385	O
the	386	389	O
animal	390	396	O
.	396	397	O

Given	398	403	O
the	404	407	O
unique	408	414	O
NCC	415	418	B-Cell
origin	419	425	O
of	426	428	O
PF	429	431	B-Multi-tissue_structure
suture	432	438	I-Multi-tissue_structure
complex	439	446	O
(	447	448	O
analogous	448	457	O
to	458	460	O
metopic	461	468	B-Multi-tissue_structure
suture	469	475	I-Multi-tissue_structure
in	476	478	O
humans	479	485	O
)	485	486	O
,	486	487	O
we	488	490	O
performed	491	500	O
quantitative	501	513	O
real	514	518	O
-	518	519	O
time	519	523	O
PCR	524	527	O
and	528	531	O
immunohistochemistry	532	552	O
to	553	555	O
study	556	561	O
the	562	565	O
expression	566	576	O
pattern	577	584	O
of	585	587	O
the	588	591	O
NCC	592	595	B-Cell
determinant	596	607	O
gene	608	612	O
Sox9	613	617	O
and	618	621	O
select	622	628	O
markers	629	636	O
of	637	639	O
extracellular	640	653	B-Cellular_component
matrix	654	660	I-Cellular_component
.	660	661	O

Our	662	665	O
results	666	673	O
indicated	674	683	O
a	684	685	O
unique	686	692	O
up	693	695	O
-	695	696	O
regulated	696	705	O
expression	706	716	O
of	717	719	O
Sox9	720	724	O
,	724	725	O
a	726	727	O
regulator	728	737	O
of	738	740	O
chondrogenesis	741	755	O
,	755	756	O
during	757	763	O
initiation	764	774	O
of	775	777	O
PF	778	780	B-Multi-tissue_structure
suture	781	787	I-Multi-tissue_structure
closure	788	795	O
,	795	796	O
along	797	802	O
with	803	807	O
the	808	811	O
expression	812	822	O
of	823	825	O
specific	826	834	O
cartilage	835	844	B-Tissue
markers	845	852	O
(	853	854	O
Type	854	858	O
II	859	861	O
Collagen	862	870	O
and	871	874	O
Type	875	879	O
X	880	881	O
Collagen	882	890	O
)	890	891	O
,	891	892	O
as	893	895	O
well	896	900	O
as	901	903	O
cartilage	904	913	B-Tissue
tissue	914	920	I-Tissue
formation	921	930	O
in	931	933	O
the	934	937	O
PF	938	940	B-Multi-tissue_structure
suture	941	947	I-Multi-tissue_structure
.	947	948	O

This	949	953	O
process	954	961	O
was	962	965	O
followed	966	974	O
by	975	977	O
expression	978	988	O
of	989	991	O
bone	992	996	B-Tissue
markers	997	1004	O
(	1005	1006	O
Type	1006	1010	O
I	1011	1012	O
Collagen	1013	1021	O
and	1022	1025	O
Osteocalcin	1026	1037	O
)	1037	1038	O
,	1038	1039	O
suggesting	1040	1050	O
endochondral	1051	1063	O
ossification	1064	1076	O
.	1076	1077	O

Moreover	1078	1086	O
,	1086	1087	O
we	1088	1090	O
studied	1091	1098	O
the	1099	1102	O
effect	1103	1109	O
of	1110	1112	O
haploinsufficiency	1113	1131	O
of	1132	1134	O
the	1135	1138	O
NCC	1139	1142	B-Cell
determinant	1143	1154	O
gene	1155	1159	O
Sox9	1160	1164	O
in	1165	1167	O
the	1168	1171	O
NCC	1172	1175	B-Cell
derived	1176	1183	O
PF	1184	1186	B-Multi-tissue_structure
suture	1187	1193	I-Multi-tissue_structure
complex	1194	1201	O
.	1201	1202	O

A	1203	1204	O
decrease	1205	1213	O
in	1214	1216	O
dosage	1217	1223	O
of	1224	1226	O
Sox9	1227	1231	O
by	1232	1234	O
haploinsufficiency	1235	1253	O
in	1254	1256	O
NCC	1257	1260	B-Tissue
-	1260	1261	I-Tissue
derived	1261	1268	I-Tissue
tissues	1269	1276	I-Tissue
resulted	1277	1285	O
in	1286	1288	O
delayed	1289	1296	O
PF	1297	1299	B-Multi-tissue_structure
suture	1300	1306	I-Multi-tissue_structure
closure	1307	1314	O
.	1314	1315	O

These	1316	1321	O
results	1322	1329	O
demonstrate	1330	1341	O
a	1342	1343	O
unique	1344	1350	O
development	1351	1362	O
of	1363	1365	O
the	1366	1369	O
PF	1370	1372	B-Multi-tissue_structure
suture	1373	1379	I-Multi-tissue_structure
complex	1380	1387	O
and	1388	1391	O
the	1392	1395	O
role	1396	1400	O
of	1401	1403	O
Sox9	1404	1408	O
as	1409	1411	O
an	1412	1414	O
important	1415	1424	O
contributor	1425	1436	O
to	1437	1439	O
timely	1440	1446	O
and	1447	1450	O
proper	1451	1457	O
closure	1458	1465	O
of	1466	1468	O
the	1469	1472	O
PF	1473	1475	B-Multi-tissue_structure
suture	1476	1482	I-Multi-tissue_structure
through	1483	1490	O
endochondral	1491	1503	O
ossification	1504	1516	O
.	1516	1517	O

Experimental	0	12	O
investigation	13	26	O
of	27	29	O
equibiaxial	30	41	O
extension	42	51	O
and	52	55	O
breakup	56	63	O
of	64	66	O
drops	67	72	O
in	73	75	O
a	76	77	O
molten	78	84	O
two	85	88	O
-	88	89	O
phase	89	94	O
polymer	95	102	O
blend	103	108	O
.	108	109	O

We	110	112	O
experimentally	113	127	O
investigate	128	139	O
the	140	143	O
breakup	144	151	O
of	152	154	O
an	155	157	O
equibiaxially	158	171	O
elongated	172	181	O
polystyrene	182	193	O
(	194	195	O
PS	195	197	O
)	197	198	O
drop	199	203	O
in	204	206	O
a	207	208	O
poly	209	213	O
(	213	214	O
methyl	214	220	O
methacrylate	221	233	O
)	233	234	O
(	235	236	O
PMMA	236	240	O
)	240	241	O
matrix	242	248	O
during	249	255	O
relaxation	256	266	O
after	267	272	O
melt	273	277	O
elongation	278	288	O
.	288	289	O

In	290	292	O
equibiaxial	293	304	O
elongation	305	315	O
,	315	316	O
the	317	320	O
initially	321	330	O
spherical	331	340	O
PS	341	343	O
drop	344	348	O
is	349	351	O
deformed	352	360	O
into	361	365	O
an	366	368	O
ellipsoidal	369	380	O
disclike	381	389	O
shape	390	395	O
for	396	399	O
our	400	403	O
test	404	408	O
parameters	409	419	O
.	419	420	O

Using	421	426	O
a	427	428	O
hotstage	429	437	O
in	438	440	O
combination	441	452	O
with	453	457	O
a	458	459	O
light	460	465	O
microscope	466	476	O
,	476	477	O
we	478	480	O
observe	481	488	O
the	489	492	O
evolution	493	502	O
of	503	505	O
the	506	509	O
drop	510	514	O
shape	515	520	O
during	521	527	O
relaxation	528	538	O
.	538	539	O

In	540	542	O
the	543	546	O
initial	547	554	O
stage	555	560	O
of	561	563	O
relaxation	564	574	O
,	574	575	O
fingers	576	583	O
and	584	587	O
holes	588	593	O
are	594	597	O
formed	598	604	O
.	604	605	O

The	606	609	O
holes	610	615	O
are	616	619	O
located	620	627	O
preferentially	628	642	O
near	643	647	O
the	648	651	O
rim	652	655	O
of	656	658	O
the	659	662	O
drop	663	667	O
.	667	668	O

The	669	672	O
number	673	679	O
and	680	683	O
the	684	687	O
size	688	692	O
of	693	695	O
the	696	699	O
holes	700	705	O
increase	706	714	O
with	715	719	O
time	720	724	O
such	725	729	O
that	730	734	O
the	735	738	O
elongated	739	748	O
PS	749	751	O
drop	752	756	O
attains	757	764	O
a	765	766	O
complex	767	774	O
shape	775	780	O
during	781	787	O
relaxation	788	798	O
.	798	799	O

The	800	803	O
fingers	804	811	O
form	812	816	O
bulbous	817	824	O
ends	825	829	O
which	830	835	O
separate	836	844	O
from	845	849	O
the	850	853	O
fingers	854	861	O
.	861	862	O

We	863	865	O
discuss	866	873	O
the	874	877	O
dynamics	878	886	O
of	887	889	O
this	890	894	O
breakup	895	902	O
process	903	910	O
by	911	913	O
taking	914	920	O
into	921	925	O
account	926	933	O
the	934	937	O
interfacial	938	949	O
energy	950	956	O
between	957	964	O
PS	965	967	O
and	968	971	O
PMMA	972	976	O
.	976	977	O

Our	978	981	O
analysis	982	990	O
shows	991	996	O
that	997	1001	O
a	1002	1003	O
very	1004	1008	O
large	1009	1014	O
number	1015	1021	O
of	1022	1024	O
small	1025	1030	O
PS	1031	1033	O
droplets	1034	1042	O
can	1043	1046	O
be	1047	1049	O
generated	1050	1059	O
by	1060	1062	O
the	1063	1066	O
sequential	1067	1077	O
breakup	1078	1085	O
of	1086	1088	O
the	1089	1092	O
elongated	1093	1102	O
PS	1103	1105	O
drop	1106	1110	O
.	1110	1111	O

Management	0	10	O
of	11	13	O
extremity	14	23	O
trauma	24	30	O
and	31	34	O
related	35	42	O
infections	43	53	O
occurring	54	63	O
in	64	66	O
the	67	70	O
aquatic	71	78	O
environment	79	90	O
.	90	91	O

Wounds	92	98	B-Pathological_formation
sustained	99	108	O
in	109	111	O
oceans	112	118	O
,	118	119	O
lakes	120	125	O
,	125	126	O
and	127	130	O
streams	131	138	O
are	139	142	O
exposed	143	150	O
to	151	153	O
a	154	155	O
milieu	156	162	O
of	163	165	O
bacteria	166	174	O
rarely	175	181	O
encountered	182	193	O
in	194	196	O
typical	197	204	O
land	205	209	O
-	209	210	O
based	210	215	O
injuries	216	224	O
.	224	225	O

These	226	231	O
include	232	239	O
Vibrio	240	246	O
species	247	254	O
,	254	255	O
Aeromonas	256	265	O
hydrophila	266	276	O
,	276	277	O
Pseudomonas	278	289	O
and	290	293	O
Plesiomonas	294	305	O
species	306	313	O
,	313	314	O
Erysipelothrix	315	329	O
rhusiopathiae	330	343	O
,	343	344	O
Mycobacterium	345	358	O
marinum	359	366	O
,	366	367	O
and	368	371	O
other	372	377	O
microbes	378	386	O
.	386	387	O

Failure	388	395	O
to	396	398	O
recognize	399	408	O
and	409	412	O
treat	413	418	O
these	419	424	O
less	425	429	O
common	430	436	O
pathogens	437	446	O
in	447	449	O
a	450	451	O
timely	452	458	O
manner	459	465	O
may	466	469	O
result	470	476	O
in	477	479	O
significant	480	491	O
morbidity	492	501	O
or	502	504	O
death	505	510	O
.	510	511	O

Initial	512	519	O
antibiotic	520	530	O
therapy	531	538	O
should	539	545	O
address	546	553	O
common	554	560	O
gram	561	565	O
-	565	566	O
positive	566	574	O
and	575	578	O
gram	579	583	O
-	583	584	O
negative	584	592	O
aquatic	593	600	O
bacteria	601	609	O
,	609	610	O
depending	611	620	O
on	621	623	O
the	624	627	O
environment	628	639	O
.	639	640	O

Trauma	641	647	O
occurring	648	657	O
in	658	660	O
brackish	661	669	O
or	670	672	O
salt	673	677	O
water	678	683	O
should	684	690	O
be	691	693	O
treated	694	701	O
with	702	706	O
doxycycline	707	718	O
and	719	722	O
ceftazidime	723	734	O
,	734	735	O
or	736	738	O
a	739	740	O
fluoroquinolone	741	756	O
(	757	758	O
eg	758	760	O
,	760	761	O
ciprofloxacin	762	775	O
or	776	778	O
levofloxacin	779	791	O
)	791	792	O
.	792	793	O

Freshwater	794	804	O
wounds	805	811	B-Pathological_formation
should	812	818	O
be	819	821	O
managed	822	829	O
with	830	834	O
ciprofloxacin	835	848	O
,	848	849	O
levofloxacin	850	862	O
,	862	863	O
or	864	866	O
a	867	868	O
third	869	874	O
-	874	875	O
or	876	878	O
fourth	879	885	O
-	885	886	O
generation	886	896	O
cephalosporin	897	910	O
(	911	912	O
eg	912	914	O
,	914	915	O
ceftazidime	916	927	O
)	927	928	O
.	928	929	O

Injuries	930	938	O
sustained	939	948	O
in	949	951	O
a	952	953	O
marine	954	960	O
or	961	963	O
freshwater	964	974	O
environment	975	986	O
may	987	990	O
result	991	997	O
from	998	1002	O
bites	1003	1008	O
or	1009	1011	O
venomous	1012	1020	O
stings	1021	1027	O
of	1028	1030	O
aquatic	1031	1038	O
organisms	1039	1048	O
as	1049	1051	O
well	1052	1056	O
as	1057	1059	O
from	1060	1064	O
accidental	1065	1075	O
trauma	1076	1082	O
.	1082	1083	O

Musculoskeletal	1084	1099	B-Pathological_formation
trauma	1100	1106	I-Pathological_formation
caused	1107	1113	O
by	1114	1116	O
venomous	1117	1125	O
underwater	1126	1136	O
species	1137	1144	O
(	1145	1146	O
eg	1146	1148	O
,	1148	1149	O
stingrays	1150	1159	O
,	1159	1160	O
stinging	1161	1169	O
fish	1170	1174	O
,	1174	1175	O
sea	1176	1179	O
urchins	1180	1187	O
,	1187	1188	O
and	1189	1192	O
coral	1193	1198	O
)	1198	1199	O
requires	1200	1208	O
immediate	1209	1218	O
neutralization	1219	1233	O
of	1234	1236	O
the	1237	1240	O
heat	1241	1245	O
-	1245	1246	O
labile	1246	1252	O
toxin	1253	1258	O
with	1259	1263	O
immersion	1264	1273	O
in	1274	1276	O
nonscalding	1277	1288	O
water	1289	1294	O
for	1295	1298	O
30	1299	1301	O
to	1302	1304	O
90	1305	1307	O
minutes	1308	1315	O
.	1315	1316	O

Appropriate	1317	1328	O
management	1329	1339	O
of	1340	1342	O
aquatic	1343	1350	O
wounds	1351	1357	B-Pathological_formation
requires	1358	1366	O
recognition	1367	1378	O
of	1379	1381	O
the	1382	1385	O
mechanism	1386	1395	O
of	1396	1398	O
injury	1399	1405	O
,	1405	1406	O
neutralization	1407	1421	O
of	1422	1424	O
venom	1425	1430	O
,	1430	1431	O
antibiotic	1432	1442	O
administration	1443	1457	O
,	1457	1458	O
radiographic	1459	1471	O
assessment	1472	1482	O
,	1482	1483	O
surgical	1484	1492	O
debridement	1493	1504	O
with	1505	1509	O
irrigation	1510	1520	O
,	1520	1521	O
wound	1522	1527	B-Pathological_formation
cultures	1528	1536	O
,	1536	1537	O
and	1538	1541	O
structural	1542	1552	O
repair	1553	1559	O
or	1560	1562	O
amputation	1563	1573	O
as	1574	1576	O
indicated	1577	1586	O
by	1587	1589	O
the	1590	1593	O
severity	1594	1602	O
of	1603	1605	O
the	1606	1609	O
injury	1610	1616	O
.	1616	1617	O

Involvement	0	11	O
of	12	14	O
de	15	17	O
novo	18	22	O
ceramide	23	31	O
synthesis	32	41	O
in	42	44	O
radiocontrast	45	58	O
-	58	59	O
induced	59	66	O
renal	67	72	B-Cell
tubular	73	80	I-Cell
cell	81	85	I-Cell
injury	86	92	O
.	92	93	O

We	94	96	O
reported	97	105	O
previously	106	116	O
that	117	121	O
various	122	129	O
radiocontrast	130	143	O
media	144	149	O
cause	150	155	O
apoptosis	156	165	O
in	166	168	O
porcine	169	176	O
proximal	177	185	B-Cell
tubular	186	193	I-Cell
(	194	195	I-Cell
LLC	195	198	I-Cell
-	198	199	I-Cell
PK	199	201	I-Cell
(	201	202	I-Cell
1	202	203	I-Cell
)	203	204	I-Cell
)	204	205	I-Cell
cells	206	211	I-Cell
,	211	212	O
in	213	215	O
which	216	221	O
reduction	222	231	O
in	232	234	O
B	235	236	O
-	236	237	O
cell	237	241	O
lymphoma	242	250	O
(	251	252	O
Bcl	252	255	O
)	255	256	O
-	256	257	O
2	257	258	O
expression	259	269	O
and	270	273	O
caspase	274	281	O
-	281	282	O
3	282	283	O
activation	284	294	O
are	295	298	O
implicated	299	309	O
.	309	310	O

In	311	313	O
the	314	317	O
present	318	325	O
study	326	331	O
,	331	332	O
we	333	335	O
investigated	336	348	O
a	349	350	O
role	351	355	O
for	356	359	O
ceramide	360	368	O
in	369	371	O
radiocontrast	372	385	O
media	386	391	O
-	391	392	O
induced	392	399	O
apoptosis	400	409	O
in	410	412	O
renal	413	418	B-Cell
tubular	419	426	I-Cell
cells	427	432	I-Cell
.	432	433	O

LLC	434	437	B-Cell
-	437	438	I-Cell
PK	438	440	I-Cell
(	440	441	I-Cell
1	441	442	I-Cell
)	442	443	I-Cell
cells	444	449	I-Cell
were	450	454	O
exposed	455	462	O
to	463	465	O
radiocontrast	466	479	O
media	480	485	O
for	486	489	O
30	490	492	O
min	493	496	O
,	496	497	O
followed	498	506	O
by	507	509	O
incubation	510	520	O
for	521	524	O
24	525	527	O
h	528	529	O
in	530	532	O
normal	533	539	O
medium	540	546	O
.	546	547	O

Cell	548	552	B-Cell
viability	553	562	O
was	563	566	O
assessed	567	575	O
by	576	578	O
2	579	580	O
-	580	581	O
(	581	582	O
2	582	583	O
-	583	584	O
methoxy	584	591	O
-	591	592	O
4	592	593	O
-	593	594	O
nitrophenyl	594	605	O
)	605	606	O
-	606	607	O
3	607	608	O
-	608	609	O
(	609	610	O
4	610	611	O
-	611	612	O
nitrophenyl	612	623	O
)	623	624	O
-	624	625	O
5	625	626	O
-	626	627	O
(	627	628	O
2	628	629	O
,	629	630	O
4	630	631	O
-	631	632	O
disulfophenyl	632	645	O
)	645	646	O
-	646	647	O
2H	647	649	O
-	649	650	O
tetrazolium	650	661	O
monosodium	662	672	O
salt	673	677	O
assay	678	683	O
,	683	684	O
while	685	690	O
apoptosis	691	700	O
was	701	704	O
determined	705	715	O
by	716	718	O
terminal	719	727	O
deoxynucleotidyl	728	744	O
transferase	745	756	O
-	756	757	O
mediated	757	765	O
dUTP	766	770	O
nick	771	775	O
end	776	779	O
labeling	780	788	O
stain	789	794	O
.	794	795	O

Immunofluorescent	796	813	O
stains	814	820	O
were	821	825	O
performed	826	835	O
using	836	841	O
antibodies	842	852	O
against	853	860	O
phosphorylated	861	875	O
Akt	876	879	O
(	880	881	O
pAkt	881	885	O
)	885	886	O
and	887	890	O
cAMP	891	895	O
response	896	904	O
element	905	912	O
binding	913	920	O
protein	921	928	O
(	929	930	O
CREB	930	934	O
)	934	935	O
(	936	937	O
pCREB	937	942	O
)	942	943	O
,	943	944	O
and	945	948	O
ceramide	949	957	O
.	957	958	O

The	959	962	O
mRNA	963	967	O
expression	968	978	O
and	979	982	O
protein	983	990	O
content	991	998	O
of	999	1001	O
Bcl	1002	1005	O
-	1005	1006	O
2	1006	1007	O
were	1008	1012	O
determined	1013	1023	O
by	1024	1026	O
reverse	1027	1034	O
transcriptase	1035	1048	O
-	1048	1049	O
polymerase	1049	1059	O
chain	1060	1065	O
reaction	1066	1074	O
and	1075	1078	O
enzyme	1079	1085	O
immunoassay	1086	1097	O
,	1097	1098	O
respectively	1099	1111	O
.	1111	1112	O

In	1113	1115	O
vivo	1116	1120	O
model	1121	1126	O
of	1127	1129	O
contrast	1130	1138	O
-	1138	1139	O
induced	1139	1146	O
renal	1147	1152	B-Organ
injury	1153	1159	O
was	1160	1163	O
induced	1164	1171	O
in	1172	1174	O
mice	1175	1179	O
with	1180	1184	O
unilateral	1185	1195	O
renal	1196	1201	B-Organ
occlusion	1202	1211	O
.	1211	1212	O

The	1213	1216	O
cell	1217	1221	B-Cell
injury	1222	1228	O
induced	1229	1236	O
by	1237	1239	O
the	1240	1243	O
nonionic	1244	1252	O
radiocontrast	1253	1266	O
medium	1267	1273	O
ioversol	1274	1282	O
was	1283	1286	O
reversed	1287	1295	O
by	1296	1298	O
inhibiting	1299	1309	O
de	1310	1312	O
novo	1313	1317	O
ceramide	1318	1326	O
synthesis	1327	1336	O
with	1337	1341	O
fumonisin	1342	1351	O
B	1352	1353	O
(	1353	1354	O
1	1354	1355	O
)	1355	1356	O
(	1357	1358	O
FB	1358	1360	O
(	1360	1361	O
1	1361	1362	O
)	1362	1363	O
)	1363	1364	O
and	1365	1368	O
L	1369	1370	O
-	1370	1371	O
cycloserine	1371	1382	O
,	1382	1383	O
but	1384	1387	O
not	1388	1391	O
by	1392	1394	O
suppressing	1395	1406	O
sphingomyelin	1407	1420	O
breakdown	1421	1430	O
with	1431	1435	O
D609	1436	1440	O
.	1440	1441	O

FB	1442	1444	O
(	1444	1445	O
1	1445	1446	O
)	1446	1447	O
reversed	1448	1456	O
ioversol	1457	1465	O
-	1465	1466	O
induced	1466	1473	O
decrease	1474	1482	O
in	1483	1485	O
the	1486	1489	O
immunoreactivities	1490	1508	O
of	1509	1511	O
pAkt	1512	1516	O
and	1517	1520	O
pCREB	1521	1526	O
,	1526	1527	O
reduction	1528	1537	O
in	1538	1540	O
Bcl	1541	1544	O
-	1544	1545	O
2	1545	1546	O
expression	1547	1557	O
and	1558	1561	O
caspase	1562	1569	O
-	1569	1570	O
3	1570	1571	O
activation	1572	1582	O
.	1582	1583	O

Like	1584	1588	O
ioversol	1589	1597	O
,	1597	1598	O
C2	1599	1601	O
ceramide	1602	1610	O
and	1611	1614	O
the	1615	1618	O
Akt	1619	1622	O
inhibitor	1623	1632	O
Src	1633	1636	O
homology	1637	1645	O
-	1645	1646	O
6	1646	1647	O
induced	1648	1655	O
apoptosis	1656	1665	O
by	1666	1668	O
reducing	1669	1677	O
pAkt	1678	1682	O
and	1683	1686	O
pCREB	1687	1692	O
-	1692	1693	O
like	1693	1697	O
immunoreactivities	1698	1716	O
,	1716	1717	O
lowering	1718	1726	O
Bcl	1727	1730	O
-	1730	1731	O
2	1731	1732	O
expression	1733	1743	O
and	1744	1747	O
enhancing	1748	1757	O
caspase	1758	1765	O
-	1765	1766	O
3	1766	1767	O
activity	1768	1776	O
.	1776	1777	O

Indeed	1778	1784	O
,	1784	1785	O
various	1786	1793	O
radiocontrast	1794	1807	O
media	1808	1813	O
,	1813	1814	O
excluding	1815	1824	O
iodixanol	1825	1834	O
which	1835	1840	O
showed	1841	1847	O
the	1848	1851	O
least	1852	1857	O
nephrotoxicity	1858	1872	O
,	1872	1873	O
enhanced	1874	1882	O
ceramide	1883	1891	O
-	1891	1892	O
like	1892	1896	O
immunoreactivity	1897	1913	O
.	1913	1914	O

The	1915	1918	O
role	1919	1923	O
for	1924	1927	O
de	1928	1930	O
novo	1931	1935	O
ceramide	1936	1944	O
synthesis	1945	1954	O
was	1955	1958	O
also	1959	1963	O
shown	1964	1969	O
in	1970	1972	O
the	1973	1976	O
in	1977	1979	O
vivo	1980	1984	O
model	1985	1990	O
of	1991	1993	O
radiocontrast	1994	2007	O
nephropathy	2008	2019	O
.	2019	2020	O

We	2021	2023	O
demonstrated	2024	2036	O
here	2037	2041	O
for	2042	2045	O
the	2046	2049	O
first	2050	2055	O
time	2056	2060	O
that	2061	2065	O
the	2066	2069	O
enhancement	2070	2081	O
of	2082	2084	O
de	2085	2087	O
novo	2088	2092	O
ceramide	2093	2101	O
synthesis	2102	2111	O
contributes	2112	2123	O
to	2124	2126	O
radiocontrast	2127	2140	O
nephropathy	2141	2152	O
.	2152	2153	O

A	0	1	O
potential	2	11	O
role	12	16	O
for	17	20	O
the	21	24	O
Src	25	28	O
-	28	29	O
like	29	33	O
adapter	34	41	O
protein	42	49	O
SLAP	50	54	O
-	54	55	O
2	55	56	O
in	57	59	O
signaling	60	69	O
by	70	72	O
the	73	76	O
colony	77	83	O
stimulating	84	95	O
factor	96	102	O
-	102	103	O
1	103	104	O
receptor	105	113	O
.	113	114	O

The	115	118	O
development	119	130	O
of	131	133	O
macrophages	134	145	B-Cell
from	146	150	O
myeloid	151	158	B-Cell
progenitor	159	169	I-Cell
cells	170	175	I-Cell
is	176	178	O
primarily	179	188	O
controlled	189	199	O
by	200	202	O
the	203	206	O
growth	207	213	O
factor	214	220	O
colony	221	227	O
stimulating	228	239	O
factor	240	246	O
-	246	247	O
1	247	248	O
(	249	250	O
CSF	250	253	O
-	253	254	O
1	254	255	O
)	255	256	O
and	257	260	O
its	261	264	O
cognate	265	272	O
receptor	273	281	O
,	281	282	O
a	283	284	O
transmembrane	285	298	B-Cellular_component
tyrosine	299	307	O
kinase	308	314	O
encoded	315	322	O
by	323	325	O
the	326	329	O
c	330	331	O
-	331	332	O
Fms	332	335	O
proto	336	341	O
-	341	342	O
oncogene	342	350	O
.	350	351	O

The	352	355	O
CSF	356	359	O
-	359	360	O
1	360	361	O
receptor	362	370	O
exerts	371	377	O
its	378	381	O
biological	382	392	O
effects	393	400	O
on	401	403	O
cells	404	409	B-Cell
via	410	413	O
a	414	415	O
range	416	421	O
of	422	424	O
signaling	425	434	O
proteins	435	443	O
including	444	453	O
Erk1	454	458	O
/	458	459	O
2	459	460	O
and	461	464	O
Akt	465	468	O
.	468	469	O

Here	470	474	O
we	475	477	O
have	478	482	O
investigated	483	495	O
the	496	499	O
potential	500	509	O
involvement	510	521	O
of	522	524	O
the	525	528	O
Src	529	532	O
-	532	533	O
like	533	537	O
adapter	538	545	O
protein	546	553	O
(	554	555	O
SLAP	555	559	O
-	559	560	O
2	560	561	O
)	561	562	O
in	563	565	O
signaling	566	575	O
by	576	578	O
the	579	582	O
CSF	583	586	O
-	586	587	O
1	587	588	O
receptor	589	597	O
in	598	600	O
mouse	601	606	O
bone	607	611	B-Multi-tissue_structure
marrow	612	618	I-Multi-tissue_structure
-	618	619	O
derived	619	626	O
macrophages	627	638	B-Cell
.	638	639	O

RT	640	642	O
-	642	643	O
PCR	643	646	O
analysis	647	655	O
revealed	656	664	O
constitutive	665	677	O
expression	678	688	O
of	689	691	O
the	692	695	O
SLAP	696	700	O
-	700	701	O
2	701	702	O
gene	703	707	O
in	708	710	O
bone	711	715	B-Cell
marrow	716	722	I-Cell
macrophages	723	734	I-Cell
.	734	735	O

Surprisingly	736	748	O
,	748	749	O
co	750	752	O
-	752	753	O
immunoprecipitation	753	772	O
and	773	776	O
GST	777	780	O
binding	781	788	O
experiments	789	800	O
demonstrated	801	813	O
that	814	818	O
the	819	822	O
CSF	823	826	O
-	826	827	O
1	827	828	O
receptor	829	837	O
could	838	843	O
bind	844	848	O
to	849	851	O
SLAP	852	856	O
-	856	857	O
2	857	858	O
in	859	861	O
a	862	863	O
ligand	864	870	O
-	870	871	O
independent	871	882	O
manner	883	889	O
.	889	890	O

Furthermore	891	902	O
,	902	903	O
the	904	907	O
binding	908	915	O
of	916	918	O
SLAP	919	923	O
-	923	924	O
2	924	925	O
to	926	928	O
the	929	932	O
CSF	933	936	O
-	936	937	O
1	937	938	O
receptor	939	947	O
involved	948	956	O
multiple	957	965	O
domains	966	973	O
of	974	976	O
SLAP	977	981	O
-	981	982	O
2	982	983	O
.	983	984	O

SLAP	985	989	O
-	989	990	O
2	990	991	O
also	992	996	O
bound	997	1002	O
c	1003	1004	O
-	1004	1005	O
Cbl	1005	1008	O
,	1008	1009	O
with	1010	1014	O
the	1015	1018	O
interaction	1019	1030	O
being	1031	1036	O
mediated	1037	1045	O
,	1045	1046	O
at	1047	1049	O
least	1050	1055	O
in	1056	1058	O
part	1059	1063	O
,	1063	1064	O
by	1065	1067	O
the	1068	1071	O
unique	1072	1078	O
C	1079	1080	O
-	1080	1081	O
terminal	1081	1089	O
domain	1090	1096	O
of	1097	1099	O
SLAP	1100	1104	O
-	1104	1105	O
2	1105	1106	O
.	1106	1107	O

Overexpression	1108	1122	O
of	1123	1125	O
SLAP	1126	1130	O
-	1130	1131	O
2	1131	1132	O
in	1133	1135	O
bone	1136	1140	B-Cell
marrow	1141	1147	I-Cell
macrophages	1148	1159	I-Cell
partially	1160	1169	O
suppressed	1170	1180	O
the	1181	1184	O
CSF	1185	1188	O
-	1188	1189	O
1	1189	1190	O
-	1190	1191	O
induced	1191	1198	O
tyrosine	1199	1207	O
phosphorylation	1208	1223	O
and	1224	1227	O
/	1227	1228	O
or	1228	1230	O
expression	1231	1241	O
level	1242	1247	O
of	1248	1250	O
a	1251	1252	O
approximately	1253	1266	O
80	1267	1269	O
kDa	1270	1273	O
protein	1274	1281	O
without	1282	1289	O
affecting	1290	1299	O
CSF	1300	1303	O
-	1303	1304	O
1	1304	1305	O
-	1305	1306	O
induced	1306	1313	O
global	1314	1320	O
tyrosine	1321	1329	O
phosphorylation	1330	1345	O
,	1345	1346	O
or	1347	1349	O
activation	1350	1360	O
of	1361	1363	O
Akt	1364	1367	O
or	1368	1370	O
Erk1	1371	1375	O
/	1375	1376	O
2	1376	1377	O
.	1377	1378	O

Significantly	1379	1392	O
,	1392	1393	O
CSF	1394	1397	O
-	1397	1398	O
1	1398	1399	O
stimulation	1400	1411	O
induced	1412	1419	O
serine	1420	1426	O
phosphorylation	1427	1442	O
of	1443	1445	O
SLAP	1446	1450	O
-	1450	1451	O
2	1451	1452	O
.	1452	1453	O

Pharmacologic	1454	1467	O
inhibition	1468	1478	O
of	1479	1481	O
specific	1482	1490	O
protein	1491	1498	O
kinases	1499	1506	O
revealed	1507	1515	O
that	1516	1520	O
CSF	1521	1524	O
-	1524	1525	O
1	1525	1526	O
-	1526	1527	O
induced	1527	1534	O
phosphorylation	1535	1550	O
of	1551	1553	O
SLAP	1554	1558	O
-	1558	1559	O
2	1559	1560	O
was	1561	1564	O
dependent	1565	1574	O
on	1575	1577	O
JNK	1578	1581	O
activity	1582	1590	O
.	1590	1591	O

Taken	1592	1597	O
together	1598	1606	O
,	1606	1607	O
our	1608	1611	O
results	1612	1619	O
suggest	1620	1627	O
that	1628	1632	O
SLAP	1633	1637	O
-	1637	1638	O
2	1638	1639	O
could	1640	1645	O
potentially	1646	1657	O
be	1658	1660	O
involved	1661	1669	O
in	1670	1672	O
signaling	1673	1682	O
by	1683	1685	O
the	1686	1689	O
CSF	1690	1693	O
-	1693	1694	O
1	1694	1695	O
receptor	1696	1704	O
.	1704	1705	O

Structure	0	9	O
of	10	12	O
the	13	16	O
genetic	17	24	O
code	25	29	O
suggested	30	39	O
by	40	42	O
the	43	46	O
hydropathy	47	57	O
correlation	58	69	O
between	70	77	O
anticodons	78	88	O
and	89	92	O
amino	93	98	O
acid	99	103	O
residues	104	112	O
.	112	113	O

The	114	117	O
correlation	118	129	O
between	130	137	O
hydropathies	138	150	O
of	151	153	O
anticodons	154	164	O
and	165	168	O
amino	169	174	O
acids	175	180	O
,	180	181	O
detected	182	190	O
by	191	193	O
other	194	199	O
authors	200	207	O
utilizing	208	217	O
scales	218	224	O
of	225	227	O
amino	228	233	O
acid	234	238	O
molecules	239	248	O
in	249	251	O
solution	252	260	O
,	260	261	O
was	262	265	O
improved	266	274	O
with	275	279	O
the	280	283	O
utilization	284	295	O
of	296	298	O
scales	299	305	O
of	306	308	O
amino	309	314	O
acid	315	319	O
residues	320	328	O
in	329	331	O
proteins	332	340	O
.	340	341	O

Three	342	347	O
partitions	348	358	O
were	359	363	O
discerned	364	373	O
in	374	376	O
the	377	380	O
correlation	381	392	O
plot	393	397	O
with	398	402	O
the	403	406	O
principal	407	416	O
dinucleotides	417	430	O
of	431	433	O
anticodons	434	444	O
(	445	446	O
pDiN	446	450	O
,	450	451	O
excluding	452	461	O
the	462	465	O
wobble	466	472	O
position	473	481	O
)	481	482	O
.	482	483	O

(	484	485	O
a	485	486	O
)	486	487	O
The	488	491	O
set	492	495	O
of	496	498	O
outliers	499	507	O
of	508	510	O
the	511	514	O
correlation	515	526	O
:	526	527	O
Gly	528	531	O
-	531	532	O
CC	532	534	O
,	534	535	O
Pro	536	539	O
-	539	540	O
GG	540	542	O
,	542	543	O
Ser	544	547	O
-	547	548	O
GA	548	550	O
and	551	554	O
Ser	555	558	O
-	558	559	O
CU	559	561	O
.	561	562	O

The	563	566	O
amino	567	572	O
acids	573	578	O
are	579	582	O
consistently	583	595	O
small	596	601	O
,	601	602	O
hydro	603	608	O
-	608	609	O
apathetic	609	618	O
,	618	619	O
stabilizers	620	631	O
of	632	634	O
protein	635	642	O
N	643	644	O
-	644	645	O
ends	645	649	O
,	649	650	O
preferred	651	660	O
in	661	663	O
aperiodic	664	673	O
protein	674	681	O
conformations	682	695	O
and	696	699	O
belong	700	706	O
to	707	709	O
synthetases	710	721	O
class	722	727	O
II	728	730	O
.	730	731	O

The	732	735	O
pDiN	736	740	O
sequences	741	750	O
are	751	754	O
representative	755	769	O
of	770	772	O
the	773	776	O
homogeneous	777	788	O
sector	789	795	O
(	796	797	O
triplets	797	805	O
NRR	806	809	O
and	810	813	O
NYY	814	817	O
)	817	818	O
,	818	819	O
distinguished	820	833	O
from	834	838	O
the	839	842	O
mixed	843	848	O
sector	849	855	O
(	856	857	O
triplets	857	865	O
NRY	866	869	O
and	870	873	O
NYR	874	877	O
)	877	878	O
,	878	879	O
that	880	884	O
depict	885	891	O
a	892	893	O
70	894	896	O
%	896	897	O
correspondence	898	912	O
to	913	915	O
the	916	919	O
synthetases	920	931	O
class	932	937	O
II	938	940	O
and	941	944	O
I	945	946	O
,	946	947	O
respectively	948	960	O
.	960	961	O

The	962	965	O
triplet	966	973	O
pairs	974	979	O
proposed	980	988	O
to	989	991	O
be	992	994	O
responsible	995	1006	O
for	1007	1010	O
the	1011	1014	O
coherence	1015	1024	O
in	1025	1027	O
the	1028	1031	O
set	1032	1035	O
of	1036	1038	O
outliers	1039	1047	O
are	1048	1051	O
of	1052	1054	O
the	1055	1058	O
palindromic	1059	1070	O
kind	1071	1075	O
,	1075	1076	O
where	1077	1082	O
the	1083	1086	O
lateral	1087	1094	O
bases	1095	1100	O
are	1101	1104	O
the	1105	1108	O
same	1109	1113	O
,	1113	1114	O
CCC	1115	1118	O
:	1118	1119	O
GGG	1120	1123	O
and	1124	1127	O
AGA	1128	1131	O
:	1131	1132	O
UCU	1133	1136	O
.	1136	1137	O

This	1138	1142	O
suggests	1143	1151	O
that	1152	1156	O
UCU	1157	1160	O
previously	1161	1171	O
belonged	1172	1180	O
to	1181	1183	O
Ser	1184	1187	O
,	1187	1188	O
adding	1189	1195	O
to	1196	1198	O
other	1199	1204	O
indications	1205	1216	O
that	1217	1221	O
the	1222	1225	O
attribution	1226	1237	O
of	1238	1240	O
Arg	1241	1244	O
to	1245	1247	O
YCU	1248	1251	O
was	1252	1255	O
due	1256	1259	O
to	1260	1262	O
an	1263	1265	O
expansion	1266	1275	O
of	1276	1278	O
the	1279	1282	O
Arg	1283	1286	O
-	1286	1287	O
tRNA	1287	1291	O
synthetase	1292	1302	O
specificity	1303	1314	O
.	1314	1315	O

The	1316	1319	O
other	1320	1325	O
attributions	1326	1338	O
produced	1339	1347	O
two	1348	1351	O
correlation	1352	1363	O
sets	1364	1368	O
.	1368	1369	O

(	1370	1371	O
b	1371	1372	O
)	1372	1373	O
One	1374	1377	O
corresponds	1378	1389	O
to	1390	1392	O
the	1393	1396	O
remaining	1397	1406	O
pDiN	1407	1411	O
of	1412	1414	O
the	1415	1418	O
homogeneous	1419	1430	O
sector	1431	1437	O
,	1437	1438	O
containing	1439	1449	O
both	1450	1454	O
synthetase	1455	1465	O
classes	1466	1473	O
;	1473	1474	O
its	1475	1478	O
regression	1479	1489	O
line	1490	1494	O
overlapped	1495	1505	O
the	1506	1509	O
one	1510	1513	O
formed	1514	1520	O
by	1521	1523	O
the	1524	1527	O
remaining	1528	1537	O
attributions	1538	1550	O
to	1551	1553	O
class	1554	1559	O
II	1560	1562	O
.	1562	1563	O

(	1564	1565	O
c	1565	1566	O
)	1566	1567	O
The	1568	1571	O
other	1572	1577	O
contains	1578	1586	O
the	1587	1590	O
pDiN	1591	1595	O
of	1596	1598	O
the	1599	1602	O
mixed	1603	1608	O
sector	1609	1615	O
and	1616	1619	O
produced	1620	1628	O
steeper	1629	1636	O
slopes	1637	1643	O
,	1643	1644	O
especially	1645	1655	O
with	1656	1660	O
the	1661	1664	O
class	1665	1670	O
I	1671	1672	O
attributions	1673	1685	O
.	1685	1686	O

It	1687	1689	O
is	1690	1692	O
suggested	1693	1702	O
that	1703	1707	O
the	1708	1711	O
correlation	1712	1723	O
was	1724	1727	O
established	1728	1739	O
when	1740	1744	O
the	1745	1748	O
amino	1749	1754	O
acid	1755	1759	O
composition	1760	1771	O
of	1772	1774	O
the	1775	1778	O
protein	1779	1786	O
synthetases	1787	1798	O
became	1799	1805	O
progressively	1806	1819	O
enriched	1820	1828	O
and	1829	1832	O
that	1833	1837	O
the	1838	1841	O
set	1842	1845	O
of	1846	1848	O
outliers	1849	1857	O
were	1858	1862	O
the	1863	1866	O
earliest	1867	1875	O
to	1876	1878	O
have	1879	1883	O
been	1884	1888	O
fixed	1889	1894	O
.	1894	1895	O

Hypocholesterolaemic	0	20	O
and	21	24	O
antioxidant	25	36	O
effects	37	44	O
of	45	47	O
Glycyrrhiza	48	59	O
glabra	60	66	O
(	67	68	O
Linn	68	72	O
)	72	73	O
in	74	76	O
rats	77	81	O
.	81	82	O

The	83	86	O
hypocholesterolaemic	87	107	O
and	108	111	O
antioxidant	112	123	O
effects	124	131	O
of	132	134	O
Glycyrrhiza	135	146	O
glabra	147	153	O
(	154	155	O
GG	155	157	O
)	157	158	O
root	159	163	B-Organ
powder	164	170	O
were	171	175	O
examined	176	184	O
in	185	187	O
hypercholesterolaemic	188	209	O
male	210	214	O
albino	215	221	O
rats	222	226	O
.	226	227	O

A	228	229	O
4	230	231	O
-	231	232	O
week	232	236	O
administration	237	251	O
of	252	254	O
GG	255	257	O
root	258	262	B-Organ
powder	263	269	O
(	270	271	O
5	271	272	O
and	273	276	O
10	277	279	O
gm	280	282	O
%	282	283	O
in	284	286	O
diet	287	291	O
)	291	292	O
to	293	295	O
hypercholesterolaemic	296	317	O
rats	318	322	O
resulted	323	331	O
in	332	334	O
significant	335	346	O
reduction	347	356	O
in	357	359	O
plasma	360	366	B-Organism_substance
,	366	367	O
hepatic	368	375	B-Organ
total	376	381	O
lipids	382	388	O
,	388	389	O
cholesterol	390	401	O
,	401	402	O
triglycerides	403	416	O
and	417	420	O
plasma	421	427	B-Organism_substance
low	428	431	O
-	431	432	O
density	432	439	O
lipoprotein	440	451	O
and	452	455	O
VLDL	456	460	O
-	460	461	O
cholesterol	461	472	O
accompanied	473	484	O
by	485	487	O
significant	488	499	O
increases	500	509	O
in	510	512	O
HDL	513	516	O
-	516	517	O
cholesterol	517	528	O
levels	529	535	O
.	535	536	O

Furthermore	537	548	O
,	548	549	O
significant	550	561	O
increases	562	571	O
in	572	574	O
fecal	575	580	B-Organism_substance
cholesterol	581	592	O
,	592	593	O
neutral	594	601	O
sterols	602	609	O
and	610	613	O
bile	614	618	O
acid	619	623	O
excretion	624	633	O
along	634	639	O
with	640	644	O
an	645	647	O
increase	648	656	O
in	657	659	O
hepatic	660	667	B-Organ
HMG	668	671	O
-	671	672	O
CoA	672	675	O
reductase	676	685	O
activity	686	694	O
and	695	698	O
bile	699	703	O
acid	704	708	O
production	709	719	O
were	720	724	O
observed	725	733	O
in	734	736	O
these	737	742	O
animals	743	750	O
.	750	751	O

The	752	755	O
root	756	760	B-Organ
powder	761	767	O
administration	768	782	O
to	783	785	O
hypercholesterolaemic	786	807	O
rats	808	812	O
also	813	817	O
decreased	818	827	O
hepatic	828	835	B-Organ
lipid	836	841	O
peroxidation	842	854	O
with	855	859	O
a	860	861	O
concomitant	862	873	O
increase	874	882	O
in	883	885	O
superoxide	886	896	O
dismutase	897	906	O
(	907	908	O
SOD	908	911	O
)	911	912	O
and	913	916	O
catalase	917	925	O
activities	926	936	O
and	937	940	O
total	941	946	O
ascorbic	947	955	O
acid	956	960	O
content	961	968	O
.	968	969	O

Thus	970	974	O
,	974	975	O
the	976	979	O
hypocholesterolaemic	980	1000	O
and	1001	1004	O
antioxidant	1005	1016	O
effects	1017	1024	O
of	1025	1027	O
GG	1028	1030	O
root	1031	1035	B-Organ
appeared	1036	1044	O
to	1045	1047	O
be	1048	1050	O
mediated	1051	1059	O
via	1060	1063	O
(	1064	1065	O
i	1065	1066	O
)	1066	1067	O
accelerated	1068	1079	O
cholesterol	1080	1091	O
,	1091	1092	O
neutral	1093	1100	O
sterol	1101	1107	O
and	1108	1111	O
bile	1112	1116	O
acid	1117	1121	O
elimination	1122	1133	O
through	1134	1141	O
fecal	1142	1147	B-Organism_substance
matter	1148	1154	I-Organism_substance
with	1155	1159	O
an	1160	1162	O
increased	1163	1172	O
hepatic	1173	1180	B-Organ
bile	1181	1185	O
acid	1186	1190	O
production	1191	1201	O
and	1202	1205	O
(	1206	1207	O
ii	1207	1209	O
)	1209	1210	O
improving	1211	1220	O
the	1221	1224	O
activities	1225	1235	O
of	1236	1238	O
hepatic	1239	1246	B-Organ
SOD	1247	1250	O
,	1250	1251	O
catalase	1252	1260	O
and	1261	1264	O
increasing	1265	1275	O
the	1276	1279	O
ascorbic	1280	1288	O
acid	1289	1293	O
content	1294	1301	O
.	1301	1302	O

The	1303	1306	O
normo	1307	1312	O
-	1312	1313	O
cholesterolaemic	1313	1329	O
animals	1330	1337	O
when	1338	1342	O
fed	1343	1346	O
with	1347	1351	O
GG	1352	1354	O
root	1355	1359	B-Organ
powder	1360	1366	O
at	1367	1369	O
10	1370	1372	O
gm	1373	1375	O
%	1375	1376	O
level	1377	1382	O
,	1382	1383	O
registered	1384	1394	O
a	1395	1396	O
significant	1397	1408	O
decline	1409	1416	O
in	1417	1419	O
plasma	1420	1426	B-Organism_substance
lipid	1427	1432	O
profiles	1433	1441	O
and	1442	1445	O
an	1446	1448	O
increase	1449	1457	O
in	1458	1460	O
HDL	1461	1464	O
-	1464	1465	O
cholesterol	1465	1476	O
content	1477	1484	O
.	1484	1485	O

The	1486	1489	O
antioxidant	1490	1501	O
status	1502	1508	O
of	1509	1511	O
these	1512	1517	O
animals	1518	1525	O
also	1526	1530	O
was	1531	1534	O
improved	1535	1543	O
upon	1544	1548	O
treatment	1549	1558	O
.	1558	1559	O

Multicentre	0	11	O
study	12	17	O
on	18	20	O
peri	21	25	O
-	25	26	O
and	27	30	O
postoperative	31	44	O
central	45	52	B-Multi-tissue_structure
venous	53	59	I-Multi-tissue_structure
oxygen	60	66	O
saturation	67	77	O
in	78	80	O
high	81	85	O
-	85	86	O
risk	86	90	O
surgical	91	99	O
patients	100	108	O
.	108	109	O

INTRODUCTION	110	122	O
:	122	123	O

Low	124	127	O
central	128	135	B-Multi-tissue_structure
venous	136	142	I-Multi-tissue_structure
oxygen	143	149	O
saturation	150	160	O
(	161	162	O
ScvO2	162	167	O
)	167	168	O
has	169	172	O
been	173	177	O
associated	178	188	O
with	189	193	O
increased	194	203	O
risk	204	208	O
of	209	211	O
postoperative	212	225	O
complications	226	239	O
in	240	242	O
high	243	247	O
-	247	248	O
risk	248	252	O
surgery	253	260	O
.	260	261	O

Whether	262	269	O
this	270	274	O
association	275	286	O
is	287	289	O
centre	290	296	O
-	296	297	O
specific	297	305	O
or	306	308	O
more	309	313	O
generalisable	314	327	O
is	328	330	O
not	331	334	O
known	335	340	O
.	340	341	O

The	342	345	O
aim	346	349	O
of	350	352	O
this	353	357	O
study	358	363	O
was	364	367	O
to	368	370	O
assess	371	377	O
the	378	381	O
association	382	393	O
between	394	401	O
peri	402	406	O
-	406	407	O
and	408	411	O
postoperative	412	425	O
ScvO2	426	431	O
and	432	435	O
outcome	436	443	O
in	444	446	O
high	447	451	O
-	451	452	O
risk	452	456	O
surgical	457	465	O
patients	466	474	O
in	475	477	O
a	478	479	O
multicentre	480	491	O
setting	492	499	O
.	499	500	O

METHODS	501	508	O
:	508	509	O

Three	510	515	O
large	516	521	O
European	522	530	O
university	531	541	O
hospitals	542	551	O
(	552	553	O
two	553	556	O
in	557	559	O
Finland	560	567	O
,	567	568	O
one	569	572	O
in	573	575	O
Switzerland	576	587	O
)	587	588	O
participated	589	601	O
.	601	602	O

In	603	605	O
60	606	608	O
patients	609	617	O
with	618	622	O
intra	623	628	O
-	628	629	O
abdominal	629	638	B-Organism_subdivision
surgery	639	646	O
lasting	647	654	O
more	655	659	O
than	660	664	O
90	665	667	O
minutes	668	675	O
,	675	676	O
the	677	680	O
presence	681	689	O
of	690	692	O
at	693	695	O
least	696	701	O
two	702	705	O
of	706	708	O
Shoemaker	709	718	O
'	718	719	O
s	719	720	O
criteria	721	729	O
,	729	730	O
and	731	734	O
ASA	735	738	O
(	739	740	O
American	740	748	O
Society	749	756	O
of	757	759	O
Anesthesiologists	760	777	O
)	777	778	O
class	779	784	O
greater	785	792	O
than	793	797	O
2	798	799	O
,	799	800	O
ScvO2	801	806	O
was	807	810	O
determined	811	821	O
preoperatively	822	836	O
and	837	840	O
at	841	843	O
two	844	847	O
hour	848	852	O
intervals	853	862	O
during	863	869	O
the	870	873	O
operation	874	883	O
until	884	889	O
12	890	892	O
hours	893	898	O
postoperatively	899	914	O
.	914	915	O

Hospital	916	924	O
length	925	931	O
of	932	934	O
stay	935	939	O
(	940	941	O
LOS	941	944	O
)	944	945	O
mortality	946	955	O
,	955	956	O
and	957	960	O
predefined	961	971	O
postoperative	972	985	O
complications	986	999	O
were	1000	1004	O
recorded	1005	1013	O
.	1013	1014	O

RESULTS	1015	1022	O
:	1022	1023	O

The	1024	1027	O
age	1028	1031	O
of	1032	1034	O
the	1035	1038	O
patients	1039	1047	O
was	1048	1051	O
72	1052	1054	O
+	1055	1056	O
/	1056	1057	O
-	1057	1058	O
10	1059	1061	O
years	1062	1067	O
(	1068	1069	O
mean	1069	1073	O
+	1074	1075	O
/	1075	1076	O
-	1076	1077	O
standard	1078	1086	O
deviation	1087	1096	O
)	1096	1097	O
,	1097	1098	O
and	1099	1102	O
simplified	1103	1113	O
acute	1114	1119	O
physiology	1120	1130	O
score	1131	1136	O
(	1137	1138	O
SAPS	1138	1142	O
II	1143	1145	O
)	1145	1146	O
was	1147	1150	O
32	1151	1153	O
+	1154	1155	O
/	1155	1156	O
-	1156	1157	O
12	1158	1160	O
.	1160	1161	O

Hospital	1162	1170	O
LOS	1171	1174	O
was	1175	1178	O
10	1179	1181	O
.	1181	1182	O
5	1182	1183	O
(	1184	1185	O
8	1185	1186	O
to	1187	1189	O
14	1190	1192	O
)	1192	1193	O
days	1194	1198	O
,	1198	1199	O
and	1200	1203	O
28	1204	1206	O
-	1206	1207	O
day	1207	1210	O
hospital	1211	1219	O
mortality	1220	1229	O
was	1230	1233	O
10	1234	1236	O
.	1236	1237	O
0	1237	1238	O
%	1238	1239	O
.	1239	1240	O

Preoperative	1241	1253	O
ScvO2	1254	1259	O
decreased	1260	1269	O
from	1270	1274	O
77	1275	1277	O
%	1277	1278	O
+	1279	1280	O
/	1280	1281	O
-	1281	1282	O
10	1283	1285	O
%	1285	1286	O
to	1287	1289	O
70	1290	1292	O
%	1292	1293	O
+	1294	1295	O
/	1295	1296	O
-	1296	1297	O
11	1298	1300	O
%	1300	1301	O
(	1302	1303	O
p	1303	1304	O
<	1305	1306	O
0	1307	1308	O
.	1308	1309	O
001	1309	1312	O
)	1312	1313	O
immediately	1314	1325	O
after	1326	1331	O
surgery	1332	1339	O
and	1340	1343	O
remained	1344	1352	O
unchanged	1353	1362	O
12	1363	1365	O
hours	1366	1371	O
later	1372	1377	O
.	1377	1378	O

A	1379	1380	O
total	1381	1386	O
of	1387	1389	O
67	1390	1392	O
postoperative	1393	1406	O
complications	1407	1420	O
were	1421	1425	O
recorded	1426	1434	O
in	1435	1437	O
32	1438	1440	O
patients	1441	1449	O
.	1449	1450	O

After	1451	1456	O
multivariate	1457	1469	O
analysis	1470	1478	O
,	1478	1479	O
mean	1480	1484	O
ScvO2	1485	1490	O
value	1491	1496	O
(	1497	1498	O
odds	1498	1502	O
ratio	1503	1508	O
[	1509	1510	O
OR	1510	1512	O
]	1512	1513	O
1	1514	1515	O
.	1515	1516	O
23	1516	1518	O
[	1519	1520	O
95	1520	1522	O
%	1522	1523	O
confidence	1524	1534	O
interval	1535	1543	O
(	1544	1545	O
CI	1545	1547	O
)	1547	1548	O
1	1549	1550	O
.	1550	1551	O
01	1551	1553	O
to	1554	1556	O
1	1557	1558	O
.	1558	1559	O
50	1559	1561	O
]	1561	1562	O
,	1562	1563	O
p	1564	1565	O
=	1566	1567	O
0	1568	1569	O
.	1569	1570	O
037	1570	1573	O
)	1573	1574	O
,	1574	1575	O
hospital	1576	1584	O
LOS	1585	1588	O
(	1589	1590	O
OR	1590	1592	O
0	1593	1594	O
.	1594	1595	O
75	1595	1597	O
[	1598	1599	O
95	1599	1601	O
%	1601	1602	O
CI	1603	1605	O
0	1606	1607	O
.	1607	1608	O
59	1608	1610	O
to	1611	1613	O
0	1614	1615	O
.	1615	1616	O
94	1616	1618	O
]	1618	1619	O
,	1619	1620	O
p	1621	1622	O
=	1623	1624	O
0	1625	1626	O
.	1626	1627	O
012	1627	1630	O
)	1630	1631	O
,	1631	1632	O
and	1633	1636	O
SAPS	1637	1641	O
II	1642	1644	O
(	1645	1646	O
OR	1646	1648	O
0	1649	1650	O
.	1650	1651	O
90	1651	1653	O
[	1654	1655	O
95	1655	1657	O
%	1657	1658	O
CI	1659	1661	O
0	1662	1663	O
.	1663	1664	O
82	1664	1666	O
to	1667	1669	O
0	1670	1671	O
.	1671	1672	O
99	1672	1674	O
]	1674	1675	O
,	1675	1676	O
p	1677	1678	O
=	1679	1680	O
0	1681	1682	O
.	1682	1683	O
029	1683	1686	O
)	1686	1687	O
were	1688	1692	O
independently	1693	1706	O
associated	1707	1717	O
with	1718	1722	O
postoperative	1723	1736	O
complications	1737	1750	O
.	1750	1751	O

The	1752	1755	O
optimal	1756	1763	O
value	1764	1769	O
of	1770	1772	O
mean	1773	1777	O
ScvO2	1778	1783	O
to	1784	1786	O
discriminate	1787	1799	O
between	1800	1807	O
patients	1808	1816	O
who	1817	1820	O
did	1821	1824	O
or	1825	1827	O
did	1828	1831	O
not	1832	1835	O
develop	1836	1843	O
complications	1844	1857	O
was	1858	1861	O
73	1862	1864	O
%	1864	1865	O
(	1866	1867	O
sensitivity	1867	1878	O
72	1879	1881	O
%	1881	1882	O
,	1882	1883	O
specificity	1884	1895	O
61	1896	1898	O
%	1898	1899	O
)	1899	1900	O
.	1900	1901	O

CONCLUSION	1902	1912	O
:	1912	1913	O

Low	1914	1917	O
ScvO2	1918	1923	O
perioperatively	1924	1939	O
is	1940	1942	O
related	1943	1950	O
to	1951	1953	O
increased	1954	1963	O
risk	1964	1968	O
of	1969	1971	O
postoperative	1972	1985	O
complications	1986	1999	O
in	2000	2002	O
high	2003	2007	O
-	2007	2008	O
risk	2008	2012	O
surgery	2013	2020	O
.	2020	2021	O

This	2022	2026	O
warrants	2027	2035	O
trials	2036	2042	O
with	2043	2047	O
goal	2048	2052	O
-	2052	2053	O
directed	2053	2061	O
therapy	2062	2069	O
using	2070	2075	O
ScvO2	2076	2081	O
as	2082	2084	O
a	2085	2086	O
target	2087	2093	O
in	2094	2096	O
high	2097	2101	O
-	2101	2102	O
risk	2102	2106	O
surgery	2107	2114	O
patients	2115	2123	O
.	2123	2124	O

[	0	1	O
Treatment	1	10	O
of	11	13	O
squamous	14	22	B-Pathological_formation
intraepithelial	23	38	I-Pathological_formation
lesion	39	45	I-Pathological_formation
of	46	48	O
type	49	53	O
CIN2	54	58	O
et	59	61	O
CIN3	62	66	O
with	67	71	O
laser	72	77	O
CO2	78	81	O
vaporization	82	94	O
:	94	95	O
retrospective	96	109	O
study	110	115	O
of	116	118	O
52	119	121	O
cases	122	127	O
]	127	128	O
.	128	129	O

OBJECTIVES	130	140	O
:	140	141	O

This	142	146	O
study	147	152	O
was	153	156	O
carried	157	164	O
out	165	168	O
over	169	173	O
an	174	176	O
8	177	178	O
-	178	179	O
year	179	183	O
period	184	190	O
in	191	193	O
order	194	199	O
to	200	202	O
evaluate	203	211	O
the	212	215	O
long	216	220	O
-	220	221	O
term	221	225	O
effectiveness	226	239	O
of	240	242	O
laser	243	248	O
CO2	249	252	O
vaporization	253	265	O
in	266	268	O
the	269	272	O
treatment	273	282	O
of	283	285	O
squamous	286	294	B-Pathological_formation
intraepithelial	295	310	I-Pathological_formation
lesion	311	317	I-Pathological_formation
of	318	320	O
type	321	325	O
CIN2	326	330	O
and	331	334	O
CIN3	335	339	O
.	339	340	O

MATERIALS	341	350	O
AND	351	354	O
METHODS	355	362	O
:	362	363	O

A	364	365	O
retrospective	366	379	O
study	380	385	O
of	386	388	O
52	389	391	O
cases	392	397	O
of	398	400	O
cervical	401	409	B-Pathological_formation
lesions	410	417	I-Pathological_formation
of	418	420	O
type	421	425	O
CIN2	426	430	O
and	431	434	O
CIN3	435	439	O
treated	440	447	O
in	448	450	O
first	451	456	O
intention	457	466	O
by	467	469	O
laser	470	475	O
CO2	476	479	O
vaporization	480	492	O
was	493	496	O
carried	497	504	O
out	505	508	O
at	509	511	O
the	512	515	O
hospital	516	524	O
Jeanne	525	531	O
-	531	532	O
de	532	534	O
-	534	535	O
Flandre	535	542	O
in	543	545	O
CHRU	546	550	O
of	551	553	O
Lille	554	559	O
from	560	564	O
1996	565	569	O
to	570	572	O
2003	573	577	O
.	577	578	O

This	579	583	O
treatment	584	593	O
was	594	597	O
performed	598	607	O
on	608	610	O
only	611	615	O
high	616	620	O
-	620	621	O
grade	621	626	O
exo	627	630	B-Pathological_formation
-	630	631	I-Pathological_formation
cervical	631	639	I-Pathological_formation
lesions	640	647	I-Pathological_formation
,	647	648	O
of	649	651	O
small	652	657	O
size	658	662	O
(	663	664	O
<	664	665	O
2cm2	665	669	O
)	669	670	O
,	670	671	O
after	672	677	O
a	678	679	O
complete	680	688	O
colposcopic	689	700	O
examination	701	712	O
.	712	713	O

RESULTS	714	721	O
:	721	722	O

Fifty	723	728	O
-	728	729	O
two	729	732	O
patients	733	741	O
were	742	746	O
treated	747	754	O
by	755	757	O
first	758	763	O
-	763	764	O
intention	764	773	O
laser	774	779	O
vaporization	780	792	O
only	793	797	O
.	797	798	O

Mean	799	803	O
age	804	807	O
was	808	811	O
29	812	814	O
.	814	815	O
4	815	816	O
years	817	822	O
and	823	826	O
51	827	829	O
.	829	830	O
9	830	831	O
%	831	832	O
were	833	837	O
nulliparous	838	849	O
.	849	850	O

At	851	853	O
the	854	857	O
first	858	863	O
cyto	864	868	O
-	868	869	O
colposcopic	869	880	O
control	881	888	O
,	888	889	O
there	890	895	O
were	896	900	O
17	901	903	O
persistent	904	914	O
lesions	915	922	B-Pathological_formation
(	923	924	O
32	924	926	O
.	926	927	O
7	927	928	O
%	928	929	O
)	929	930	O
.	930	931	O

Among	932	937	O
the	938	941	O
35	942	944	O
patients	945	953	O
without	954	961	O
persistent	962	972	O
lesion	973	979	B-Pathological_formation
,	979	980	O
29	981	983	O
achieved	984	992	O
cure	993	997	O
(	998	999	O
absence	999	1006	O
of	1007	1009	O
recurrence	1010	1020	O
)	1020	1021	O
,	1021	1022	O
4	1023	1024	O
presented	1025	1034	O
a	1035	1036	O
recurrence	1037	1047	O
and	1048	1051	O
2	1052	1053	O
were	1054	1058	O
lost	1059	1063	O
to	1064	1066	O
follow	1067	1073	O
-	1073	1074	O
up	1074	1076	O
.	1076	1077	O

CONCLUSION	1078	1088	O
:	1088	1089	O

The	1090	1093	O
current	1094	1101	O
data	1102	1106	O
of	1107	1109	O
the	1110	1113	O
literature	1114	1124	O
concerning	1125	1135	O
the	1136	1139	O
treatment	1140	1149	O
by	1150	1152	O
laser	1153	1158	O
CO2	1159	1162	O
vaporization	1163	1175	O
authorize	1176	1185	O
application	1186	1197	O
of	1198	1200	O
this	1201	1205	O
method	1206	1212	O
for	1213	1216	O
certain	1217	1224	O
high	1225	1229	O
-	1229	1230	O
grade	1230	1235	O
exocervical	1236	1247	B-Pathological_formation
lesions	1248	1255	I-Pathological_formation
after	1256	1261	O
a	1262	1263	O
complete	1264	1272	O
colposcopic	1273	1284	O
examination	1285	1296	O
.	1296	1297	O

This	1298	1302	O
type	1303	1307	O
of	1308	1310	O
treatment	1311	1320	O
remains	1321	1328	O
less	1329	1333	O
aggressive	1334	1344	O
than	1345	1349	O
a	1350	1351	O
surgical	1352	1360	O
treatment	1361	1370	O
.	1370	1371	O

The	1372	1375	O
high	1376	1380	O
rate	1381	1385	O
of	1386	1388	O
residual	1389	1397	O
lesions	1398	1405	B-Pathological_formation
in	1406	1408	O
particular	1409	1419	O
in	1420	1422	O
the	1423	1426	O
event	1427	1432	O
of	1433	1435	O
CIN3	1436	1440	O
can	1441	1444	O
be	1445	1447	O
due	1448	1451	O
to	1452	1454	O
an	1455	1457	O
incomplete	1458	1468	O
destruction	1469	1480	O
of	1481	1483	O
the	1484	1487	O
lesion	1488	1494	B-Pathological_formation
.	1494	1495	O

Patients	1496	1504	O
should	1505	1511	O
thus	1512	1516	O
be	1517	1519	O
advised	1520	1527	O
that	1528	1532	O
monitoring	1533	1543	O
is	1544	1546	O
an	1547	1549	O
integral	1550	1558	O
part	1559	1563	O
of	1564	1566	O
the	1567	1570	O
treatment	1571	1580	O
.	1580	1581	O

Laser	1582	1587	O
vaporization	1588	1600	O
could	1601	1606	O
be	1607	1609	O
limited	1610	1617	O
to	1618	1620	O
CIN1	1621	1625	O
and	1626	1629	O
CIN2	1630	1634	O
lesions	1635	1642	B-Pathological_formation
.	1642	1643	O

Segmental	0	9	O
atrial	10	16	B-Multi-tissue_structure
contraction	17	28	O
in	29	31	O
patients	32	40	O
restored	41	49	O
to	50	52	O
sinus	53	58	B-Immaterial_anatomical_entity
rhythm	59	65	O
after	66	71	O
cardioversion	72	85	O
for	86	89	O
chronic	90	97	O
atrial	98	104	B-Multi-tissue_structure
fibrillation	105	117	O
:	117	118	O
a	119	120	O
colour	121	127	O
Doppler	128	135	O
tissue	136	142	B-Tissue
imaging	143	150	O
study	151	156	O
.	156	157	O

AIMS	158	162	O
:	162	163	O

There	164	169	O
is	170	172	O
little	173	179	O
known	180	185	O
about	186	191	O
segmental	192	201	O
atrial	202	208	B-Multi-tissue_structure
function	209	217	O
in	218	220	O
patients	221	229	O
with	230	234	O
atrial	235	241	B-Multi-tissue_structure
arrhythmias	242	253	O
.	253	254	O

We	255	257	O
evaluated	258	267	O
segmental	268	277	O
atrial	278	284	B-Multi-tissue_structure
contractility	285	298	O
using	299	304	O
colour	305	311	O
Doppler	312	319	O
tissue	320	326	B-Tissue
imaging	327	334	O
(	335	336	O
CDTI	336	340	O
)	340	341	O
in	342	344	O
patients	345	353	O
with	354	358	O
chronic	359	366	O
atrial	367	373	B-Multi-tissue_structure
fibrillation	374	386	O
(	387	388	O
CAF	388	391	O
)	391	392	O
who	393	396	O
were	397	401	O
successfully	402	414	O
restored	415	423	O
and	424	427	O
maintained	428	438	O
in	439	441	O
sinus	442	447	B-Immaterial_anatomical_entity
rhythm	448	454	O
(	455	456	O
SR	456	458	O
)	458	459	O
.	459	460	O

METHODS	461	468	O
AND	469	472	O
RESULTS	473	480	O
:	480	481	O

We	482	484	O
compared	485	493	O
the	494	497	O
segmental	498	507	O
atrial	508	514	B-Multi-tissue_structure
contractility	515	528	O
in	529	531	O
39	532	534	O
CAF	535	538	O
patients	539	547	O
who	548	551	O
were	552	556	O
successfully	557	569	O
cardioverted	570	582	O
and	583	586	O
maintained	587	597	O
in	598	600	O
SR	601	603	O
for	604	607	O
6	608	609	O
months	610	616	O
.	616	617	O

Follow	618	624	O
up	625	627	O
echocardiograms	628	643	O
were	644	648	O
performed	649	658	O
at	659	661	O
baseline	662	670	O
,	670	671	O
1	672	673	O
week	674	678	O
,	678	679	O
1	680	681	O
month	682	687	O
and	688	691	O
6	692	693	O
months	694	700	O
and	701	704	O
compared	705	713	O
to	714	716	O
a	717	718	O
normal	719	725	O
age	726	729	O
matched	730	737	O
cohort	738	744	O
(	745	746	O
n	746	747	O
=	748	749	O
34	750	752	O
)	752	753	O
.	753	754	O

Using	755	760	O
CDTI	761	765	O
,	765	766	O
mean	767	771	O
peak	772	776	O
velocities	777	787	O
of	788	790	O
atrial	791	797	B-Multi-tissue_structure
contraction	798	809	O
were	810	814	O
measured	815	823	O
from	824	828	O
annular	829	836	O
,	836	837	O
mid	838	841	O
and	842	845	O
superior	846	854	O
segments	855	863	O
of	864	866	O
lateral	867	874	B-Multi-tissue_structure
and	875	878	O
septal	879	885	B-Multi-tissue_structure
walls	886	891	I-Multi-tissue_structure
of	892	894	O
the	895	898	O
left	899	903	B-Multi-tissue_structure
atrium	904	910	I-Multi-tissue_structure
and	911	914	O
right	915	920	B-Multi-tissue_structure
atrium	921	927	I-Multi-tissue_structure
in	928	930	O
the	931	934	O
apical	935	941	O
four	942	946	O
-	946	947	O
chamber	947	954	O
view	955	959	O
.	959	960	O

Segmental	961	970	O
velocities	971	981	O
from	982	986	O
the	987	990	O
posterior	991	1000	O
and	1001	1004	O
anterior	1005	1013	O
walls	1014	1019	O
of	1020	1022	O
the	1023	1026	O
left	1027	1031	B-Multi-tissue_structure
atrium	1032	1038	I-Multi-tissue_structure
were	1039	1043	O
measured	1044	1052	O
from	1053	1057	O
the	1058	1061	O
apical	1062	1068	O
two	1069	1072	O
-	1072	1073	O
chamber	1073	1080	O
view	1081	1085	O
.	1085	1086	O

Segmental	1087	1096	O
left	1097	1101	B-Multi-tissue_structure
atrial	1102	1108	I-Multi-tissue_structure
velocities	1109	1119	O
improved	1120	1128	O
over	1129	1133	O
time	1134	1138	O
in	1139	1141	O
the	1142	1145	O
CAF	1146	1149	O
group	1150	1155	O
,	1155	1156	O
with	1157	1161	O
the	1162	1165	O
majority	1166	1174	O
of	1175	1177	O
the	1178	1181	O
recovery	1182	1190	O
occurring	1191	1200	O
in	1201	1203	O
the	1204	1207	O
first	1208	1213	O
month	1214	1219	O
,	1219	1220	O
but	1221	1224	O
failed	1225	1231	O
to	1232	1234	O
normalise	1235	1244	O
even	1245	1249	O
at	1250	1252	O
6	1253	1254	O
months	1255	1261	O
.	1261	1262	O

In	1263	1265	O
comparison	1266	1276	O
,	1276	1277	O
the	1278	1281	O
right	1282	1287	B-Multi-tissue_structure
atrial	1288	1294	I-Multi-tissue_structure
velocities	1295	1305	O
in	1306	1308	O
the	1309	1312	O
AF	1313	1315	O
group	1316	1321	O
had	1322	1325	O
normalised	1326	1336	O
at	1337	1339	O
1	1340	1341	O
month	1342	1347	O
.	1347	1348	O

CONCLUSION	1349	1359	O
:	1359	1360	O

Patients	1361	1369	O
with	1370	1374	O
CAF	1375	1378	O
have	1379	1383	O
persistent	1384	1394	O
segmental	1395	1404	O
left	1405	1409	B-Multi-tissue_structure
atrial	1410	1416	I-Multi-tissue_structure
dysfunction	1417	1428	O
even	1429	1433	O
6	1434	1435	O
months	1436	1442	O
after	1443	1448	O
restoration	1449	1460	O
and	1461	1464	O
maintenance	1465	1476	O
of	1477	1479	O
SR	1480	1482	O
,	1482	1483	O
though	1484	1490	O
right	1491	1496	B-Multi-tissue_structure
atrial	1497	1503	I-Multi-tissue_structure
velocities	1504	1514	O
appear	1515	1521	O
to	1522	1524	O
normalise	1525	1534	O
.	1534	1535	O

This	1536	1540	O
differential	1541	1553	O
recovery	1554	1562	O
indicates	1563	1572	O
that	1573	1577	O
left	1578	1582	B-Multi-tissue_structure
atrial	1583	1589	I-Multi-tissue_structure
function	1590	1598	O
remains	1599	1606	O
subnormal	1607	1616	O
in	1617	1619	O
patients	1620	1628	O
with	1629	1633	O
CAF	1634	1637	O
despite	1638	1645	O
maintenance	1646	1657	O
of	1658	1660	O
SR	1661	1663	O
,	1663	1664	O
suggesting	1665	1675	O
underlying	1676	1686	O
atrial	1687	1693	B-Multi-tissue_structure
myopathy	1694	1702	O
or	1703	1705	O
fibrosis	1706	1714	O
as	1715	1717	O
a	1718	1719	O
consequence	1720	1731	O
of	1732	1734	O
CAF	1735	1738	O
.	1738	1739	O

[	0	1	O
Anomalous	1	10	O
origin	11	17	O
of	18	20	O
the	21	24	O
right	25	30	B-Multi-tissue_structure
coronary	31	39	I-Multi-tissue_structure
artery	40	46	I-Multi-tissue_structure
from	47	51	O
the	52	55	O
left	56	60	O
sinus	61	66	B-Immaterial_anatomical_entity
of	67	69	O
Valsalva	70	78	O
:	78	79	O
case	80	84	O
report	85	91	O
and	92	95	O
literature	96	106	O
review	107	113	O
]	113	114	O
.	114	115	O

We	116	118	O
describe	119	127	O
the	128	131	O
case	132	136	O
of	137	139	O
a	140	141	O
patient	142	149	O
in	150	152	O
whom	153	157	O
evaluation	158	168	O
of	169	171	O
effort	172	178	O
angina	179	185	O
revealed	186	194	O
a	195	196	O
tight	197	202	O
stenosis	203	211	O
of	212	214	O
a	215	216	O
right	217	222	B-Multi-tissue_structure
coronary	223	231	I-Multi-tissue_structure
artery	232	238	I-Multi-tissue_structure
anomalously	239	250	O
arising	251	258	O
from	259	263	O
the	264	267	O
left	268	272	O
sinus	273	278	B-Immaterial_anatomical_entity
of	279	281	O
Valsalva	282	290	O
,	290	291	O
which	292	297	O
was	298	301	O
successfully	302	314	O
treated	315	322	O
by	323	325	O
stent	326	331	O
implantation	332	344	O
.	344	345	O

The	346	349	O
abnormal	350	358	O
origin	359	365	O
of	366	368	O
the	369	372	O
right	373	378	B-Multi-tissue_structure
coronary	379	387	I-Multi-tissue_structure
artery	388	394	I-Multi-tissue_structure
from	395	399	O
the	400	403	O
left	404	408	O
aortic	409	415	B-Immaterial_anatomical_entity
sinus	416	421	I-Immaterial_anatomical_entity
coursing	422	430	O
between	431	438	O
the	439	442	O
aorta	443	448	B-Multi-tissue_structure
and	449	452	O
the	453	456	O
pulmonary	457	466	B-Multi-tissue_structure
trunk	467	472	I-Multi-tissue_structure
is	473	475	O
a	476	477	O
rare	478	482	O
congenital	483	493	O
anomaly	494	501	O
.	501	502	O

It	503	505	O
may	506	509	O
remain	510	516	O
asymptomatic	517	529	O
,	529	530	O
but	531	534	O
can	535	538	O
also	539	543	O
cause	544	549	O
major	550	555	O
cardiac	556	563	B-Organ
events	564	570	O
,	570	571	O
even	572	576	O
in	577	579	O
the	580	583	O
absence	584	591	O
of	592	594	O
coronary	595	603	B-Multi-tissue_structure
atherosclerosis	604	619	O
.	619	620	O

We	621	623	O
discuss	624	631	O
the	632	635	O
clinical	636	644	O
importance	645	655	O
of	656	658	O
this	659	663	O
anomaly	664	671	O
and	672	675	O
review	676	682	O
the	683	686	O
literature	687	697	O
concerning	698	708	O
current	709	716	O
views	717	722	O
and	723	726	O
therapy	727	734	O
.	734	735	O

Determination	0	13	O
of	14	16	O
eprosartan	17	27	O
in	28	30	O
human	31	36	O
plasma	37	43	B-Organism_substance
and	44	47	O
urine	48	53	B-Organism_substance
by	54	56	O
LC	57	59	O
/	59	60	O
MS	60	62	O
/	62	63	O
MS	63	65	O
.	65	66	O

A	67	68	O
protein	69	76	O
precipitation	77	90	O
,	90	91	O
liquid	92	98	O
chromatography	99	113	O
/	113	114	O
tandem	114	120	O
mass	121	125	O
spectrometry	126	138	O
(	139	140	O
LC	140	142	O
/	142	143	O
MS	143	145	O
/	145	146	O
MS	146	148	O
)	148	149	O
method	150	156	O
has	157	160	O
been	161	165	O
developed	166	175	O
and	176	179	O
validated	180	189	O
for	190	193	O
the	194	197	O
determination	198	211	O
of	212	214	O
eprosartan	215	225	O
in	226	228	O
human	229	234	O
plasma	235	241	B-Organism_substance
and	242	245	O
urine	246	251	B-Organism_substance
.	251	252	O

The	253	256	O
solvent	257	264	O
system	265	271	O
also	272	276	O
served	277	283	O
as	284	286	O
a	287	288	O
protein	289	296	O
precipitation	297	310	O
reagent	311	318	O
.	318	319	O

The	320	323	O
chromatographic	324	339	O
separation	340	350	O
was	351	354	O
achieved	355	363	O
on	364	366	O
a	367	368	O
CAPCELL	369	376	O
PAK	377	380	O
C18	381	384	O
column	385	391	O
(	392	393	O
50	393	395	O
mmx2	396	400	O
.	400	401	O
0	401	402	O
mm	403	405	O
,	405	406	O
5	407	408	O
microm	409	415	O
,	415	416	O
Shiseido	417	425	O
)	425	426	O
.	426	427	O

A	428	429	O
mobile	430	436	O
phase	437	442	O
was	443	446	O
consisted	447	456	O
of	457	459	O
0	460	461	O
.	461	462	O
5	462	463	O
%	463	464	O
formic	465	471	O
acid	472	476	O
in	477	479	O
water	480	485	O
and	486	489	O
0	490	491	O
.	491	492	O
5	492	493	O
%	493	494	O
formic	495	501	O
acid	502	506	O
in	507	509	O
acetonitrile	510	522	O
(	523	524	O
72	524	526	O
:	526	527	O
28	527	529	O
)	529	530	O
.	530	531	O

Detection	532	541	O
was	542	545	O
by	546	548	O
positive	549	557	O
ion	558	561	O
electrospray	562	574	O
tandem	575	581	O
mass	582	586	O
spectrometry	587	599	O
on	600	602	O
a	603	604	O
Sciex	605	610	O
API3000	611	618	O
.	618	619	O

The	620	623	O
standard	624	632	O
curves	633	639	O
,	639	640	O
which	641	646	O
ranged	647	653	O
from	654	658	O
5	659	660	O
to	661	663	O
2000	664	668	O
ng	669	671	O
/	671	672	O
mL	672	674	O
in	675	677	O
human	678	683	O
plasma	684	690	B-Organism_substance
and	691	694	O
from	695	699	O
0	700	701	O
.	701	702	O
25	702	704	O
to	705	707	O
50	708	710	O
microg	711	717	O
/	717	718	O
mL	718	720	O
in	721	723	O
urine	724	729	B-Organism_substance
,	729	730	O
were	731	735	O
fitted	736	742	O
to	743	745	O
a	746	747	O
1	748	749	O
/	749	750	O
x	750	751	O
weighted	752	760	O
quadratic	761	770	O
regression	771	781	O
model	782	787	O
.	787	788	O

The	789	792	O
method	793	799	O
proved	800	806	O
to	807	809	O
be	810	812	O
accurate	813	821	O
,	821	822	O
specific	823	831	O
and	832	835	O
sensitive	836	845	O
enough	846	852	O
to	853	855	O
be	856	858	O
successfully	859	871	O
applied	872	879	O
to	880	882	O
a	883	884	O
pharmacokinetic	885	900	O
study	901	906	O
.	906	907	O

[	0	1	O
Synthetic	1	10	O
fragments	11	20	O
of	21	23	O
the	24	27	O
NS1	28	31	O
protein	32	39	O
of	40	42	O
the	43	46	O
tick	47	51	O
-	51	52	O
borne	52	57	O
encephalitis	58	70	O
virus	71	76	O
exhibiting	77	87	O
a	88	89	O
protective	90	100	O
effect	101	107	O
]	107	108	O
.	108	109	O

Potentially	110	121	O
immunoactive	122	134	O
regions	135	142	O
of	143	145	O
the	146	149	O
NS1	150	153	O
nonstructural	154	167	O
protein	168	175	O
of	176	178	O
the	179	182	O
tick	183	187	O
-	187	188	O
borne	188	193	O
encephalitis	194	206	O
virus	207	212	O
that	213	217	O
can	218	221	O
stimulate	222	231	O
the	232	235	O
antibody	236	244	O
formation	245	254	O
in	255	257	O
vivo	258	262	O
and	263	266	O
protect	267	274	O
animals	275	282	O
from	283	287	O
this	288	292	O
disease	293	300	O
were	301	305	O
chosen	306	312	O
on	313	315	O
the	316	319	O
basis	320	325	O
of	326	328	O
theoretical	329	340	O
calculations	341	353	O
.	353	354	O

Eleven	355	361	O
16	362	364	O
-	364	365	O
to	366	368	O
27	369	371	O
-	371	372	O
aa	372	374	O
peptides	375	383	O
containing	384	394	O
the	395	398	O
chosen	399	405	O
regions	406	413	O
were	414	418	O
synthesized	419	430	O
.	430	431	O

The	432	435	O
ability	436	443	O
of	444	446	O
the	447	450	O
free	451	455	O
peptides	456	464	O
(	465	466	O
without	466	473	O
any	474	477	O
high	478	482	O
-	482	483	O
molecular	483	492	O
-	492	493	O
mass	493	497	O
carrier	498	505	O
)	505	506	O
to	507	509	O
stimulate	510	519	O
the	520	523	O
production	524	534	O
of	535	537	O
antipeptide	538	549	O
antibodies	550	560	O
in	561	563	O
mice	564	568	O
of	569	571	O
three	572	577	O
lines	578	583	O
and	584	587	O
ensure	588	594	O
the	595	598	O
formation	599	608	O
of	609	611	O
protective	612	622	O
immunity	623	631	O
was	632	635	O
studied	636	643	O
.	643	644	O

Most	645	649	O
of	650	652	O
these	653	658	O
peptides	659	667	O
were	668	672	O
shown	673	678	O
to	679	681	O
exhibit	682	689	O
the	690	693	O
immunogenic	694	705	O
activity	706	714	O
in	715	717	O
a	718	719	O
free	720	724	O
state	725	730	O
.	730	731	O

Five	732	736	O
fragments	737	746	O
that	747	751	O
can	752	755	O
protect	756	763	O
mice	764	768	O
from	769	773	O
the	774	777	O
infection	778	787	O
by	788	790	O
a	791	792	O
lethal	793	799	O
dose	800	804	O
of	805	807	O
tick	808	812	O
-	812	813	O
borne	813	818	O
encephalitis	819	831	O
virus	832	837	O
were	838	842	O
found	843	848	O
.	848	849	O

Long	0	4	O
-	4	5	O
term	5	9	O
immunosuppression	10	27	O
in	28	30	O
burned	31	37	O
patients	38	46	O
assessed	47	55	O
by	56	58	O
in	59	61	O
vitro	62	67	O
neutrophil	68	78	B-Cell
oxidative	79	88	O
burst	89	94	O
(	95	96	O
Phagoburst	96	106	O
)	106	107	O
.	107	108	O

OBJECTIVE	109	118	O
:	118	119	O

To	120	122	O
assess	123	129	O
the	130	133	O
duration	134	142	O
and	143	146	O
magnitude	147	156	O
of	157	159	O
immunosuppression	160	177	O
induced	178	185	O
by	186	188	O
burns	189	194	O
as	195	197	O
measured	198	206	O
by	207	209	O
the	210	213	O
neutrophil	214	224	B-Cell
oxidative	225	234	O
burst	235	240	O
in	241	243	O
vitro	244	249	O
.	249	250	O

DESIGN	251	257	O
:	257	258	O

Prospective	259	270	O
exploratory	271	282	O
cohort	283	289	O
study	290	295	O
.	295	296	O

SETTING	297	304	O
:	304	305	O

Tertiary	306	314	O
referral	315	323	O
unit	324	328	O
,	328	329	O
University	330	340	O
Hospital	341	349	O
,	349	350	O
Linkoping	351	360	O
,	360	361	O
Sweden	362	368	O
(	369	370	O
National	370	378	O
Burn	379	383	O
Unit	384	388	O
)	388	389	O
.	389	390	O

PATIENTS	391	399	O
AND	400	403	O
HEALTHY	404	411	O
VOLUNTEERS	412	422	O
(	423	424	O
CONTROLS	424	432	O
)	432	433	O
:	433	434	O
Twenty	435	441	O
-	441	442	O
eight	442	447	O
subjects	448	456	O
consecutively	457	470	O
admitted	471	479	O
to	480	482	O
the	483	486	O
Burn	487	491	O
Unit	492	496	O
.	496	497	O

The	498	501	O
mean	502	506	O
total	507	512	O
burn	513	517	O
surface	518	525	O
area	526	530	O
(	531	532	O
TBSA	532	536	O
%	536	537	O
)	537	538	O
was	539	542	O
36	543	545	O
(	546	547	O
range	547	552	O
13	553	555	O
-	555	556	O
87	556	558	O
)	558	559	O
and	560	563	O
mean	564	568	O
age	569	572	O
44	573	575	O
years	576	581	O
(	582	583	O
range	583	588	O
14	589	591	O
-	591	592	O
89	592	594	O
)	594	595	O
.	595	596	O

Patients	597	605	O
'	605	606	O
data	607	611	O
were	612	616	O
collected	617	626	O
prospectively	627	640	O
in	641	643	O
the	644	647	O
burn	648	652	O
unit	653	657	O
,	657	658	O
which	659	664	O
also	665	669	O
included	670	678	O
sequential	679	689	O
organ	690	695	B-Organ
failure	696	703	O
assessment	704	714	O
(	715	716	O
SOFA	716	720	O
)	720	721	O
score	722	727	O
.	727	728	O

INTERVENTIONS	729	742	O
:	742	743	O

None	744	748	O
.	748	749	O

MEASUREMENTS	750	762	O
AND	763	766	O
RESULTS	767	774	O
:	774	775	O

To	776	778	O
assess	779	785	O
the	786	789	O
changes	790	797	O
in	798	800	O
the	801	804	O
oxidative	805	814	O
capacity	815	823	O
of	824	826	O
neutrophils	827	838	B-Cell
after	839	844	O
the	845	848	O
burn	849	853	O
,	853	854	O
blood	855	860	B-Organism_substance
samples	861	868	I-Organism_substance
for	869	872	O
the	873	876	O
Phagoburst	877	887	O
analysis	888	896	O
were	897	901	O
taken	902	907	O
on	908	910	O
admission	911	920	O
and	921	924	O
at	925	927	O
least	928	933	O
once	934	938	O
every	939	944	O
second	945	951	O
week	952	956	O
for	957	960	O
the	961	964	O
duration	965	973	O
of	974	976	O
stay	977	981	O
in	982	984	O
hospital	985	993	O
and	994	997	O
thereafter	998	1008	O
monthly	1009	1016	O
up	1017	1019	O
to	1020	1022	O
12	1023	1025	O
months	1026	1032	O
after	1033	1038	O
the	1039	1042	O
burn	1043	1047	O
.	1047	1048	O

Neutrophils	1049	1060	B-Cell
were	1061	1065	O
stimulated	1066	1076	O
in	1077	1079	O
vitro	1080	1085	O
by	1086	1088	O
Escherichia	1089	1100	O
coli	1101	1105	O
,	1105	1106	O
phorbol	1107	1114	O
12	1115	1117	O
-	1117	1118	O
phorbol	1118	1125	O
myristate	1126	1135	O
13	1136	1138	O
-	1138	1139	O
acetate	1139	1146	O
(	1147	1148	O
PMA	1148	1151	O
)	1151	1152	O
,	1152	1153	O
and	1154	1157	O
peptide	1158	1165	O
N	1166	1167	O
-	1167	1168	O
formyl	1168	1174	O
-	1174	1175	O
Met	1175	1178	O
-	1178	1179	O
Leu	1179	1182	O
-	1182	1183	O
Phe	1183	1186	O
(	1187	1188	O
fMLP	1188	1192	O
)	1192	1193	O
.	1193	1194	O

Oxidative	1195	1204	O
burst	1205	1210	O
was	1211	1214	O
measured	1215	1223	O
by	1224	1226	O
flow	1227	1231	O
cytometry	1232	1241	O
.	1241	1242	O

Oxidative	1243	1252	O
capacity	1253	1261	O
of	1262	1264	O
the	1265	1268	O
neutrophils	1269	1280	B-Cell
decreased	1281	1290	O
similarly	1291	1300	O
for	1301	1304	O
all	1305	1308	O
three	1309	1314	O
stimulants	1315	1325	O
:	1325	1326	O
there	1327	1332	O
was	1333	1336	O
a	1337	1338	O
pathological	1339	1351	O
decrease	1352	1360	O
shortly	1361	1368	O
after	1369	1374	O
admission	1375	1384	O
,	1384	1385	O
with	1386	1390	O
the	1391	1394	O
lowest	1395	1401	O
value	1402	1407	O
occurring	1408	1417	O
between	1418	1425	O
days	1426	1430	O
7	1431	1432	O
and	1433	1436	O
10	1437	1439	O
,	1439	1440	O
followed	1441	1449	O
by	1450	1452	O
a	1453	1454	O
gradual	1455	1462	O
recovery	1463	1471	O
during	1472	1478	O
the	1479	1482	O
ensuing	1483	1490	O
months	1491	1497	O
.	1497	1498	O

Full	1499	1503	O
recovery	1504	1512	O
(	1513	1514	O
to	1514	1516	O
the	1517	1520	O
values	1521	1527	O
of	1528	1530	O
the	1531	1534	O
controls	1535	1543	O
)	1543	1544	O
was	1545	1548	O
seen	1549	1553	O
first	1554	1559	O
3	1560	1561	O
.	1561	1562	O
5	1562	1563	O
months	1564	1570	O
after	1571	1576	O
the	1577	1580	O
burn	1581	1585	O
.	1585	1586	O

Using	1587	1592	O
multiple	1593	1601	O
regression	1602	1612	O
,	1612	1613	O
we	1614	1616	O
found	1617	1622	O
that	1623	1627	O
only	1628	1632	O
age	1633	1636	O
and	1637	1640	O
time	1641	1645	O
since	1646	1651	O
the	1652	1655	O
burn	1656	1660	O
significantly	1661	1674	O
(	1675	1676	O
p	1676	1677	O
<	1677	1678	O
0	1678	1679	O
.	1679	1680	O
05	1680	1682	O
)	1682	1683	O
affected	1684	1692	O
the	1693	1696	O
oxidative	1697	1706	O
burst	1707	1712	O
.	1712	1713	O

White	1714	1719	B-Cell
cell	1720	1724	I-Cell
count	1725	1730	O
(	1731	1732	O
WCC	1732	1735	O
)	1735	1736	O
and	1737	1740	O
C	1741	1742	O
-	1742	1743	O
reactive	1743	1751	O
protein	1752	1759	O
(	1760	1761	O
CRP	1761	1764	O
)	1764	1765	O
values	1766	1772	O
returned	1773	1781	O
to	1782	1784	O
reference	1785	1794	O
ranges	1795	1801	O
long	1802	1806	O
before	1807	1813	O
the	1814	1817	O
oxidative	1818	1827	O
burst	1828	1833	O
.	1833	1834	O

CONCLUSIONS	1835	1846	O
:	1846	1847	O

This	1848	1852	O
study	1853	1858	O
provides	1859	1867	O
evidence	1868	1876	O
that	1877	1881	O
immunosuppression	1882	1899	O
in	1900	1902	O
those	1903	1908	O
injured	1909	1916	O
by	1917	1919	O
burns	1920	1925	O
,	1925	1926	O
as	1927	1929	O
assessed	1930	1938	O
by	1939	1941	O
the	1942	1945	O
in	1946	1948	O
vitro	1949	1954	O
oxidative	1955	1964	O
burst	1965	1970	O
of	1971	1973	O
neutrophils	1974	1985	B-Cell
,	1985	1986	O
remains	1987	1994	O
long	1995	1999	O
after	2000	2005	O
the	2006	2009	O
event	2010	2015	O
of	2016	2018	O
the	2019	2022	O
burn	2023	2027	O
(	2028	2029	O
up	2029	2031	O
to	2032	2034	O
3	2035	2036	O
.	2036	2037	O
5	2037	2038	O
months	2039	2045	O
after	2046	2051	O
burn	2052	2056	O
)	2056	2057	O
.	2057	2058	O

Absence	2059	2066	O
of	2067	2069	O
correlations	2070	2082	O
to	2083	2085	O
TBSA	2086	2090	O
%	2090	2091	O
,	2091	2092	O
FTB	2093	2096	O
%	2096	2097	O
,	2097	2098	O
blood	2099	2104	B-Organism_substance
transfusion	2105	2116	O
,	2116	2117	O
opiates	2118	2125	O
provided	2126	2134	O
,	2134	2135	O
and	2136	2139	O
multiple	2140	2148	O
organ	2149	2154	B-Organ
failure	2155	2162	O
score	2163	2168	O
and	2169	2172	O
laboratory	2173	2183	O
infection	2184	2193	O
variables	2194	2203	O
together	2204	2212	O
with	2213	2217	O
the	2218	2221	O
finding	2222	2229	O
that	2230	2234	O
decreased	2235	2244	O
oxidative	2245	2254	O
burst	2255	2260	O
was	2261	2264	O
uniform	2265	2272	O
after	2273	2278	O
the	2279	2282	O
injury	2283	2289	O
,	2289	2290	O
suggesting	2291	2301	O
that	2302	2306	O
this	2307	2311	O
immunosuppression	2312	2329	O
is	2330	2332	O
primarily	2333	2342	O
due	2343	2346	O
to	2347	2349	O
the	2350	2353	O
general	2354	2361	O
metabolic	2362	2371	O
response	2372	2380	O
rather	2381	2387	O
than	2388	2392	O
recurring	2393	2402	O
infections	2403	2413	O
.	2413	2414	O

Neurohypophyseal	0	16	B-Pathological_formation
granulomatous	17	30	I-Pathological_formation
germinoma	31	40	I-Pathological_formation
invading	41	49	O
the	50	53	O
right	54	59	B-Immaterial_anatomical_entity
cavernous	60	69	I-Immaterial_anatomical_entity
sinus	70	75	I-Immaterial_anatomical_entity
:	75	76	O
case	77	81	O
report	82	88	O
and	89	92	O
review	93	99	O
of	100	102	O
the	103	106	O
literature	107	117	O
.	117	118	O

We	119	121	O
encountered	122	133	O
a	134	135	O
rare	136	140	O
case	141	145	O
of	146	148	O
neurohypophyseal	149	165	B-Pathological_formation
germinoma	166	175	I-Pathological_formation
with	176	180	O
a	181	182	O
prominent	183	192	O
granulomatous	193	206	O
reaction	207	215	O
,	215	216	O
which	217	222	O
invaded	223	230	O
the	231	234	O
right	235	240	B-Immaterial_anatomical_entity
cavernous	241	250	I-Immaterial_anatomical_entity
sinus	251	256	I-Immaterial_anatomical_entity
.	256	257	O

The	258	261	O
neuroimaging	262	274	O
and	275	278	O
histopathology	279	293	O
features	294	302	O
in	303	305	O
this	306	310	O
case	311	315	O
were	316	320	O
unique	321	327	O
,	327	328	O
distinguishing	329	343	O
it	344	346	O
from	347	351	O
other	352	357	O
types	358	363	O
of	364	366	O
suprasellar	367	378	B-Pathological_formation
lesions	379	386	I-Pathological_formation
.	386	387	O

A	388	389	O
13	390	392	O
-	392	393	O
year	393	397	O
-	397	398	O
old	398	401	O
boy	402	405	O
presented	406	415	O
with	416	420	O
loss	421	425	O
of	426	428	O
appetite	429	437	O
and	438	441	O
polyuria	442	450	O
;	450	451	O
both	452	456	O
symptoms	457	465	O
were	466	470	O
present	471	478	O
for	479	482	O
1	483	484	O
year	485	489	O
,	489	490	O
and	491	494	O
headache	495	503	O
,	503	504	O
general	505	512	O
fatigue	513	520	O
and	521	524	O
blurred	525	532	O
vision	533	539	O
present	540	547	O
for	548	551	O
the	552	555	O
prior	556	561	O
2	562	563	O
months	564	570	O
.	570	571	O

On	572	574	O
admission	575	584	O
,	584	585	O
neurological	586	598	O
examination	599	610	O
indicated	611	620	O
bitemporal	621	631	O
hemianopsia	632	643	O
and	644	647	O
optic	648	653	O
atrophy	654	661	O
.	661	662	O

Endocrinological	663	679	O
exam	680	684	O
showed	685	691	O
panhypopituitarism	692	710	O
.	710	711	O

Tumor	712	717	B-Pathological_formation
markers	718	725	O
such	726	730	O
as	731	733	O
alpha	734	739	O
-	739	740	O
fetoprotein	740	751	O
,	751	752	O
human	753	758	O
growth	759	765	O
hormone	766	773	O
,	773	774	O
carcinoembryonic	775	791	O
antigen	792	799	O
,	799	800	O
and	801	804	O
placental	805	814	B-Organ
alkaline	815	823	O
phosphatase	824	835	O
were	836	840	O
negative	841	849	O
.	849	850	O

Brain	851	856	B-Organ
CT	857	859	O
revealed	860	868	O
a	869	870	O
suprasellar	871	882	B-Pathological_formation
tumor	883	888	I-Pathological_formation
with	889	893	O
calcification	894	907	O
.	907	908	O

MR	909	911	O
T	912	913	O
(	913	914	O
1	914	915	O
)	915	916	O
-	916	917	O
weighted	917	925	O
and	926	929	O
T	930	931	O
(	931	932	O
2	932	933	O
)	933	934	O
-	934	935	O
weighted	935	943	O
images	944	950	O
showed	951	957	O
the	958	961	O
tumor	962	967	B-Pathological_formation
to	968	970	O
be	971	973	O
isointense	974	984	O
to	985	987	O
normal	988	994	O
brain	995	1000	B-Organ
parenchyma	1001	1011	O
and	1012	1015	O
to	1016	1018	O
be	1019	1021	O
enhanced	1022	1030	O
densely	1031	1038	O
.	1038	1039	O

The	1040	1043	O
tumor	1044	1049	B-Pathological_formation
also	1050	1054	O
involved	1055	1063	O
the	1064	1067	O
right	1068	1073	B-Immaterial_anatomical_entity
cavernous	1074	1083	I-Immaterial_anatomical_entity
sinus	1084	1089	I-Immaterial_anatomical_entity
,	1089	1090	O
so	1091	1093	O
that	1094	1098	O
a	1099	1100	O
biopsy	1101	1107	O
was	1108	1111	O
performed	1112	1121	O
by	1122	1124	O
the	1125	1128	O
transsphenoidal	1129	1144	B-Multi-tissue_structure
approach	1145	1153	O
.	1153	1154	O

On	1155	1157	O
pathologic	1158	1168	O
examination	1169	1180	O
of	1181	1183	O
the	1184	1187	O
specimen	1188	1196	O
,	1196	1197	O
typical	1198	1205	O
large	1206	1211	O
tumor	1212	1217	B-Cell
cells	1218	1223	I-Cell
with	1224	1228	O
lymphocytic	1229	1240	B-Cell
cell	1241	1245	I-Cell
infiltration	1246	1258	O
and	1259	1262	O
prominent	1263	1272	O
granulomatous	1273	1286	O
reaction	1287	1295	O
were	1296	1300	O
observed	1301	1309	O
.	1309	1310	O

Neurohypophyseal	1311	1327	B-Pathological_formation
granulomatous	1328	1341	I-Pathological_formation
germinoma	1342	1351	I-Pathological_formation
was	1352	1355	O
diagnosed	1356	1365	O
.	1365	1366	O

Radiotherapy	1367	1379	O
was	1380	1383	O
performed	1384	1393	O
with	1394	1398	O
a	1399	1400	O
total	1401	1406	O
dose	1407	1411	O
of	1412	1414	O
51	1415	1417	O
Gy	1418	1420	O
and	1421	1424	O
the	1425	1428	O
tumor	1429	1434	B-Pathological_formation
shrank	1435	1441	O
remarkably	1442	1452	O
.	1452	1453	O

The	1454	1457	O
patient	1458	1465	O
returned	1466	1474	O
to	1475	1477	O
school	1478	1484	O
under	1485	1490	O
hormone	1491	1498	O
replacement	1499	1510	O
therapy	1511	1518	O
.	1518	1519	O

Melanoma	0	8	B-Pathological_formation
/	8	9	O
skin	9	13	B-Pathological_formation
cancer	14	20	I-Pathological_formation
screening	21	30	O
clinics	31	38	O
:	38	39	O
experiences	40	51	O
in	52	54	O
The	55	58	O
Netherlands	59	70	O
.	70	71	O

In	72	74	O
1989	75	79	O
and	80	83	O
1990	84	88	O
we	89	91	O
conducted	92	101	O
two	102	105	O
free	106	110	O
melanoma	111	119	B-Pathological_formation
/	119	120	O
skin	120	124	B-Organ
screening	125	134	O
clinics	135	142	O
in	143	145	O
Oss	146	149	O
and	150	153	O
Arnhem	154	160	O
in	161	163	O
the	164	167	O
Netherlands	168	179	O
.	179	180	O

The	181	184	O
study	185	190	O
was	191	194	O
carried	195	202	O
out	203	206	O
along	207	212	O
the	213	216	O
lines	217	222	O
of	223	225	O
the	226	229	O
recent	230	236	O
campaigns	237	246	O
supported	247	256	O
by	257	259	O
the	260	263	O
American	264	272	O
Academy	273	280	O
of	281	283	O
Dermatology	284	295	O
.	295	296	O

Of	297	299	O
2564	300	304	O
persons	305	312	O
screened	313	321	O
,	321	322	O
53	323	325	O
had	326	329	O
melanoma	330	338	B-Pathological_formation
or	339	341	O
nonmelanoma	342	353	B-Pathological_formation
skin	354	358	I-Pathological_formation
cancer	359	365	I-Pathological_formation
(	366	367	O
2	367	368	O
.	368	369	O
1	369	370	O
%	370	371	O
)	371	372	O
.	372	373	O

Compliance	374	384	O
with	385	389	O
follow	390	396	O
-	396	397	O
up	397	399	O
for	400	403	O
persons	404	411	O
with	412	416	O
suspected	417	426	O
melanoma	427	435	B-Pathological_formation
/	435	436	O
skin	436	440	B-Pathological_formation
cancer	441	447	I-Pathological_formation
was	448	451	O
adequate	452	460	O
(	461	462	O
93	462	464	O
of	465	467	O
103	468	471	O
;	471	472	O
90	473	475	O
.	475	476	O
3	476	477	O
%	477	478	O
)	478	479	O
.	479	480	O

Impact	0	6	O
of	7	9	O
dexamethasone	10	23	O
-	23	24	O
induced	24	31	O
immunosuppression	32	49	O
on	50	52	O
the	53	56	O
duration	57	65	O
and	66	69	O
level	70	75	O
of	76	78	O
shedding	79	87	O
of	88	90	O
Escherichia	91	102	O
coli	103	107	O
O157	108	112	O
:	112	113	O
H7	113	115	O
in	116	118	O
calves	119	125	O
.	125	126	O

The	127	130	O
goal	131	135	O
of	136	138	O
this	139	143	O
study	144	149	O
was	150	153	O
to	154	156	O
determine	157	166	O
whether	167	174	O
immunosuppression	175	192	O
plays	193	198	O
a	199	200	O
role	201	205	O
in	206	208	O
the	209	212	O
level	213	218	O
and	219	222	O
duration	223	231	O
of	232	234	O
fecal	235	240	B-Organism_substance
shedding	241	249	O
of	250	252	O
Escherichia	253	264	O
coli	265	269	O
O157	270	274	O
.	274	275	O

Immunosuppression	276	293	O
was	294	297	O
induced	298	305	O
in	306	308	O
calves	309	315	O
by	316	318	O
administering	319	332	O
dexamethasone	333	346	O
.	346	347	O

Six	348	351	O
1	352	353	O
-	353	354	O
week	354	358	O
-	358	359	O
old	359	362	O
Holstein	363	371	O
bull	372	376	O
calves	377	383	O
were	384	388	O
injected	389	397	O
intramuscularly	398	413	B-Tissue
with	414	418	O
dexamethasone	419	432	O
and	433	436	O
orally	437	443	O
inoculated	444	454	O
with	455	459	O
10	460	462	O
(	462	463	O
9	463	464	O
)	464	465	O
CFU	466	469	O
of	470	472	O
a	473	474	O
mixture	475	482	O
of	483	485	O
three	486	491	O
nalidixic	492	501	O
-	501	502	O
acid	502	506	O
resistant	507	516	O
strains	517	524	O
of	525	527	O
E	528	529	O
.	529	530	O
coli	531	535	O
O157	536	540	O
:	540	541	O
H7	541	543	O
.	543	544	O

Five	545	549	O
1	550	551	O
-	551	552	O
week	552	556	O
-	556	557	O
old	557	560	O
Holstein	561	569	O
bull	570	574	O
calves	575	581	O
that	582	586	O
were	587	591	O
given	592	597	O
the	598	601	O
same	602	606	O
oral	607	611	O
inoculation	612	623	O
of	624	626	O
E	627	628	O
.	628	629	O
coli	630	634	O
O157	635	639	O
:	639	640	O
H7	640	642	O
,	642	643	O
but	644	647	O
not	648	651	O
the	652	655	O
dexamethasone	656	669	O
injections	670	680	O
,	680	681	O
served	682	688	O
as	689	691	O
controls	692	700	O
.	700	701	O

All	702	705	O
calves	706	712	O
were	713	717	O
examined	718	726	O
daily	727	732	O
and	733	736	O
fecal	737	742	B-Organism_substance
samples	743	750	O
were	751	755	O
collected	756	765	O
three	766	771	O
times	772	777	O
a	778	779	O
week	780	784	O
for	785	788	O
detection	789	798	O
and	799	802	O
enumeration	803	814	O
of	815	817	O
the	818	821	O
nalidixic	822	831	O
-	831	832	O
acid	832	836	O
resistant	837	846	O
E	847	848	O
.	848	849	O
coli	850	854	O
O157	855	859	O
.	859	860	O

Four	861	865	O
weeks	866	871	O
after	872	877	O
the	878	881	O
last	882	886	O
calf	887	891	O
stopped	892	899	O
shedding	900	908	O
,	908	909	O
all	910	913	O
calves	914	920	O
were	921	925	O
necropsied	926	936	O
and	937	940	O
samples	941	948	O
from	949	953	O
the	954	957	O
gastrointestinal	958	974	B-Organism_subdivision
tract	975	980	I-Organism_subdivision
were	981	985	O
taken	986	991	O
for	992	995	O
the	996	999	O
detection	1000	1009	O
of	1010	1012	O
the	1013	1016	O
nalidixic	1017	1026	O
-	1026	1027	O
acid	1027	1031	O
resistant	1032	1041	O
E	1042	1043	O
.	1043	1044	O
coli	1045	1049	O
O157	1050	1054	O
.	1054	1055	O

Dexamethasone	1056	1069	O
-	1069	1070	O
injected	1070	1078	O
calves	1079	1085	O
shed	1086	1090	O
at	1091	1093	O
higher	1094	1100	O
levels	1101	1107	O
(	1108	1109	O
P	1109	1110	O
=	1111	1112	O
0	1113	1114	O
.	1114	1115	O
04	1115	1117	O
)	1117	1118	O
on	1119	1121	O
days	1122	1126	O
4	1127	1128	O
and	1129	1132	O
7	1133	1134	O
postinoculation	1135	1150	O
,	1150	1151	O
but	1152	1155	O
not	1156	1159	O
thereafter	1160	1170	O
.	1170	1171	O

None	1172	1176	O
of	1177	1179	O
the	1180	1183	O
samples	1184	1191	O
collected	1192	1201	O
at	1202	1204	O
necropsy	1205	1213	O
were	1214	1218	O
positive	1219	1227	O
for	1228	1231	O
E	1232	1233	O
.	1233	1234	O
coli	1235	1239	O
O157	1240	1244	O
.	1244	1245	O

Data	1246	1250	O
from	1251	1255	O
this	1256	1260	O
study	1261	1266	O
suggest	1267	1274	O
that	1275	1279	O
there	1280	1285	O
may	1286	1289	O
be	1290	1292	O
a	1293	1294	O
time	1295	1299	O
-	1299	1300	O
dependent	1300	1309	O
relationship	1310	1322	O
between	1323	1330	O
dexamethasone	1331	1344	O
immunosuppression	1345	1362	O
and	1363	1366	O
the	1367	1370	O
fecal	1371	1376	B-Organism_substance
concentration	1377	1390	O
of	1391	1393	O
E	1394	1395	O
.	1395	1396	O
coli	1397	1401	O
O157	1402	1406	O
but	1407	1410	O
that	1411	1415	O
transient	1416	1425	O
immunosuppression	1426	1443	O
does	1444	1448	O
not	1449	1452	O
appear	1453	1459	O
to	1460	1462	O
prolong	1463	1470	O
shedding	1471	1479	O
of	1480	1482	O
E	1483	1484	O
.	1484	1485	O
coli	1486	1490	O
O157	1491	1495	O
.	1495	1496	O

Analysis	0	8	O
of	9	11	O
processivity	12	24	O
of	25	27	O
mungbean	28	36	O
dideoxynucleotide	37	54	O
-	54	55	O
sensitive	55	64	O
DNA	65	68	O
polymerase	69	79	O
and	80	83	O
detection	84	93	O
of	94	96	O
the	97	100	O
activity	101	109	O
and	110	113	O
expression	114	124	O
of	125	127	O
the	128	131	O
enzyme	132	138	O
in	139	141	O
the	142	145	O
meristematic	146	158	B-Tissue
and	159	162	O
meiotic	163	170	B-Tissue
tissues	171	178	I-Tissue
and	179	182	O
following	183	192	O
DNA	193	196	O
damaging	197	205	O
agent	206	211	O
.	211	212	O

Analysis	213	221	O
of	222	224	O
the	225	228	O
processivity	229	241	O
of	242	244	O
mungbean	245	253	O
ddNTP	254	259	O
-	259	260	O
sensitive	260	269	O
DNA	270	273	O
polymerase	274	284	O
showed	285	291	O
the	292	295	O
incorporation	296	309	O
of	310	312	O
approximately	313	326	O
35	327	329	O
-	329	330	O
40	330	332	O
nucleotides	333	344	O
per	345	348	O
binding	349	356	O
event	357	362	O
in	363	365	O
the	366	369	O
replication	370	381	O
assays	382	388	O
involving	389	398	O
M13	399	402	O
ss	403	405	O
DNA	406	409	O
template	410	418	O
with	419	423	O
5	424	425	O
'	425	426	O
-	426	427	O
labeled	427	434	O
17	435	437	O
-	437	438	O
mer	438	441	O
primer	442	448	O
.	448	449	O

Optimal	450	457	O
processivity	458	470	O
was	471	474	O
obtained	475	483	O
with	484	488	O
100	489	492	O
-	492	493	O
150	493	496	O
mM	497	499	O
KCl	500	503	O
and	504	507	O
6	508	509	O
-	509	510	O
8	510	511	O
mM	512	514	O
Mg2	515	518	O
+	518	519	O
at	520	522	O
pH	523	525	O
7	526	527	O
.	527	528	O
5	528	529	O
.	529	530	O

The	531	534	O
enzyme	535	541	O
showed	542	548	O
preference	549	559	O
for	560	563	O
Mg2	564	567	O
+	567	568	O
over	569	573	O
Mn2	574	577	O
+	577	578	O
as	579	581	O
the	582	585	O
metal	586	591	O
activator	592	601	O
for	602	605	O
processivity	606	618	O
.	618	619	O

2	620	621	O
'	621	622	O
,	622	623	O
3	624	625	O
'	625	626	O
dideoxythymidine	627	643	O
5	644	645	O
'	645	646	O
triphosphate	647	659	O
(	660	661	O
ddTTP	661	666	O
)	666	667	O
and	668	671	O
rat	672	675	O
DNA	676	679	O
pol	680	683	O
beta	684	688	O
antibody	689	697	O
strongly	698	706	O
influenced	707	717	O
distributive	718	730	O
synthesis	731	740	O
.	740	741	O

Considerable	742	754	O
enhancement	755	766	O
in	767	769	O
processivity	770	782	O
was	783	786	O
noticed	787	794	O
at	795	797	O
1mM	798	801	O
ATP	802	805	O
and	806	809	O
2	810	811	O
-	811	812	O
4	812	813	O
mM	814	816	O
spermidine	817	827	O
while	828	833	O
higher	834	840	O
concentrations	841	855	O
of	856	858	O
spermidine	859	869	O
caused	870	876	O
distributive	877	889	O
synthesis	890	899	O
.	899	900	O

The	901	904	O
enzyme	905	911	O
was	912	915	O
found	916	921	O
to	922	924	O
be	925	927	O
active	928	934	O
in	935	937	O
both	938	942	O
meristematic	943	955	B-Tissue
and	956	959	O
meiotic	960	967	B-Tissue
tissues	968	975	I-Tissue
and	976	979	O
distinctly	980	990	O
induced	991	998	O
by	999	1001	O
EMS	1002	1005	O
treatment	1006	1015	O
.	1015	1016	O

DNA	1017	1020	O
-	1020	1021	O
binding	1021	1028	O
assays	1029	1035	O
revealed	1036	1044	O
distinct	1045	1053	O
binding	1054	1061	O
ability	1062	1069	O
of	1070	1072	O
the	1073	1076	O
enzyme	1077	1083	O
to	1084	1086	O
template	1087	1095	O
/	1095	1096	O
primer	1096	1102	O
and	1103	1106	O
damaged	1107	1114	O
DNA	1115	1118	O
substrate	1119	1128	O
.	1128	1129	O

Together	1130	1138	O
these	1139	1144	O
observations	1145	1157	O
illustrate	1158	1168	O
the	1169	1172	O
probable	1173	1181	O
involvement	1182	1193	O
of	1194	1196	O
the	1197	1200	O
enzyme	1201	1207	O
in	1208	1210	O
replication	1211	1222	O
and	1223	1226	O
repair	1227	1233	O
machinery	1234	1243	O
in	1244	1246	O
higher	1247	1253	O
plants	1254	1260	O
.	1260	1261	O

The	0	3	O
detection	4	13	O
of	14	16	O
macrosomia	17	27	O
at	28	30	O
a	31	32	O
teaching	33	41	O
hospital	42	50	O
.	50	51	O

We	52	54	O
sought	55	61	O
to	62	64	O
determine	65	74	O
the	75	78	O
detection	79	88	O
(	89	90	O
clinical	90	98	O
or	99	101	O
sonographic	102	113	O
)	113	114	O
rate	115	119	O
of	120	122	O
macrosomic	123	133	O
newborns	134	142	O
(	143	144	O
at	144	146	O
least	147	152	O
4000	153	157	O
g	158	159	O
)	159	160	O
and	161	164	O
the	165	168	O
peripartum	169	179	O
factors	180	187	O
among	188	193	O
those	194	199	O
who	200	203	O
were	204	208	O
or	209	211	O
were	212	216	O
not	217	220	O
identified	221	231	O
accurately	232	242	O
.	242	243	O

We	244	246	O
retrospectively	247	262	O
reviewed	263	271	O
all	272	275	O
deliveries	276	286	O
over	287	291	O
1	292	293	O
year	294	298	O
and	299	302	O
all	303	306	O
maternal	307	315	O
and	316	319	O
neonatal	320	328	O
charts	329	335	O
of	336	338	O
macrosomic	339	349	O
newborns	350	358	O
delivered	359	368	O
during	369	375	O
that	376	380	O
year	381	385	O
.	385	386	O

Odds	387	391	O
ratio	392	397	O
(	398	399	O
ORs	399	402	O
)	402	403	O
and	404	407	O
95	408	410	O
%	410	411	O
confidence	412	422	O
intervals	423	432	O
(	433	434	O
CIs	434	437	O
)	437	438	O
were	439	443	O
calculated	444	454	O
.	454	455	O

Over	456	460	O
a	461	462	O
12	463	465	O
-	465	466	O
month	466	471	O
period	472	478	O
,	478	479	O
the	480	483	O
rate	484	488	O
of	489	491	O
macrosomia	492	502	O
was	503	506	O
10	507	509	O
%	509	510	O
(	511	512	O
421	512	515	O
/	515	516	O
4194	516	520	O
)	520	521	O
and	522	525	O
of	526	528	O
those	529	534	O
,	534	535	O
only	536	540	O
11	541	543	O
%	543	544	O
(	545	546	O
95	546	548	O
%	548	549	O
CI	550	552	O
8	553	554	O
to	555	557	O
14	558	560	O
%	560	561	O
)	561	562	O
were	563	567	O
suspected	568	577	O
clinically	578	588	O
or	589	591	O
sonographically	592	607	O
.	607	608	O

None	609	613	O
of	614	616	O
the	617	620	O
newborns	621	629	O
weighing	630	638	O
4500	639	643	O
g	644	645	O
or	646	648	O
more	649	653	O
were	654	658	O
recognized	659	669	O
before	670	676	O
birth	677	682	O
(	683	684	O
0	684	685	O
/	685	686	O
57	686	688	O
;	688	689	O
95	690	692	O
%	692	693	O
CI	694	696	O
0	697	698	O
to	699	701	O
6	702	703	O
%	703	704	O
)	704	705	O
.	705	706	O

The	707	710	O
rate	711	715	O
of	716	718	O
cesarean	719	727	O
delivery	728	736	O
was	737	740	O
significantly	741	754	O
higher	755	761	O
among	762	767	O
newborns	768	776	O
correctly	777	786	O
identified	787	797	O
as	798	800	O
macrosomic	801	811	O
(	812	813	O
58	813	815	O
%	815	816	O
)	816	817	O
versus	818	824	O
those	825	830	O
missed	831	837	O
(	838	839	O
36	839	841	O
%	841	842	O
;	842	843	O
OR	844	846	O
2	847	848	O
.	848	849	O
76	849	851	O
,	851	852	O
95	853	855	O
%	855	856	O
CI	857	859	O
1	860	861	O
.	861	862	O
46	862	864	O
,	864	865	O
5	866	867	O
.	867	868	O
16	868	870	O
)	870	871	O
.	871	872	O

The	873	876	O
incidence	877	886	O
of	887	889	O
newborns	890	898	O
weighing	899	907	O
in	908	910	O
excess	911	917	O
of	918	920	O
4000	921	925	O
g	926	927	O
is	928	930	O
10	931	933	O
%	933	934	O
,	934	935	O
and	936	939	O
approximately	940	953	O
90	954	956	O
%	956	957	O
of	958	960	O
these	961	966	O
macrosomic	967	977	O
newborns	978	986	O
were	987	991	O
unsuspected	992	1003	O
before	1004	1010	O
birth	1011	1016	O
.	1016	1017	O

Heart	0	5	B-Organ
sound	6	11	O
and	12	15	O
electrocardiogram	16	33	O
recording	34	43	O
devices	44	51	O
for	52	55	O
telemedicine	56	68	O
environments	69	81	O
.	81	82	O

There	83	88	O
is	89	91	O
currently	92	101	O
a	102	103	O
worldwide	104	113	O
trend	114	119	O
to	120	122	O
bring	123	128	O
healthcare	129	139	O
services	140	148	O
as	149	151	O
close	152	157	O
as	158	160	O
possible	161	169	O
to	170	172	O
the	173	176	O
patient	177	184	O
,	184	185	O
either	186	192	O
through	193	200	O
home	201	205	O
healthcare	206	216	O
systems	217	224	O
,	224	225	O
or	226	228	O
telemedicine	229	241	O
.	241	242	O

There	243	248	O
is	249	251	O
thus	252	256	O
a	257	258	O
general	259	266	O
need	267	271	O
for	272	275	O
equipment	276	285	O
that	286	290	O
can	291	294	O
capture	295	302	O
patient	303	310	O
data	311	315	O
electronically	316	330	O
for	331	334	O
automated	335	344	O
review	345	351	O
or	352	354	O
analysis	355	363	O
by	364	366	O
a	367	368	O
medical	369	376	O
practitioner	377	389	O
.	389	390	O

This	391	395	O
paper	396	401	O
presents	402	410	O
prototype	411	420	O
systems	421	428	O
that	429	433	O
were	434	438	O
developed	439	448	O
with	449	453	O
the	454	457	O
ultimate	458	466	O
aim	467	470	O
for	471	474	O
use	475	478	O
in	479	481	O
telemedicine	482	494	O
settings	495	503	O
in	504	506	O
rural	507	512	O
Africa	513	519	O
.	519	520	O

These	521	526	O
devices	527	534	O
can	535	538	O
be	539	541	O
used	542	546	O
to	547	549	O
electronically	550	564	O
capture	565	572	O
data	573	577	O
on	578	580	O
patients	581	589	O
from	590	594	O
several	595	602	O
sensors	603	610	O
in	611	613	O
a	614	615	O
quick	616	621	O
an	622	624	O
easy	625	629	O
manner	630	636	O
.	636	637	O

In	638	640	O
our	641	644	O
presented	645	654	O
cases	655	660	O
we	661	663	O
focus	664	669	O
on	670	672	O
cardiovascular	673	687	B-Anatomical_system
information	688	699	O
.	699	700	O

One	701	704	O
of	705	707	O
the	708	711	O
main	712	716	O
advantages	717	727	O
of	728	730	O
the	731	734	O
proposed	735	743	O
systems	744	751	O
is	752	754	O
that	755	759	O
the	760	763	O
data	764	768	O
are	769	772	O
captured	773	781	O
simultaneously	782	796	O
from	797	801	O
multiple	802	810	O
sensors	811	818	O
.	818	819	O

The	820	823	O
data	824	828	O
can	829	832	O
be	833	835	O
stored	836	842	O
and	843	846	O
sent	847	851	O
electronically	852	866	O
for	867	870	O
review	871	877	O
and	878	881	O
analysis	882	890	O
,	890	891	O
and	892	895	O
knowledge	896	905	O
-	905	906	O
based	906	911	O
systems	912	919	O
or	920	922	O
neural	923	929	O
network	930	937	O
type	938	942	O
models	943	949	O
can	950	953	O
be	954	956	O
used	957	961	O
in	962	964	O
the	965	968	O
future	969	975	O
for	976	979	O
semi	980	984	O
-	984	985	O
autonomous	985	995	O
screening	996	1005	O
of	1006	1008	O
the	1009	1012	O
recordings	1013	1023	O
,	1023	1024	O
before	1025	1031	O
a	1032	1033	O
patient	1034	1041	O
is	1042	1044	O
referred	1045	1053	O
to	1054	1056	O
a	1057	1058	O
specialist	1059	1069	O
.	1069	1070	O

An	0	2	O
introduction	3	15	O
to	16	18	O
evidence	19	27	O
-	27	28	O
based	28	33	O
practice	34	42	O
for	43	46	O
hand	47	51	B-Organism_subdivision
surgeons	52	60	O
and	61	64	O
therapists	65	75	O
.	75	76	O

Evidence	77	85	O
-	85	86	O
based	86	91	O
practice	92	100	O
is	101	103	O
a	104	105	O
methodical	106	116	O
approach	117	125	O
to	126	128	O
clinical	129	137	O
practice	138	146	O
where	147	152	O
experience	153	163	O
,	163	164	O
best	165	169	O
research	170	178	O
evidence	179	187	O
,	187	188	O
and	189	192	O
patient	193	200	O
goals	201	206	O
and	207	210	O
values	211	217	O
are	218	221	O
integrated	222	232	O
to	233	235	O
make	236	240	O
optimal	241	248	O
decisions	249	258	O
when	259	263	O
making	264	270	O
a	271	272	O
diagnosis	273	282	O
,	282	283	O
selecting	284	293	O
a	294	295	O
diagnostic	296	306	O
test	307	311	O
,	311	312	O
picking	313	320	O
an	321	323	O
intervention	324	336	O
or	337	339	O
determining	340	351	O
prognosis	352	361	O
.	361	362	O

There	363	368	O
are	369	372	O
five	373	377	O
steps	378	383	O
in	384	386	O
this	387	391	O
process	392	399	O
.	399	400	O

Hand	401	405	B-Organism_subdivision
surgeons	406	414	O
and	415	418	O
therapists	419	429	O
can	430	433	O
use	434	437	O
the	438	441	O
evidence	442	450	O
-	450	451	O
based	451	456	O
process	457	464	O
to	465	467	O
attain	468	474	O
optimal	475	482	O
management	483	493	O
of	494	496	O
individual	497	507	O
patients	508	516	O
,	516	517	O
manage	518	524	O
their	525	530	O
overall	531	538	O
practice	539	547	O
,	547	548	O
guide	549	554	O
the	555	558	O
ongoing	559	566	O
professional	567	579	O
development	580	591	O
,	591	592	O
and	593	596	O
deal	597	601	O
with	602	606	O
funding	607	614	O
and	615	618	O
policy	619	625	O
makers	626	632	O
.	632	633	O

Prolonged	0	9	O
control	10	17	O
of	18	20	O
patterned	21	30	O
biofilm	31	38	B-Cell
formation	39	48	O
by	49	51	O
bio	52	55	O
-	55	56	O
inert	56	61	O
surface	62	69	O
chemistry	70	79	O
.	79	80	O

A	81	82	O
bio	83	86	O
-	86	87	O
inert	87	92	O
surface	93	100	O
chemistry	101	110	O
was	111	114	O
developed	115	124	O
that	125	129	O
can	130	133	O
confine	134	141	O
biofilm	142	149	B-Cell
formation	150	159	O
in	160	162	O
designed	163	171	O
patterns	172	180	O
for	181	184	O
at	185	187	O
least	188	193	O
26	194	196	O
days	197	201	O
.	201	202	O

Women	0	5	O
'	5	6	O
s	6	7	O
attitudes	8	17	O
,	17	18	O
preferences	19	30	O
,	30	31	O
and	32	35	O
perceived	36	45	O
barriers	46	54	O
to	55	57	O
treatment	58	67	O
for	68	71	O
perinatal	72	81	O
depression	82	92	O
.	92	93	O

BACKGROUND	94	104	O
:	104	105	O

Perinatal	106	115	O
depression	116	126	O
is	127	129	O
associated	130	140	O
with	141	145	O
potential	146	155	O
negative	156	164	O
consequences	165	177	O
for	178	181	O
the	182	185	O
mother	186	192	O
and	193	196	O
infant	197	203	O
,	203	204	O
and	205	208	O
therefore	209	218	O
efforts	219	226	O
to	227	229	O
improve	230	237	O
treatment	238	247	O
access	248	254	O
and	255	258	O
efficacy	259	267	O
are	268	271	O
warranted	272	281	O
.	281	282	O

The	283	286	O
purpose	287	294	O
of	295	297	O
this	298	302	O
study	303	308	O
was	309	312	O
to	313	315	O
examine	316	323	O
pregnant	324	332	O
women	333	338	O
'	338	339	O
s	339	340	O
preferences	341	352	O
and	353	356	O
attitudes	357	366	O
about	367	372	O
treatment	373	382	O
for	383	386	O
depression	387	397	O
,	397	398	O
and	399	402	O
perceived	403	412	O
potential	413	422	O
barriers	423	431	O
to	432	434	O
accessing	435	444	O
treatment	445	454	O
.	454	455	O

METHODS	456	463	O
:	463	464	O

Data	465	469	O
were	470	474	O
collected	475	484	O
by	485	487	O
means	488	493	O
of	494	496	O
a	497	498	O
questionnaire	499	512	O
from	513	517	O
a	518	519	O
convenience	520	531	O
sample	532	538	O
of	539	541	O
509	542	545	O
predominantly	546	559	O
well	560	564	O
-	564	565	O
educated	565	573	O
,	573	574	O
high	575	579	O
-	579	580	O
income	580	586	O
,	586	587	O
married	588	595	O
women	596	601	O
in	602	604	O
the	605	608	O
northeastern	609	621	O
United	622	628	O
States	629	635	O
during	636	642	O
the	643	646	O
last	647	651	O
trimester	652	661	O
of	662	664	O
pregnancy	665	674	O
.	674	675	O

Participants	676	688	O
were	689	693	O
queried	694	701	O
as	702	704	O
to	705	707	O
treatment	708	717	O
modalities	718	728	O
in	729	731	O
which	732	737	O
they	738	742	O
would	743	748	O
most	749	753	O
likely	754	760	O
participate	761	772	O
if	773	775	O
they	776	780	O
wanted	781	787	O
help	788	792	O
for	793	796	O
depression	797	807	O
,	807	808	O
their	809	814	O
attitudes	815	824	O
toward	825	831	O
psychotherapeutic	832	849	O
and	850	853	O
pharmacological	854	869	O
treatments	870	880	O
,	880	881	O
and	882	885	O
perceived	886	895	O
barriers	896	904	O
to	905	907	O
receiving	908	917	O
help	918	922	O
.	922	923	O

RESULTS	924	931	O
:	931	932	O

Most	933	937	O
women	938	943	O
(	944	945	O
92	945	947	O
%	947	948	O
)	948	949	O
indicated	950	959	O
that	960	964	O
would	965	970	O
likely	971	977	O
participate	978	989	O
in	990	992	O
individual	993	1003	O
therapy	1004	1011	O
if	1012	1014	O
help	1015	1019	O
was	1020	1023	O
needed	1024	1030	O
.	1030	1031	O

Only	1032	1036	O
35	1037	1039	O
percent	1040	1047	O
stated	1048	1054	O
that	1055	1059	O
they	1060	1064	O
would	1065	1070	O
likely	1071	1077	O
take	1078	1082	O
medication	1083	1093	O
if	1094	1096	O
recommended	1097	1108	O
,	1108	1109	O
and	1110	1113	O
14	1114	1116	O
percent	1117	1124	O
indicated	1125	1134	O
that	1135	1139	O
they	1140	1144	O
would	1145	1150	O
participate	1151	1162	O
in	1163	1165	O
group	1166	1171	O
therapy	1172	1179	O
.	1179	1180	O

The	1181	1184	O
greatest	1185	1193	O
perceived	1194	1203	O
potential	1204	1213	O
barriers	1214	1222	O
to	1223	1225	O
treatment	1226	1235	O
were	1236	1240	O
lack	1241	1245	O
of	1246	1248	O
time	1249	1253	O
(	1254	1255	O
65	1255	1257	O
%	1257	1258	O
)	1258	1259	O
,	1259	1260	O
stigma	1261	1267	O
(	1268	1269	O
43	1269	1271	O
%	1271	1272	O
)	1272	1273	O
,	1273	1274	O
and	1275	1278	O
childcare	1279	1288	O
issues	1289	1295	O
(	1296	1297	O
33	1297	1299	O
%	1299	1300	O
)	1300	1301	O
.	1301	1302	O

Most	1303	1307	O
women	1308	1313	O
indicated	1314	1323	O
a	1324	1325	O
preference	1326	1336	O
to	1337	1339	O
receive	1340	1347	O
mental	1348	1354	O
health	1355	1361	O
care	1362	1366	O
at	1367	1369	O
the	1370	1373	O
obstetrics	1374	1384	O
clinic	1385	1391	O
,	1391	1392	O
either	1393	1399	O
from	1400	1404	O
their	1405	1410	O
obstetrics	1411	1421	O
practitioner	1422	1434	O
or	1435	1437	O
from	1438	1442	O
a	1443	1444	O
mental	1445	1451	O
health	1452	1458	O
practitioner	1459	1471	O
located	1472	1479	O
at	1480	1482	O
the	1483	1486	O
clinic	1487	1493	O
.	1493	1494	O

Factors	1495	1502	O
associated	1503	1513	O
with	1514	1518	O
acceptability	1519	1532	O
of	1533	1535	O
various	1536	1543	O
depression	1544	1554	O
treatments	1555	1565	O
are	1566	1569	O
presented	1570	1579	O
.	1579	1580	O

CONCLUSIONS	1581	1592	O
:	1592	1593	O

Understanding	1594	1607	O
what	1608	1612	O
prevents	1613	1621	O
women	1622	1627	O
from	1628	1632	O
seeking	1633	1640	O
or	1641	1643	O
obtaining	1644	1653	O
help	1654	1658	O
for	1659	1662	O
depression	1663	1673	O
and	1674	1677	O
determining	1678	1689	O
what	1690	1694	O
they	1695	1699	O
prefer	1700	1706	O
in	1707	1709	O
the	1710	1713	O
way	1714	1717	O
of	1718	1720	O
treatment	1721	1730	O
may	1731	1734	O
lead	1735	1739	O
to	1740	1742	O
improved	1743	1751	O
depression	1752	1762	O
treatment	1763	1772	O
rates	1773	1778	O
and	1779	1782	O
hold	1783	1787	O
promise	1788	1795	O
for	1796	1799	O
improving	1800	1809	O
the	1810	1813	O
overall	1814	1821	O
health	1822	1828	O
of	1829	1831	O
childbearing	1832	1844	O
women	1845	1850	O
.	1850	1851	O

The	0	3	O
impact	4	10	O
of	11	13	O
tracheal	14	22	B-Multi-tissue_structure
intubation	23	33	O
on	34	36	O
host	37	41	O
defenses	42	50	O
and	51	54	O
risks	55	60	O
for	61	64	O
nosocomial	65	75	O
pneumonia	76	85	O
.	85	86	O

Nosocomial	87	97	O
pneumonia	98	107	O
remains	108	115	O
a	116	117	O
common	118	124	O
complication	125	137	O
in	138	140	O
patients	141	149	O
treated	150	157	O
with	158	162	O
endotracheal	163	175	O
intubation	176	186	O
and	187	190	O
mechanical	191	201	O
ventilation	202	213	O
and	214	217	O
continues	218	227	O
to	228	230	O
have	231	235	O
a	236	237	O
significant	238	249	O
impact	250	256	O
on	257	259	O
the	260	263	O
mortality	264	273	O
rate	274	278	O
of	279	281	O
these	282	287	O
patients	288	296	O
.	296	297	O

Epidemiologic	298	311	O
studies	312	319	O
have	320	324	O
shown	325	330	O
that	331	335	O
the	336	339	O
risk	340	344	O
of	345	347	O
pneumonia	348	357	O
increases	358	367	O
with	368	372	O
the	373	376	O
duration	377	385	O
of	386	388	O
intubation	389	399	O
but	400	403	O
that	404	408	O
the	409	412	O
period	413	419	O
of	420	422	O
highest	423	430	O
risk	431	435	O
is	436	438	O
the	439	442	O
first	443	448	O
2	449	450	O
weeks	451	456	O
of	457	459	O
therapy	460	467	O
.	467	468	O

Gram	469	473	O
-	473	474	O
negative	474	482	O
bacteria	483	491	O
account	492	499	O
for	500	503	O
most	504	508	O
nosocomial	509	519	O
pneumonias	520	530	O
in	531	533	O
intubated	534	543	O
patients	544	552	O
,	552	553	O
but	554	557	O
Staphylococcus	558	572	O
aureus	573	579	O
may	580	583	O
also	584	588	O
play	589	593	O
a	594	595	O
role	596	600	O
in	601	603	O
what	604	608	O
may	609	612	O
be	613	615	O
a	616	617	O
polymicrobial	618	631	O
infection	632	641	O
.	641	642	O

In	643	645	O
the	646	649	O
most	650	654	O
seriously	655	664	O
ill	665	668	O
individuals	669	680	O
,	680	681	O
and	682	685	O
in	686	688	O
those	689	694	O
treated	695	702	O
with	703	707	O
long	708	712	O
-	712	713	O
term	713	717	O
mechanical	718	728	O
ventilation	729	740	O
,	740	741	O
Pseudomonas	742	753	O
aeruginosa	754	764	O
is	765	767	O
a	768	769	O
common	770	776	O
pathogen	777	785	O
.	785	786	O

Endotracheal	787	799	O
intubation	800	810	O
and	811	814	O
mechanical	815	825	O
ventilation	826	837	O
predispose	838	848	O
to	849	851	O
pneumonia	852	861	O
for	862	865	O
a	866	867	O
variety	868	875	O
of	876	878	O
reasons	879	886	O
(	887	888	O
see	888	891	O
Fig	892	895	O
.	895	896	O
1	897	898	O
)	898	899	O
.	899	900	O

The	901	904	O
endotracheal	905	917	B-Multi-tissue_structure
tube	918	922	I-Multi-tissue_structure
can	923	926	O
have	927	931	O
direct	932	938	O
effects	939	946	O
on	947	949	O
the	950	953	O
airway	954	960	B-Multi-tissue_structure
that	961	965	O
result	966	972	O
in	973	975	O
a	976	977	O
reduction	978	987	O
in	988	990	O
local	991	996	O
host	997	1001	O
defenses	1002	1010	O
.	1010	1011	O

Thus	1012	1016	O
,	1016	1017	O
mucosal	1018	1025	B-Multi-tissue_structure
injury	1026	1032	O
can	1033	1036	O
reduce	1037	1043	O
mucociliary	1044	1055	B-Tissue
function	1056	1064	O
,	1064	1065	O
while	1066	1071	O
upper	1072	1077	O
airway	1078	1084	B-Multi-tissue_structure
defenses	1085	1093	O
are	1094	1097	O
bypassed	1098	1106	O
and	1107	1110	O
the	1111	1114	O
effectiveness	1115	1128	O
of	1129	1131	O
cough	1132	1137	O
is	1138	1140	O
reduced	1141	1148	O
.	1148	1149	O

Indirectly	1150	1160	O
,	1160	1161	O
intubation	1162	1172	O
can	1173	1176	O
result	1177	1183	O
in	1184	1186	O
an	1187	1189	O
enhanced	1190	1198	O
capacity	1199	1207	O
of	1208	1210	O
tracheobronchial	1211	1227	B-Cell
cells	1228	1233	I-Cell
to	1234	1236	O
bind	1237	1241	O
gram	1242	1246	O
-	1246	1247	O
negative	1247	1255	O
bacteria	1256	1264	O
,	1264	1265	O
an	1266	1268	O
effect	1269	1275	O
that	1276	1280	O
favors	1281	1287	O
airway	1288	1294	B-Multi-tissue_structure
colonization	1295	1307	O
and	1308	1311	O
pneumonia	1312	1321	O
.	1321	1322	O

The	1323	1326	O
injury	1327	1333	O
to	1334	1336	O
the	1337	1340	O
airway	1341	1347	B-Multi-tissue_structure
can	1348	1351	O
create	1352	1358	O
binding	1359	1366	O
sites	1367	1372	O
for	1373	1376	O
bacteria	1377	1385	O
in	1386	1388	O
the	1389	1392	O
basement	1393	1401	B-Multi-tissue_structure
membrane	1402	1410	I-Multi-tissue_structure
of	1411	1413	O
the	1414	1417	O
bronchial	1418	1427	B-Multi-tissue_structure
tree	1428	1432	I-Multi-tissue_structure
and	1433	1436	O
the	1437	1440	O
stimulation	1441	1452	O
of	1453	1455	O
the	1456	1459	O
secretion	1460	1469	O
of	1470	1472	O
mucus	1473	1478	B-Organism_substance
,	1478	1479	O
which	1480	1485	O
then	1486	1490	O
stagnates	1491	1500	O
and	1501	1504	O
can	1505	1508	O
create	1509	1515	O
potential	1516	1525	O
sites	1526	1531	O
for	1532	1535	O
bacterial	1536	1545	O
adherence	1546	1555	O
.	1555	1556	O

The	1557	1560	O
endotracheal	1561	1573	B-Multi-tissue_structure
tube	1574	1578	I-Multi-tissue_structure
also	1579	1583	O
enhances	1584	1592	O
bacterial	1593	1602	O
entry	1603	1608	O
to	1609	1611	O
the	1612	1615	O
lung	1616	1620	B-Organ
by	1621	1623	O
serving	1624	1631	O
as	1632	1634	O
a	1635	1636	O
reservoir	1637	1646	O
for	1647	1650	O
bacteria	1651	1659	O
to	1660	1662	O
remain	1663	1669	O
sequestered	1670	1681	O
,	1681	1682	O
safe	1683	1687	O
from	1688	1692	O
host	1693	1697	O
defenses	1698	1706	O
.	1706	1707	O

Respiratory	1708	1719	O
therapy	1720	1727	O
devices	1728	1735	O
can	1736	1739	O
allow	1740	1745	O
bacteria	1746	1754	O
to	1755	1757	O
proliferate	1758	1769	O
and	1770	1773	O
can	1774	1777	O
then	1778	1782	O
introduce	1783	1792	O
them	1793	1797	O
into	1798	1802	O
the	1803	1806	O
patient	1807	1814	O
if	1815	1817	O
not	1818	1821	O
handled	1822	1829	O
properly	1830	1838	O
.	1838	1839	O

Finally	1840	1847	O
,	1847	1848	O
patients	1849	1857	O
who	1858	1861	O
are	1862	1865	O
ill	1866	1869	O
enough	1870	1876	O
to	1877	1879	O
require	1880	1887	O
intubation	1888	1898	O
also	1899	1903	O
have	1904	1908	O
disease	1909	1916	O
-	1916	1917	O
associated	1917	1927	O
impairments	1928	1939	O
in	1940	1942	O
systemic	1943	1951	O
host	1952	1956	O
defense	1957	1964	O
,	1964	1965	O
which	1966	1971	O
add	1972	1975	O
to	1976	1978	O
the	1979	1982	O
impairments	1983	1994	O
caused	1995	2001	O
by	2002	2004	O
the	2005	2008	O
use	2009	2012	O
of	2013	2015	O
an	2016	2018	O
artificial	2019	2029	O
airway	2030	2036	B-Multi-tissue_structure
.	2036	2037	O

The	2038	2041	O
host	2042	2046	O
defense	2047	2054	O
impairments	2055	2066	O
that	2067	2071	O
occur	2072	2077	O
in	2078	2080	O
mechanically	2081	2093	O
ventilated	2094	2104	O
patients	2105	2113	O
can	2114	2117	O
lead	2118	2122	O
to	2123	2125	O
respiratory	2126	2137	B-Multi-tissue_structure
tract	2138	2143	I-Multi-tissue_structure
infection	2144	2153	O
in	2154	2156	O
the	2157	2160	O
form	2161	2165	O
of	2166	2168	O
either	2169	2175	O
febrile	2176	2183	O
tracheobronchitis	2184	2201	O
or	2202	2204	O
pneumonia	2205	2214	O
.	2214	2215	O

The	2216	2219	O
diagnosis	2220	2229	O
of	2230	2232	O
pneumonia	2233	2242	O
in	2243	2245	O
intubated	2246	2255	O
patients	2256	2264	O
is	2265	2267	O
difficult	2268	2277	O
and	2278	2281	O
controversial	2282	2295	O
.	2295	2296	O

It	2297	2299	O
can	2300	2303	O
be	2304	2306	O
made	2307	2311	O
by	2312	2314	O
either	2315	2321	O
clinical	2322	2330	O
criteria	2331	2339	O
or	2340	2342	O
microbiologic	2343	2356	O
criteria	2357	2365	O
,	2365	2366	O
the	2367	2370	O
latter	2371	2377	O
by	2378	2380	O
using	2381	2386	O
a	2387	2388	O
bronchoscopically	2389	2406	O
directed	2407	2415	O
protected	2416	2425	O
specimen	2426	2434	O
brush	2435	2440	O
.	2440	2441	O

Therapy	2442	2449	O
of	2450	2452	O
pneumonia	2453	2462	O
in	2463	2465	O
mechanically	2466	2478	O
ventilated	2479	2489	O
patients	2490	2498	O
is	2499	2501	O
not	2502	2505	O
always	2506	2512	O
successful	2513	2523	O
,	2523	2524	O
and	2525	2528	O
systemic	2529	2537	O
antibiotics	2538	2549	O
may	2550	2553	O
need	2554	2558	O
to	2559	2561	O
be	2562	2564	O
supplemented	2565	2577	O
by	2578	2580	O
topical	2581	2588	O
antimicrobials	2589	2603	O
.	2603	2604	O

No	2605	2607	O
clearly	2608	2615	O
effective	2616	2625	O
prophylactic	2626	2638	O
strategy	2639	2647	O
currently	2648	2657	O
exists	2658	2664	O
,	2664	2665	O
but	2666	2669	O
our	2670	2673	O
understanding	2674	2687	O
of	2688	2690	O
pneumonia	2691	2700	O
pathogenesis	2701	2713	O
has	2714	2717	O
led	2718	2721	O
to	2722	2724	O
some	2725	2729	O
promising	2730	2739	O
directions	2740	2750	O
.	2750	2751	O

As	2752	2754	O
more	2755	2759	O
data	2760	2764	O
are	2765	2768	O
collected	2769	2778	O
,	2778	2779	O
inhaled	2780	2787	O
antibiotics	2788	2799	O
,	2799	2800	O
selective	2801	2810	O
digestive	2811	2820	O
decontamination	2821	2836	O
,	2836	2837	O
and	2838	2841	O
enhancement	2842	2853	O
of	2854	2856	O
host	2857	2861	O
defenses	2862	2870	O
by	2871	2873	O
cytokines	2874	2883	O
and	2884	2887	O
pre	2888	2891	O
-	2891	2892	O
formed	2892	2898	O
antibodies	2899	2909	O
may	2910	2913	O
emerge	2914	2920	O
as	2921	2923	O
useful	2924	2930	O
approaches	2931	2941	O
.	2941	2942	O

Mapping	0	7	O
of	8	10	O
the	11	14	O
L	15	16	O
-	16	17	O
methylmalonyl	17	30	O
-	30	31	O
CoA	31	34	O
mutase	35	41	O
gene	42	46	O
to	47	49	O
mouse	50	55	O
chromosome	56	66	B-Cellular_component
17	67	69	I-Cellular_component
.	69	70	O

In	71	73	O
humans	74	80	O
,	80	81	O
methylmalonyl	82	95	O
acidemia	96	104	O
is	105	107	O
caused	108	114	O
by	115	117	O
a	118	119	O
deficiency	120	130	O
of	131	133	O
L	134	135	O
-	135	136	O
methylmalonyl	136	149	O
-	149	150	O
CoA	150	153	O
mutase	154	160	O
(	161	162	O
MUT	162	165	O
)	165	166	O
controlled	167	177	O
by	178	180	O
a	181	182	O
gene	183	187	O
that	188	192	O
has	193	196	O
been	197	201	O
mapped	202	208	O
to	209	211	O
chromosome	212	222	B-Cellular_component
6	223	224	I-Cellular_component
.	224	225	O

The	226	229	O
mouse	230	235	O
homolog	236	243	O
of	244	246	O
this	247	251	O
gene	252	256	O
has	257	260	O
now	261	264	O
been	265	269	O
mapped	270	276	O
to	277	279	O
mouse	280	285	O
chromosome	286	296	B-Cellular_component
17	297	299	I-Cellular_component
.	299	300	O

Recombinant	301	312	O
inbred	313	319	O
and	320	323	O
congenic	324	332	O
strains	333	340	O
place	341	346	O
the	347	350	O
mouse	351	356	O
Mut	357	360	O
locus	361	366	O
1	367	368	O
.	368	369	O
06	369	371	O
cM	372	374	O
distal	375	381	O
to	382	384	O
H	385	386	O
-	386	387	O
2	387	388	O
,	388	389	O
between	390	397	O
Pgk	398	401	O
-	401	402	O
2	402	403	O
and	404	407	O
Ce	408	410	O
-	410	411	O
2	411	412	O
.	412	413	O

The	414	417	O
relative	418	426	O
order	427	432	O
of	433	435	O
syntenic	436	444	O
probes	445	451	O
flanking	452	460	O
H	461	462	O
-	462	463	O
2	463	464	O
on	465	467	O
mouse	468	473	O
chromosome	474	484	B-Cellular_component
17	485	487	I-Cellular_component
and	488	491	O
HLA	492	495	O
on	496	498	O
human	499	504	O
chromosome	505	515	B-Cellular_component
6	516	517	I-Cellular_component
is	518	520	O
shown	521	526	O
to	527	529	O
be	530	532	O
different	533	542	O
.	542	543	O

Range	0	5	O
of	6	8	O
motion	9	15	O
limitation	16	26	O
after	27	32	O
rotator	33	40	B-Organ
cuff	41	45	I-Organ
repair	46	52	O
.	52	53	O

HYPOTHESIS	54	64	O
:	64	65	O

This	66	70	O
study	71	76	O
was	77	80	O
conducted	81	90	O
to	91	93	O
identify	94	102	O
preoperative	103	115	O
factors	116	123	O
correlating	124	135	O
with	136	140	O
limited	141	148	O
motion	149	155	O
after	156	161	O
rotator	162	169	B-Organ
cuff	170	174	I-Organ
repair	175	181	O
(	182	183	O
RCR	183	186	O
)	186	187	O
and	188	191	O
to	192	194	O
evaluate	195	203	O
the	204	207	O
affect	208	214	O
of	215	217	O
loss	218	222	O
of	223	225	O
motion	226	232	O
on	233	235	O
outcome	236	243	O
.	243	244	O

We	245	247	O
hypothesized	248	260	O
that	261	265	O
patients	266	274	O
with	275	279	O
preoperative	280	292	O
ROM	293	296	O
loss	297	301	O
,	301	302	O
diabetes	303	311	O
,	311	312	O
and	313	316	O
workman	317	324	O
'	324	325	O
s	325	326	O
compensation	327	339	O
claims	340	346	O
would	347	352	O
exhibit	353	360	O
postoperative	361	374	O
ROM	375	378	O
loss	379	383	O
at	384	386	O
3	387	388	O
months	389	395	O
.	395	396	O

MATERIAL	397	405	O
AND	406	409	O
METHODS	410	417	O
:	417	418	O

Preoperative	419	431	O
and	432	435	O
postoperative	436	449	O
evaluations	450	461	O
,	461	462	O
including	463	472	O
outcomes	473	481	O
assessment	482	492	O
and	493	496	O
physical	497	505	O
examination	506	517	O
parameters	518	528	O
,	528	529	O
were	530	534	O
reviewed	535	543	O
for	544	547	O
345	548	551	O
patients	552	560	O
who	561	564	O
underwent	565	574	O
RCR	575	578	O
.	578	579	O

Correlations	580	592	O
between	593	600	O
demographic	601	612	O
,	612	613	O
physical	614	622	O
examination	623	634	O
,	634	635	O
and	636	639	O
surgical	640	648	O
variables	649	658	O
and	659	662	O
postoperative	663	676	O
limitation	677	687	O
of	688	690	O
motion	691	697	O
and	698	701	O
need	702	706	O
for	707	710	O
capsular	711	719	O
release	720	727	O
were	728	732	O
determined	733	743	O
.	743	744	O

RESULTS	745	752	O
:	752	753	O

At	754	756	O
3	757	758	O
-	758	759	O
month	759	764	O
follow	765	771	O
-	771	772	O
up	772	774	O
,	774	775	O
mean	776	780	O
active	781	787	O
forward	788	795	O
elevation	796	805	O
(	806	807	O
AFE	807	810	O
)	810	811	O
,	811	812	O
active	813	819	O
external	820	828	O
rotation	829	837	O
(	838	839	O
AER	839	842	O
)	842	843	O
,	843	844	O
and	845	848	O
passive	849	856	O
internal	857	865	O
rotation	866	874	O
(	875	876	O
PIR	876	879	O
)	879	880	O
were	881	885	O
90	886	888	O
%	888	889	O
,	889	890	O
78	891	893	O
%	893	894	O
,	894	895	O
and	896	899	O
80	900	902	O
%	902	903	O
of	904	906	O
the	907	910	O
contralateral	911	924	O
side	925	929	O
.	929	930	O

Limitation	931	941	O
of	942	944	O
preoperative	945	957	O
motion	958	964	O
correlated	965	975	O
with	976	980	O
limitation	981	991	O
of	992	994	O
postoperative	995	1008	O
AFE	1009	1012	O
,	1012	1013	O
AER	1014	1017	O
,	1017	1018	O
and	1019	1022	O
PIR	1023	1026	O
(	1027	1028	O
P	1028	1029	O
<	1030	1031	O
.	1032	1033	O
001	1033	1036	O
)	1036	1037	O
.	1037	1038	O

Forty	1039	1044	O
-	1044	1045	O
seven	1045	1050	O
patients	1051	1059	O
considered	1060	1070	O
clinically	1071	1081	O
stiff	1082	1087	O
were	1088	1092	O
followed	1093	1101	O
at	1102	1104	O
1	1105	1106	O
year	1107	1111	O
postoperatively	1112	1127	O
.	1127	1128	O

Three	1129	1134	O
patients	1135	1143	O
required	1144	1152	O
arthroscopic	1153	1165	O
capsular	1166	1174	O
release	1175	1182	O
for	1183	1186	O
persistent	1187	1197	O
range	1198	1203	O
of	1204	1206	O
motion	1207	1213	O
loss	1214	1218	O
.	1218	1219	O

CONCLUSION	1220	1230	O
:	1230	1231	O

Early	1232	1237	O
postoperative	1238	1251	O
limitation	1252	1262	O
of	1263	1265	O
motion	1266	1272	O
after	1273	1278	O
RCR	1279	1282	O
is	1283	1285	O
associated	1286	1296	O
with	1297	1301	O
restricted	1302	1312	O
preoperative	1313	1325	O
motion	1326	1332	O
.	1332	1333	O

Other	1334	1339	O
factors	1340	1347	O
,	1347	1348	O
including	1349	1358	O
diabetes	1359	1367	O
mellitus	1368	1376	O
and	1377	1380	O
worker	1381	1387	O
'	1387	1388	O
s	1388	1389	O
compensation	1390	1402	O
claim	1403	1408	O
,	1408	1409	O
are	1410	1413	O
also	1414	1418	O
associated	1419	1429	O
with	1430	1434	O
range	1435	1440	O
of	1441	1443	O
motion	1444	1450	O
loss	1451	1455	O
.	1455	1456	O

Most	1457	1461	O
shoulders	1462	1471	B-Organism_subdivision
with	1472	1476	O
early	1477	1482	O
motion	1483	1489	O
loss	1490	1494	O
recover	1495	1502	O
motion	1503	1509	O
and	1510	1513	O
rarely	1514	1520	O
require	1521	1528	O
capsular	1529	1537	O
release	1538	1545	O
.	1545	1546	O

Neural	0	6	O
network	7	14	O
analysis	15	23	O
of	24	26	O
spectroscopic	27	40	O
data	41	45	O
of	46	48	O
lycopene	49	57	O
and	58	61	O
beta	62	66	O
-	66	67	O
carotene	67	75	O
content	76	83	O
in	84	86	O
food	87	91	O
samples	92	99	O
compared	100	108	O
to	109	111	O
HPLC	112	116	O
-	116	117	O
UV	117	119	O
-	119	120	O
vis	120	123	O
.	123	124	O

In	125	127	O
this	128	132	O
study	133	138	O
a	139	140	O
neural	141	147	O
network	148	155	O
(	156	157	O
NN	157	159	O
)	159	160	O
model	161	166	O
was	167	170	O
designed	171	179	O
to	180	182	O
predict	183	190	O
lycopene	191	199	O
and	200	203	O
beta	204	208	O
-	208	209	O
carotene	209	217	O
concentrations	218	232	O
in	233	235	O
food	236	240	O
samples	241	248	O
,	248	249	O
combined	250	258	O
with	259	263	O
a	264	265	O
simple	266	272	O
and	273	276	O
fast	277	281	O
technique	282	291	O
,	291	292	O
such	293	297	O
as	298	300	O
UV	301	303	O
-	303	304	O
vis	304	307	O
spectroscopy	308	320	O
.	320	321	O

The	322	325	O
measurement	326	337	O
of	338	340	O
the	341	344	O
absorbance	345	355	O
at	356	358	O
446	359	362	O
and	363	366	O
502	367	370	O
nm	371	373	O
of	374	376	O
different	377	386	O
beta	387	391	O
-	391	392	O
carotene	392	400	O
and	401	404	O
lycopene	405	413	O
standard	414	422	O
mixtures	423	431	O
was	432	435	O
used	436	440	O
to	441	443	O
optimize	444	452	O
a	453	454	O
neural	455	461	O
network	462	469	O
based	470	475	O
on	476	478	O
a	479	480	O
multilayer	481	491	O
perceptron	492	502	O
(	503	504	O
MLP	504	507	O
)	507	508	O
(	509	510	O
learning	510	518	O
and	519	522	O
verification	523	535	O
process	536	543	O
)	543	544	O
.	544	545	O

Then	546	550	O
,	550	551	O
for	552	555	O
validation	556	566	O
purposes	567	575	O
,	575	576	O
the	577	580	O
optimized	581	590	O
NN	591	593	O
has	594	597	O
been	598	602	O
applied	603	610	O
to	611	613	O
determine	614	623	O
the	624	627	O
concentration	628	641	O
of	642	644	O
both	645	649	O
compounds	650	659	O
in	660	662	O
food	663	667	O
samples	668	675	O
(	676	677	O
fresh	677	682	O
tomato	683	689	O
,	689	690	O
tomato	691	697	O
concentrate	698	709	B-Organism_substance
,	709	710	O
tomato	711	717	O
sauce	718	723	O
,	723	724	O
ketchup	725	732	O
,	732	733	O
tomato	734	740	O
juice	741	746	B-Organism_substance
,	746	747	O
watermelon	748	758	O
,	758	759	O
medlar	760	766	O
,	766	767	O
green	768	773	O
pepper	774	780	O
,	780	781	O
and	782	785	O
carrots	786	793	O
)	793	794	O
,	794	795	O
comparing	796	805	O
the	806	809	O
NN	810	812	O
results	813	820	O
with	821	825	O
the	826	829	O
known	830	835	O
values	836	842	O
of	843	845	O
these	846	851	O
compounds	852	861	O
obtained	862	870	O
by	871	873	O
analytical	874	884	O
techniques	885	895	O
(	896	897	O
UV	897	899	O
-	899	900	O
vis	900	903	O
and	904	907	O
HPLC	908	912	O
)	912	913	O
.	913	914	O

It	915	917	O
was	918	921	O
concluded	922	931	O
that	932	936	O
when	937	941	O
the	942	945	O
MLP	946	949	O
-	949	950	O
NN	950	952	O
is	953	955	O
used	956	960	O
within	961	967	O
the	968	971	O
range	972	977	O
studied	978	985	O
,	985	986	O
the	987	990	O
optimized	991	1000	O
NN	1001	1003	O
is	1004	1006	O
able	1007	1011	O
to	1012	1014	O
estimate	1015	1023	O
the	1024	1027	O
beta	1028	1032	O
-	1032	1033	O
carotene	1033	1041	O
and	1042	1045	O
lycopene	1046	1054	O
concentrations	1055	1069	O
in	1070	1072	O
food	1073	1077	O
samples	1078	1085	O
with	1086	1090	O
an	1091	1093	O
adequate	1094	1102	O
accuracy	1103	1111	O
,	1111	1112	O
solving	1113	1120	O
the	1121	1124	O
UV	1125	1127	O
-	1127	1128	O
vis	1128	1131	O
interference	1132	1144	O
of	1145	1147	O
beta	1148	1152	O
-	1152	1153	O
carotene	1153	1161	O
and	1162	1165	O
lycopene	1166	1174	O
.	1174	1175	O

Costs	0	5	O
of	6	8	O
hip	9	12	B-Organism_subdivision
fracture	13	21	O
.	21	22	O

Rehabilitation	23	37	O
of	38	40	O
180	41	44	O
patients	45	53	O
in	54	56	O
primary	57	64	O
health	65	71	O
care	72	76	O
.	76	77	O

Costs	78	83	O
related	84	91	O
to	92	94	O
functional	95	105	O
status	106	112	O
were	113	117	O
calculated	118	128	O
for	129	132	O
180	133	136	O
consecutive	137	148	O
hip	149	152	B-Organism_subdivision
fracture	153	161	O
patients	162	170	O
(	171	172	O
mean	172	176	O
age	177	180	O
78	181	183	O
years	184	189	O
)	189	190	O
who	191	194	O
were	195	199	O
admitted	200	208	O
from	209	213	O
their	214	219	O
own	220	223	O
home	224	228	O
and	229	232	O
rehabilitated	233	246	O
in	247	249	O
primary	250	257	O
health	258	264	O
care	265	269	O
.	269	270	O

Within	271	277	O
4	278	279	O
months	280	286	O
after	287	292	O
the	293	296	O
fracture	297	305	O
,	305	306	O
75	307	309	O
percent	310	317	O
of	318	320	O
the	321	324	O
patients	325	333	O
had	334	337	O
been	338	342	O
discharged	343	353	O
to	354	356	O
their	357	362	O
own	363	366	O
home	367	371	O
,	371	372	O
9	373	374	O
percent	375	382	O
were	383	387	O
dead	388	392	O
,	392	393	O
and	394	397	O
the	398	401	O
short	402	407	O
-	407	408	O
term	408	412	O
medical	413	420	O
treatment	421	430	O
costs	431	436	O
per	437	440	O
patient	441	448	O
were	449	453	O
SEK	454	457	O
43	458	460	O
,	460	461	O
000	461	464	O
,	464	465	O
whereas	466	473	O
the	474	477	O
total	478	483	O
costs	484	489	O
including	490	499	O
communal	500	508	O
help	509	513	O
and	514	517	O
costs	518	523	O
for	524	527	O
living	528	534	O
accommodations	535	549	O
after	550	555	O
discharge	556	565	O
were	566	570	O
twice	571	576	O
as	577	579	O
high	580	584	O
.	584	585	O

The	586	589	O
total	590	595	O
costs	596	601	O
per	602	605	O
patient	606	613	O
for	614	617	O
long	618	622	O
-	622	623	O
term	623	627	O
medical	628	635	O
treatment	636	645	O
(	646	647	O
from	647	651	O
4	652	653	O
months	654	660	O
up	661	663	O
to	664	666	O
3	667	668	O
years	669	674	O
after	675	680	O
fracture	681	689	O
)	689	690	O
were	691	695	O
7	696	697	O
percent	698	705	O
of	706	708	O
the	709	712	O
short	713	718	O
-	718	719	O
term	719	723	O
medical	724	731	O
treatment	732	741	O
costs	742	747	O
.	747	748	O

Patients	749	757	O
with	758	762	O
a	763	764	O
cervical	765	773	B-Organism_subdivision
fracture	774	782	O
discharged	783	793	O
to	794	796	O
their	797	802	O
own	803	806	O
home	807	811	O
and	812	815	O
with	816	820	O
good	821	825	O
functional	826	836	O
status	837	843	O
consumed	844	852	O
only	853	857	O
one	858	861	O
fifth	862	867	O
of	868	870	O
the	871	874	O
resources	875	884	O
that	885	889	O
patients	890	898	O
with	899	903	O
a	904	905	O
trochanteric	906	918	B-Multi-tissue_structure
fracture	919	927	O
discharged	928	938	O
to	939	941	O
institutional	942	955	O
care	956	960	O
and	961	964	O
who	965	968	O
had	969	972	O
reduced	973	980	O
functional	981	991	O
status	992	998	O
consumed	999	1007	O
.	1007	1008	O

A	1009	1010	O
substantial	1011	1022	O
part	1023	1027	O
of	1028	1030	O
the	1031	1034	O
costs	1035	1040	O
can	1041	1044	O
be	1045	1047	O
saved	1048	1053	O
by	1054	1056	O
improved	1057	1065	O
organization	1066	1078	O
of	1079	1081	O
rehabilitation	1082	1096	O
after	1097	1102	O
discharge	1103	1112	O
from	1113	1117	O
the	1118	1121	O
hospital	1122	1130	O
.	1130	1131	O

A	1132	1133	O
further	1134	1141	O
cost	1142	1146	O
reduction	1147	1156	O
would	1157	1162	O
require	1163	1170	O
a	1171	1172	O
combination	1173	1184	O
of	1185	1187	O
technologic	1188	1199	O
,	1199	1200	O
social	1201	1207	O
,	1207	1208	O
and	1209	1212	O
organizational	1213	1227	O
changes	1228	1235	O
aimed	1236	1241	O
at	1242	1244	O
early	1245	1250	O
discharge	1251	1260	O
and	1261	1264	O
continued	1265	1274	O
follow	1275	1281	O
-	1281	1282	O
up	1282	1284	O
in	1285	1287	O
primary	1288	1295	O
health	1296	1302	O
care	1303	1307	O
.	1307	1308	O

A	0	1	O
randomized	2	12	O
pilot	13	18	O
study	19	24	O
of	25	27	O
the	28	31	O
Engaging	32	40	O
Moms	41	45	O
Program	46	53	O
for	54	57	O
family	58	64	O
drug	65	69	O
court	70	75	O
.	75	76	O

In	77	79	O
response	80	88	O
to	89	91	O
the	92	95	O
need	96	100	O
for	101	104	O
effective	105	114	O
drug	115	119	O
court	120	125	O
interventions	126	139	O
,	139	140	O
the	141	144	O
effectiveness	145	158	O
of	159	161	O
the	162	165	O
Engaging	166	174	O
Moms	175	179	O
Program	180	187	O
(	188	189	O
EMP	189	192	O
)	192	193	O
versus	194	200	O
Intensive	201	210	O
Case	211	215	O
Management	216	226	O
Services	227	235	O
(	236	237	O
ICMS	237	241	O
)	241	242	O
on	243	245	O
multiple	246	254	O
outcomes	255	263	O
for	264	267	O
mothers	268	275	O
enrolled	276	284	O
in	285	287	O
family	288	294	O
drug	295	299	O
court	300	305	O
was	306	309	O
investigated	310	322	O
.	322	323	O

In	324	326	O
this	327	331	O
intent	332	338	O
-	338	339	O
to	339	341	O
-	341	342	O
treat	342	347	O
study	348	353	O
,	353	354	O
mothers	355	362	O
(	363	364	O
N	364	365	O
=	366	367	O
62	368	370	O
)	370	371	O
were	372	376	O
randomly	377	385	O
assigned	386	394	O
to	395	397	O
either	398	404	O
usual	405	410	O
drug	411	415	O
court	416	421	O
care	422	426	O
or	427	429	O
the	430	433	O
Engaging	434	442	O
Moms	443	447	O
drug	448	452	O
court	453	458	O
program	459	466	O
.	466	467	O

Mothers	468	475	O
were	476	480	O
assessed	481	489	O
at	490	492	O
intake	493	499	O
and	500	503	O
3	504	505	O
,	505	506	O
6	507	508	O
,	508	509	O
12	510	512	O
,	512	513	O
and	514	517	O
18	518	520	O
months	521	527	O
following	528	537	O
intake	538	544	O
.	544	545	O

Results	546	553	O
indicated	554	563	O
that	564	568	O
at	569	571	O
18	572	574	O
months	575	581	O
post	582	586	O
drug	587	591	O
court	592	597	O
enrollment	598	608	O
,	608	609	O
77	610	612	O
%	612	613	O
of	614	616	O
mothers	617	624	O
assigned	625	633	O
to	634	636	O
EMP	637	640	O
versus	641	647	O
55	648	650	O
%	650	651	O
of	652	654	O
mothers	655	662	O
assigned	663	671	O
to	672	674	O
ICMS	675	679	O
had	680	683	O
positive	684	692	O
child	693	698	O
welfare	699	706	O
dispositions	707	719	O
.	719	720	O

There	721	726	O
were	727	731	O
statistically	732	745	O
significant	746	757	O
time	758	762	O
effects	763	770	O
for	771	774	O
both	775	779	O
intervention	780	792	O
groups	793	799	O
on	800	802	O
multiple	803	811	O
outcomes	812	820	O
including	821	830	O
substance	831	840	O
use	841	844	O
,	844	845	O
mental	846	852	O
health	853	859	O
,	859	860	O
parenting	861	870	O
practices	871	880	O
,	880	881	O
and	882	885	O
family	886	892	O
functioning	893	904	O
.	904	905	O

EMP	906	909	O
showed	910	916	O
equal	917	922	O
or	923	925	O
better	926	932	O
improvement	933	944	O
than	945	949	O
ICMS	950	954	O
on	955	957	O
all	958	961	O
outcomes	962	970	O
.	970	971	O

The	972	975	O
results	976	983	O
suggest	984	991	O
that	992	996	O
EMP	997	1000	O
in	1001	1003	O
family	1004	1010	O
drug	1011	1015	O
court	1016	1021	O
is	1022	1024	O
a	1025	1026	O
viable	1027	1033	O
and	1034	1037	O
promising	1038	1047	O
intervention	1048	1060	O
approach	1061	1069	O
to	1070	1072	O
reduce	1073	1079	O
maternal	1080	1088	O
addiction	1089	1098	O
and	1099	1102	O
child	1103	1108	O
maltreatment	1109	1121	O
.	1121	1122	O

Absence	0	7	O
of	8	10	O
microbiota	11	21	O
(	22	23	O
germ	23	27	O
-	27	28	O
free	28	32	O
conditions	33	43	O
)	43	44	O
accelerates	45	56	O
the	57	60	O
atherosclerosis	61	76	O
in	77	79	O
ApoE	80	84	O
-	84	85	O
deficient	85	94	O
mice	95	99	O
fed	100	103	O
standard	104	112	O
low	113	116	O
cholesterol	117	128	O
diet	129	133	O
.	133	134	O

AIM	135	138	O
:	138	139	O

The	140	143	O
aim	144	147	O
of	148	150	O
our	151	154	O
work	155	159	O
was	160	163	O
to	164	166	O
determine	167	176	O
the	177	180	O
influence	181	190	O
of	191	193	O
intestinal	194	204	B-Multi-tissue_structure
bacteria	205	213	O
on	214	216	O
the	217	220	O
development	221	232	O
of	233	235	O
atherosclerotic	236	251	B-Pathological_formation
lesions	252	259	I-Pathological_formation
using	260	265	O
apolipoprotein	266	280	O
E	281	282	O
(	283	284	O
ApoE	284	288	O
)	288	289	O
-	289	290	O
deficient	290	299	O
knockout	300	308	O
mice	309	313	O
.	313	314	O

METHODS	315	322	O
:	322	323	O

The	324	327	O
experiments	328	339	O
were	340	344	O
performed	345	354	O
on	355	357	O
ApoE	358	362	O
-	362	363	O
/	363	364	O
-	364	365	O
-	365	366	O
deficient	366	375	O
mouse	376	381	O
strain	382	388	O
C57BL	389	394	O
/	394	395	O
6	395	396	O
,	396	397	O
bred	398	402	O
under	403	408	O
germ	409	413	O
-	413	414	O
free	414	418	O
(	419	420	O
GF	420	422	O
)	422	423	O
conditions	424	434	O
for	435	438	O
two	439	442	O
generations	443	454	O
or	455	457	O
under	458	463	O
conventional	464	476	O
conditions	477	487	O
with	488	492	O
defined	493	500	O
microflora	501	511	O
(	512	513	O
CV	513	515	O
)	515	516	O
.	516	517	O

The	518	521	O
mice	522	526	O
were	527	531	O
fed	532	535	O
a	536	537	O
standard	538	546	O
low	547	550	O
cholesterol	551	562	O
diet	563	567	O
or	568	570	O
cholesterol	571	582	O
-	582	583	O
rich	583	587	O
diet	588	592	O
for	593	596	O
3	597	598	O
-	598	599	O
4	599	600	O
months	601	607	O
.	607	608	O

We	609	611	O
studied	612	619	O
the	620	623	O
development	624	635	O
of	636	638	O
advanced	639	647	O
lesions	648	655	B-Pathological_formation
in	656	658	O
the	659	662	O
thoracic	663	671	B-Multi-tissue_structure
and	672	675	O
abdominal	676	685	B-Multi-tissue_structure
aorta	686	691	I-Multi-tissue_structure
by	692	694	O
histological	695	707	O
,	707	708	O
morphometric	709	721	O
and	722	725	O
immunohistological	726	744	O
methods	745	752	O
.	752	753	O

RESULTS	754	761	O
:	761	762	O

Conventionally	763	777	O
reared	778	784	O
ApoE	785	789	O
-	789	790	O
/	790	791	O
-	791	792	O
mice	793	797	O
(	798	799	O
containing	799	809	O
no	810	812	O
pathogenic	813	823	O
intestinal	824	834	B-Multi-tissue_structure
microbiota	835	845	O
)	845	846	O
and	847	850	O
fed	851	854	O
a	855	856	O
standard	857	865	O
low	866	869	O
cholesterol	870	881	O
diet	882	886	O
in	887	889	O
contrast	890	898	O
to	899	901	O
a	902	903	O
high	904	908	O
cholesterol	909	920	O
diet	921	925	O
did	926	929	O
not	930	933	O
develop	934	941	O
atherosclerotic	942	957	B-Pathological_formation
aortic	958	964	I-Pathological_formation
plaques	965	972	I-Pathological_formation
.	972	973	O

In	974	976	O
contrast	977	985	O
,	985	986	O
ApoE	987	991	O
-	991	992	O
/	992	993	O
-	993	994	O
mice	995	999	O
reared	1000	1006	O
under	1007	1012	O
germfree	1013	1021	O
conditions	1022	1032	O
for	1033	1036	O
2	1037	1038	O
generations	1039	1050	O
and	1051	1054	O
fed	1055	1058	O
a	1059	1060	O
low	1061	1064	O
cholesterol	1065	1076	O
diet	1077	1081	O
exhibited	1082	1091	O
atherosclerotic	1092	1107	B-Pathological_formation
plaques	1108	1115	I-Pathological_formation
in	1116	1118	O
the	1119	1122	O
aorta	1123	1128	B-Multi-tissue_structure
.	1128	1129	O

Characteristic	1130	1144	O
lipid	1145	1150	O
deposition	1151	1161	O
with	1162	1166	O
foam	1167	1171	O
cells	1172	1177	B-Cell
and	1178	1181	O
macrophages	1182	1193	B-Cell
was	1194	1197	O
found	1198	1203	O
in	1204	1206	O
their	1207	1212	O
arterial	1213	1221	B-Multi-tissue_structure
walls	1222	1227	I-Multi-tissue_structure
.	1227	1228	O

CONCLUSION	1229	1239	O
:	1239	1240	O

In	1241	1243	O
contrast	1244	1252	O
to	1253	1255	O
the	1256	1259	O
absence	1260	1267	O
of	1268	1270	O
atherosclerotic	1271	1286	B-Pathological_formation
plaques	1287	1294	I-Pathological_formation
in	1295	1297	O
conventionally	1298	1312	O
reared	1313	1319	O
ApoE	1320	1324	O
-	1324	1325	O
deficient	1325	1334	O
mice	1335	1339	O
,	1339	1340	O
germ	1341	1345	O
-	1345	1346	O
free	1346	1350	O
ApoE	1351	1355	O
-	1355	1356	O
/	1356	1357	O
-	1357	1358	O
mice	1359	1363	O
consuming	1364	1373	O
the	1374	1377	O
same	1378	1382	O
low	1383	1386	O
cholesterol	1387	1398	O
standard	1399	1407	O
diet	1408	1412	O
developed	1413	1422	O
atherosclerotic	1423	1438	B-Pathological_formation
plaques	1439	1446	I-Pathological_formation
in	1447	1449	O
the	1450	1453	O
aorta	1454	1459	B-Multi-tissue_structure
.	1459	1460	O

Differences	1461	1472	O
in	1473	1475	O
atherosclerotic	1476	1491	B-Pathological_formation
plaques	1492	1499	I-Pathological_formation
between	1500	1507	O
GF	1508	1510	O
and	1511	1514	O
CV	1515	1517	O
ApoE	1518	1522	O
-	1522	1523	O
/	1523	1524	O
-	1524	1525	O
mice	1526	1530	O
are	1531	1534	O
not	1535	1538	O
so	1539	1541	O
apparent	1542	1550	O
when	1551	1555	O
mice	1556	1560	O
are	1561	1564	O
fed	1565	1568	O
a	1569	1570	O
high	1571	1575	O
cholesterol	1576	1587	O
diet	1588	1592	O
.	1592	1593	O

Our	1594	1597	O
findings	1598	1606	O
thus	1607	1611	O
document	1612	1620	O
the	1621	1624	O
protective	1625	1635	O
effect	1636	1642	O
of	1643	1645	O
microbiota	1646	1656	O
(	1657	1658	O
commensal	1658	1667	O
bacteria	1668	1676	O
)	1676	1677	O
on	1678	1680	O
atherosclerosis	1681	1696	O
development	1697	1708	O
.	1708	1709	O

A	0	1	O
generative	2	12	O
model	13	18	O
for	19	22	O
image	23	28	O
segmentation	29	41	O
based	42	47	O
on	48	50	O
label	51	56	O
fusion	57	63	O
.	63	64	O

We	65	67	O
propose	68	75	O
a	76	77	O
nonparametric	78	91	O
,	91	92	O
probabilistic	93	106	O
model	107	112	O
for	113	116	O
the	117	120	O
automatic	121	130	O
segmentation	131	143	O
of	144	146	O
medical	147	154	O
images	155	161	O
,	161	162	O
given	163	168	O
a	169	170	O
training	171	179	O
set	180	183	O
of	184	186	O
images	187	193	O
and	194	197	O
corresponding	198	211	O
label	212	217	O
maps	218	222	O
.	222	223	O

The	224	227	O
resulting	228	237	O
inference	238	247	O
algorithms	248	258	O
rely	259	263	O
on	264	266	O
pairwise	267	275	O
registrations	276	289	O
between	290	297	O
the	298	301	O
test	302	306	O
image	307	312	O
and	313	316	O
individual	317	327	O
training	328	336	O
images	337	343	O
.	343	344	O

The	345	348	O
training	349	357	O
labels	358	364	O
are	365	368	O
then	369	373	O
transferred	374	385	O
to	386	388	O
the	389	392	O
test	393	397	O
image	398	403	O
and	404	407	O
fused	408	413	O
to	414	416	O
compute	417	424	O
the	425	428	O
final	429	434	O
segmentation	435	447	O
of	448	450	O
the	451	454	O
test	455	459	O
subject	460	467	O
.	467	468	O

Such	469	473	O
label	474	479	O
fusion	480	486	O
methods	487	494	O
have	495	499	O
been	500	504	O
shown	505	510	O
to	511	513	O
yield	514	519	O
accurate	520	528	O
segmentation	529	541	O
,	541	542	O
since	543	548	O
the	549	552	O
use	553	556	O
of	557	559	O
multiple	560	568	O
registrations	569	582	O
captures	583	591	O
greater	592	599	O
inter	600	605	O
-	605	606	O
subject	606	613	O
anatomical	614	624	O
variability	625	636	O
and	637	640	O
improves	641	649	O
robustness	650	660	O
against	661	668	O
occasional	669	679	O
registration	680	692	O
failures	693	701	O
.	701	702	O

To	703	705	O
the	706	709	O
best	710	714	O
of	715	717	O
our	718	721	O
knowledge	722	731	O
,	731	732	O
this	733	737	O
manuscript	738	748	O
presents	749	757	O
the	758	761	O
first	762	767	O
comprehensive	768	781	O
probabilistic	782	795	O
framework	796	805	O
that	806	810	O
rigorously	811	821	O
motivates	822	831	O
label	832	837	O
fusion	838	844	O
as	845	847	O
a	848	849	O
segmentation	850	862	O
approach	863	871	O
.	871	872	O

The	873	876	O
proposed	877	885	O
framework	886	895	O
allows	896	902	O
us	903	905	O
to	906	908	O
compare	909	916	O
different	917	926	O
label	927	932	O
fusion	933	939	O
algorithms	940	950	O
theoretically	951	964	O
and	965	968	O
practically	969	980	O
.	980	981	O

In	982	984	O
particular	985	995	O
,	995	996	O
recent	997	1003	O
label	1004	1009	O
fusion	1010	1016	O
or	1017	1019	O
multiatlas	1020	1030	O
segmentation	1031	1043	O
algorithms	1044	1054	O
are	1055	1058	O
interpreted	1059	1070	O
as	1071	1073	O
special	1074	1081	O
cases	1082	1087	O
of	1088	1090	O
our	1091	1094	O
framework	1095	1104	O
.	1104	1105	O

We	1106	1108	O
conduct	1109	1116	O
two	1117	1120	O
sets	1121	1125	O
of	1126	1128	O
experiments	1129	1140	O
to	1141	1143	O
validate	1144	1152	O
the	1153	1156	O
proposed	1157	1165	O
methods	1166	1173	O
.	1173	1174	O

In	1175	1177	O
the	1178	1181	O
first	1182	1187	O
set	1188	1191	O
of	1192	1194	O
experiments	1195	1206	O
,	1206	1207	O
we	1208	1210	O
use	1211	1214	O
39	1215	1217	O
brain	1218	1223	B-Organ
MRI	1224	1227	O
scans	1228	1233	O
-	1233	1234	O
with	1234	1238	O
manually	1239	1247	O
segmented	1248	1257	O
white	1258	1263	B-Multi-tissue_structure
matter	1264	1270	I-Multi-tissue_structure
,	1270	1271	O
cerebral	1272	1280	B-Multi-tissue_structure
cortex	1281	1287	I-Multi-tissue_structure
,	1287	1288	O
ventricles	1289	1299	B-Multi-tissue_structure
and	1300	1303	O
subcortical	1304	1315	B-Multi-tissue_structure
structures	1316	1326	I-Multi-tissue_structure
-	1326	1327	O
to	1327	1329	O
compare	1330	1337	O
different	1338	1347	O
label	1348	1353	O
fusion	1354	1360	O
algorithms	1361	1371	O
and	1372	1375	O
the	1376	1379	O
widely	1380	1386	O
-	1386	1387	O
used	1387	1391	O
FreeSurfer	1392	1402	O
whole	1403	1408	O
-	1408	1409	O
brain	1409	1414	B-Organ
segmentation	1415	1427	O
tool	1428	1432	O
.	1432	1433	O

Our	1434	1437	O
results	1438	1445	O
indicate	1446	1454	O
that	1455	1459	O
the	1460	1463	O
proposed	1464	1472	O
framework	1473	1482	O
yields	1483	1489	O
more	1490	1494	O
accurate	1495	1503	O
segmentation	1504	1516	O
than	1517	1521	O
FreeSurfer	1522	1532	O
and	1533	1536	O
previous	1537	1545	O
label	1546	1551	O
fusion	1552	1558	O
algorithms	1559	1569	O
.	1569	1570	O

In	1571	1573	O
a	1574	1575	O
second	1576	1582	O
experiment	1583	1593	O
,	1593	1594	O
we	1595	1597	O
use	1598	1601	O
brain	1602	1607	B-Organ
MRI	1608	1611	O
scans	1612	1617	O
of	1618	1620	O
282	1621	1624	O
subjects	1625	1633	O
to	1634	1636	O
demonstrate	1637	1648	O
that	1649	1653	O
the	1654	1657	O
proposed	1658	1666	O
segmentation	1667	1679	O
tool	1680	1684	O
is	1685	1687	O
sufficiently	1688	1700	O
sensitive	1701	1710	O
to	1711	1713	O
robustly	1714	1722	O
detect	1723	1729	O
hippocampal	1730	1741	B-Multi-tissue_structure
volume	1742	1748	O
changes	1749	1756	O
in	1757	1759	O
a	1760	1761	O
study	1762	1767	O
of	1768	1770	O
aging	1771	1776	O
and	1777	1780	O
Alzheimer	1781	1790	O
'	1790	1791	O
s	1791	1792	O
Disease	1793	1800	O
.	1800	1801	O

Listerine	0	9	O
:	9	10	O
past	11	15	O
,	15	16	O
present	17	24	O
and	25	28	O
future	29	35	O
-	35	36	O
-	36	37	O
a	37	38	O
test	39	43	O
of	44	46	O
thyme	47	52	O
.	52	53	O

Listerine	54	63	O
,	63	64	O
a	65	66	O
mouthrinse	67	77	O
composed	78	86	O
of	87	89	O
a	90	91	O
mixture	92	99	O
of	100	102	O
essential	103	112	O
oils	113	117	O
,	117	118	O
was	119	122	O
created	123	130	O
in	131	133	O
1879	134	138	O
and	139	142	O
was	143	146	O
originally	147	157	O
formulated	158	168	O
as	169	171	O
a	172	173	O
surgical	174	182	O
antiseptic	183	193	O
.	193	194	O

In	195	197	O
spite	198	203	O
of	204	206	O
its	207	210	O
known	211	216	O
antimicrobial	217	230	O
properties	231	241	O
it	242	244	O
was	245	248	O
thought	249	256	O
of	257	259	O
as	260	262	O
a	263	264	O
product	265	272	O
in	273	275	O
search	276	282	O
of	283	285	O
a	286	287	O
use	288	291	O
and	292	295	O
promoted	296	304	O
as	305	307	O
a	308	309	O
deterrent	310	319	O
for	320	323	O
halitosis	324	333	O
and	334	337	O
as	338	340	O
a	341	342	O
floor	343	348	O
cleaner	349	356	O
.	356	357	O

In	358	360	O
the	361	364	O
last	365	369	O
several	370	377	O
years	378	383	O
Listerine	384	393	O
has	394	397	O
emerged	398	405	O
as	406	408	O
a	409	410	O
bona	411	415	O
fide	416	420	O
therapeutic	421	432	O
agent	433	438	O
for	439	442	O
reduction	443	452	O
of	453	455	O
plaque	456	462	B-Organism_substance
induced	463	470	O
oral	471	475	B-Organism_subdivision
diseases	476	484	O
.	484	485	O

In	486	488	O
contrast	489	497	O
to	498	500	O
the	501	504	O
inconsistent	505	517	O
history	518	525	O
of	526	528	O
Listerine	529	538	O
,	538	539	O
systemic	540	548	O
antibiotics	549	560	O
discovered	561	571	O
in	572	574	O
the	575	578	O
1940	579	583	O
'	583	584	O
s	584	585	O
were	586	590	O
heralded	591	599	O
as	600	602	O
miracle	603	610	O
drugs	611	616	O
.	616	617	O

However	618	625	O
,	625	626	O
the	627	630	O
value	631	636	O
of	637	639	O
prophylactic	640	652	O
usage	653	658	O
of	659	661	O
antibiotics	662	673	O
has	674	677	O
come	678	682	O
under	683	688	O
scrutiny	689	697	O
as	698	700	O
a	701	702	O
result	703	709	O
of	710	712	O
increasing	713	723	O
resistance	724	734	O
and	735	738	O
adverse	739	746	O
reactions	747	756	O
.	756	757	O

Moreover	758	766	O
,	766	767	O
reports	768	775	O
by	776	778	O
both	779	783	O
American	784	792	O
and	793	796	O
British	797	804	O
professional	805	817	O
societies	818	827	O
have	828	832	O
led	833	836	O
to	837	839	O
a	840	841	O
re	842	844	O
-	844	845	O
evaluation	845	855	O
of	856	858	O
the	859	862	O
relative	863	871	O
risks	872	877	O
associated	878	888	O
with	889	893	O
plaque	894	900	B-Organism_substance
induced	901	908	O
bacteremia	909	919	O
when	920	924	O
twice	925	930	O
-	930	931	O
yearly	931	937	O
visits	938	944	O
to	945	947	O
dental	948	954	O
professionals	955	968	O
are	969	972	O
compared	973	981	O
to	982	984	O
daily	985	990	O
activities	991	1001	O
.	1001	1002	O

These	1003	1008	O
new	1009	1012	O
recommendations	1013	1028	O
and	1029	1032	O
revelations	1033	1044	O
open	1045	1049	O
the	1050	1053	O
door	1054	1058	O
for	1059	1062	O
local	1063	1068	O
antimicrobial	1069	1082	O
approaches	1083	1093	O
to	1094	1096	O
reduce	1097	1103	O
the	1104	1107	O
challenge	1108	1117	O
of	1118	1120	O
plaque	1121	1127	B-Organism_substance
-	1127	1128	O
induced	1128	1135	O
bacteremias	1136	1147	O
.	1147	1148	O

These	1149	1154	O
issues	1155	1161	O
will	1162	1166	O
be	1167	1169	O
discussed	1170	1179	O
in	1180	1182	O
the	1183	1186	O
context	1187	1194	O
of	1195	1197	O
Listerine	1198	1207	O
,	1207	1208	O
its	1209	1212	O
intricate	1213	1222	O
and	1223	1226	O
complicated	1227	1238	O
past	1239	1243	O
,	1243	1244	O
and	1245	1248	O
its	1249	1252	O
connection	1253	1263	O
to	1264	1266	O
current	1267	1274	O
uses	1275	1279	O
in	1280	1282	O
oral	1283	1287	B-Organism_subdivision
health	1288	1294	O
and	1295	1298	O
beyond	1299	1305	O
.	1305	1306	O

Acute	0	5	O
ablation	6	14	O
of	15	17	O
Langerhans	18	28	B-Cell
cells	29	34	I-Cell
enhances	35	43	O
skin	44	48	B-Organ
immune	49	55	O
responses	56	65	O
.	65	66	O

Understanding	67	80	O
the	81	84	O
function	85	93	O
of	94	96	O
Langerhans	97	107	B-Cell
cells	108	113	I-Cell
(	114	115	O
LCs	115	118	B-Cell
)	118	119	O
in	120	122	O
vivo	123	127	O
has	128	131	O
been	132	136	O
complicated	137	148	O
by	149	151	O
conflicting	152	163	O
results	164	171	O
from	172	176	O
LC	177	179	B-Cell
-	179	180	O
deficient	180	189	O
mice	190	194	O
.	194	195	O

Human	196	201	O
Langerin	202	210	O
-	210	211	O
DTA	211	214	O
mice	215	219	O
constitutively	220	234	O
lack	235	239	O
LCs	240	243	B-Cell
and	244	247	O
develop	248	255	O
exaggerated	256	267	O
contact	268	275	O
hypersensitivity	276	292	O
(	293	294	O
CHS	294	297	O
)	297	298	O
responses	299	308	O
.	308	309	O

Murine	310	316	O
Langerin	317	325	O
-	325	326	O
diphtheria	326	336	O
toxin	337	342	O
receptor	343	351	O
(	352	353	O
DTR	353	356	O
)	356	357	O
mice	358	362	O
allow	363	368	O
for	369	372	O
the	373	376	O
inducible	377	386	O
elimination	387	398	O
of	399	401	O
LCs	402	405	B-Cell
and	406	409	O
Langerin	410	418	B-Cell
(	418	419	I-Cell
+	419	420	I-Cell
)	420	421	I-Cell
dermal	422	428	I-Cell
dendritic	429	438	I-Cell
cells	439	444	I-Cell
(	445	446	O
dDCs	446	450	B-Cell
)	450	451	O
after	452	457	O
administration	458	472	O
of	473	475	O
diphtheria	476	486	O
toxin	487	492	O
,	492	493	O
which	494	499	O
results	500	507	O
in	508	510	O
reduced	511	518	O
CHS	519	522	O
.	522	523	O

When	524	528	O
Langerin	529	537	B-Cell
(	537	538	I-Cell
+	538	539	I-Cell
)	539	540	I-Cell
dDCs	541	545	I-Cell
have	546	550	O
partially	551	560	O
repopulated	561	572	O
the	573	576	O
skin	577	581	B-Organ
but	582	585	O
LCs	586	589	B-Cell
are	590	593	O
still	594	599	O
absent	600	606	O
,	606	607	O
CHS	608	611	O
returns	612	619	O
to	620	622	O
normal	623	629	O
.	629	630	O

Thus	631	635	O
,	635	636	O
LCs	637	640	B-Cell
appear	641	647	O
to	648	650	O
be	651	653	O
suppressive	654	665	O
in	666	668	O
human	669	674	O
Langerin	675	683	O
-	683	684	O
DTA	684	687	O
mice	688	692	O
and	693	696	O
redundant	697	706	O
in	707	709	O
murine	710	716	O
Langerin	717	725	O
-	725	726	O
DTR	726	729	O
mice	730	734	O
.	734	735	O

To	736	738	O
determine	739	748	O
whether	749	756	O
inducible	757	766	O
versus	767	773	O
constitutive	774	786	O
LC	787	789	B-Cell
ablation	790	798	O
explains	799	807	O
these	808	813	O
results	814	821	O
,	821	822	O
we	823	825	O
engineered	826	836	O
human	837	842	O
Langerin	843	851	O
-	851	852	O
DTR	852	855	O
mice	856	860	O
in	861	863	O
which	864	869	O
diphtheria	870	880	O
toxin	881	886	O
ablates	887	894	O
LCs	895	898	B-Cell
without	899	906	O
affecting	907	916	O
Langerin	917	925	B-Cell
(	925	926	I-Cell
+	926	927	I-Cell
)	927	928	I-Cell
dDCs	929	933	I-Cell
.	933	934	O

The	935	938	O
inducible	939	948	O
ablation	949	957	O
of	958	960	O
LCs	961	964	B-Cell
in	965	967	O
human	968	973	O
Langerin	974	982	O
-	982	983	O
DTR	983	986	O
mice	987	991	O
resulted	992	1000	O
in	1001	1003	O
increased	1004	1013	O
CHS	1014	1017	O
.	1017	1018	O

Thus	1019	1023	O
,	1023	1024	O
LC	1025	1027	B-Cell
-	1027	1028	O
mediated	1028	1036	O
suppression	1037	1048	O
does	1049	1053	O
not	1054	1057	O
require	1058	1065	O
their	1066	1071	O
absence	1072	1079	O
during	1080	1086	O
ontogeny	1087	1095	O
or	1096	1098	O
during	1099	1105	O
the	1106	1109	O
steady	1110	1116	O
-	1116	1117	O
state	1117	1122	O
and	1123	1126	O
is	1127	1129	O
consistent	1130	1140	O
with	1141	1145	O
a	1146	1147	O
model	1148	1153	O
in	1154	1156	O
which	1157	1162	O
LCs	1163	1166	B-Cell
actively	1167	1175	O
suppress	1176	1184	O
Ag	1185	1187	O
-	1187	1188	O
specific	1188	1196	O
CHS	1197	1200	O
responses	1201	1210	O
.	1210	1211	O

The	0	3	O
proenkephalin	4	17	O
-	17	18	O
A	18	19	O
-	19	20	O
derivative	20	30	O
Met	31	34	O
-	34	35	O
enkephalin	35	45	O
-	45	46	O
Arg	46	49	O
-	49	50	O
Gly	50	53	O
-	53	54	O
Leu	54	57	O
is	58	60	O
not	61	64	O
present	65	72	O
in	73	75	O
the	76	79	O
feline	80	86	O
species	87	94	O
.	94	95	O

No	96	98	O
opioid	99	105	O
octapeptide	106	117	O
Met	118	121	O
-	121	122	O
enkephalin	122	132	O
-	132	133	O
Arg	133	136	O
-	136	137	O
Gly	137	140	O
-	140	141	O
Leu	141	144	O
was	145	148	O
detected	149	157	O
either	158	164	O
in	165	167	O
the	168	171	O
brain	172	177	B-Organ
or	178	180	O
in	181	183	O
the	184	187	O
adrenal	188	195	B-Organ
gland	196	201	I-Organ
of	202	204	O
the	205	208	O
cat	209	212	O
using	213	218	O
a	219	220	O
specific	221	229	O
radioimmunoassay	230	246	O
.	246	247	O

Whereas	248	255	O
it	256	258	O
was	259	262	O
possible	263	271	O
to	272	274	O
determine	275	284	O
the	285	288	O
Met	289	292	O
-	292	293	O
enkephalin	293	303	O
and	304	307	O
Leu	308	311	O
-	311	312	O
enkephalin	312	322	O
contents	323	331	O
.	331	332	O

The	333	336	O
Met	337	340	O
-	340	341	O
enkephalin	341	351	O
versus	352	358	O
Leu	359	362	O
-	362	363	O
enkephalin	363	373	O
concentration	374	387	O
ratio	388	393	O
was	394	397	O
around	398	404	O
five	405	409	O
in	410	412	O
each	413	417	O
area	418	422	O
of	423	425	O
the	426	429	O
brain	430	435	B-Organ
assayed	436	443	O
.	443	444	O

The	445	448	O
presence	449	457	O
of	458	460	O
authentic	461	470	O
Met	471	474	O
-	474	475	O
enkephalin	475	485	O
and	486	489	O
Leu	490	493	O
-	493	494	O
enkephalin	494	504	O
was	505	508	O
confirmed	509	518	O
by	519	521	O
high	522	526	O
performance	527	538	O
liquid	539	545	O
chromatography	546	560	O
analysis	561	569	O
.	569	570	O

All	571	574	O
in	575	577	O
all	578	581	O
,	581	582	O
these	583	588	O
data	589	593	O
seem	594	598	O
to	599	601	O
indicate	602	610	O
that	611	615	O
the	616	619	O
cat	620	623	O
proenkephalin	624	637	O
is	638	640	O
partly	641	647	O
different	648	657	O
from	658	662	O
that	663	667	O
previously	668	678	O
analysed	679	687	O
in	688	690	O
mammalian	691	700	O
species	701	708	O
including	709	718	O
humans	719	725	O
,	725	726	O
rats	727	731	O
and	732	735	O
cows	736	740	O
.	740	741	O

Dissecting	0	10	O
genetic	11	18	O
networks	19	27	O
underlying	28	38	O
complex	39	46	O
phenotypes	47	57	O
:	57	58	O
the	59	62	O
theoretical	63	74	O
framework	75	84	O
.	84	85	O

Great	86	91	O
progress	92	100	O
has	101	104	O
been	105	109	O
made	110	114	O
in	115	117	O
genetic	118	125	O
dissection	126	136	O
of	137	139	O
quantitative	140	152	O
trait	153	158	O
variation	159	168	O
during	169	175	O
the	176	179	O
past	180	184	O
two	185	188	O
decades	189	196	O
,	196	197	O
but	198	201	O
many	202	206	O
studies	207	214	O
still	215	220	O
reveal	221	227	O
only	228	232	O
a	233	234	O
small	235	240	O
fraction	241	249	O
of	250	252	O
quantitative	253	265	O
trait	266	271	O
loci	272	276	O
(	277	278	O
QTLs	278	282	O
)	282	283	O
,	283	284	O
and	285	288	O
epistasis	289	298	O
remains	299	306	O
elusive	307	314	O
.	314	315	O

We	316	318	O
integrate	319	328	O
contemporary	329	341	O
knowledge	342	351	O
of	352	354	O
signal	355	361	O
transduction	362	374	O
pathways	375	383	O
with	384	388	O
principles	389	399	O
of	400	402	O
quantitative	403	415	O
and	416	419	O
population	420	430	O
genetics	431	439	O
to	440	442	O
characterize	443	455	O
genetic	456	463	O
networks	464	472	O
underlying	473	483	O
complex	484	491	O
traits	492	498	O
,	498	499	O
using	500	505	O
a	506	507	O
model	508	513	O
founded	514	521	O
upon	522	526	O
one	527	530	O
-	530	531	O
way	531	534	O
functional	535	545	O
dependency	546	556	O
of	557	559	O
downstream	560	570	O
genes	571	576	O
on	577	579	O
upstream	580	588	O
regulators	589	599	O
(	600	601	O
the	601	604	O
principle	605	614	O
of	615	617	O
hierarchy	618	627	O
)	627	628	O
and	629	632	O
mutual	633	639	O
functional	640	650	O
dependency	651	661	O
among	662	667	O
related	668	675	O
genes	676	681	O
(	682	683	O
functional	683	693	O
genetic	694	701	O
units	702	707	O
,	707	708	O
FGU	709	712	O
)	712	713	O
.	713	714	O

Both	715	719	O
simulated	720	729	O
and	730	733	O
real	734	738	O
data	739	743	O
suggest	744	751	O
that	752	756	O
complementary	757	770	O
epistasis	771	780	O
contributes	781	792	O
greatly	793	800	O
to	801	803	O
quantitative	804	816	O
trait	817	822	O
variation	823	832	O
,	832	833	O
and	834	837	O
obscures	838	846	O
the	847	850	O
phenotypic	851	861	O
effects	862	869	O
of	870	872	O
many	873	877	O
'	878	879	O
downstream	879	889	O
'	889	890	O
loci	891	895	O
in	896	898	O
pathways	899	907	O
.	907	908	O

The	909	912	O
mathematical	913	925	O
relationships	926	939	O
between	940	947	O
the	948	951	O
main	952	956	O
effects	957	964	O
and	965	968	O
epistatic	969	978	O
effects	979	986	O
of	987	989	O
genes	990	995	O
acting	996	1002	O
at	1003	1005	O
different	1006	1015	O
levels	1016	1022	O
of	1023	1025	O
signaling	1026	1035	O
pathways	1036	1044	O
were	1045	1049	O
established	1050	1061	O
using	1062	1067	O
the	1068	1071	O
quantitative	1072	1084	O
and	1085	1088	O
population	1089	1099	O
genetic	1100	1107	O
parameters	1108	1118	O
.	1118	1119	O

Both	1120	1124	O
loss	1125	1129	O
of	1130	1132	O
function	1133	1141	O
and	1142	1145	O
"	1146	1147	O
co	1147	1149	O
-	1149	1150	O
adapted	1150	1157	O
"	1157	1158	O
gene	1159	1163	O
complexes	1164	1173	O
formed	1174	1180	O
by	1181	1183	O
multiple	1184	1192	O
alleles	1193	1200	O
with	1201	1205	O
differentiated	1206	1220	O
functions	1221	1230	O
(	1231	1232	O
effects	1232	1239	O
)	1239	1240	O
are	1241	1244	O
predicted	1245	1254	O
to	1255	1257	O
be	1258	1260	O
frequent	1261	1269	O
types	1270	1275	O
of	1276	1278	O
allelic	1279	1286	O
diversity	1287	1296	O
at	1297	1299	O
loci	1300	1304	O
that	1305	1309	O
contribute	1310	1320	O
to	1321	1323	O
the	1324	1327	O
genetic	1328	1335	O
variation	1336	1345	O
of	1346	1348	O
complex	1349	1356	O
traits	1357	1363	O
in	1364	1366	O
populations	1367	1378	O
.	1378	1379	O

Downstream	1380	1390	O
FGUs	1391	1395	O
appear	1396	1402	O
to	1403	1405	O
be	1406	1408	O
more	1409	1413	O
vulnerable	1414	1424	O
to	1425	1427	O
loss	1428	1432	O
of	1433	1435	O
function	1436	1444	O
than	1445	1449	O
their	1450	1455	O
upstream	1456	1464	O
regulators	1465	1475	O
,	1475	1476	O
but	1477	1480	O
this	1481	1485	O
vulnerability	1486	1499	O
is	1500	1502	O
apparently	1503	1513	O
compensated	1514	1525	O
by	1526	1528	O
different	1529	1538	O
FGUs	1539	1543	O
of	1544	1546	O
similar	1547	1554	O
functions	1555	1564	O
.	1564	1565	O

Other	1566	1571	O
predictions	1572	1583	O
from	1584	1588	O
the	1589	1592	O
model	1593	1598	O
may	1599	1602	O
account	1603	1610	O
for	1611	1614	O
puzzling	1615	1623	O
results	1624	1631	O
regarding	1632	1641	O
responses	1642	1651	O
to	1652	1654	O
selection	1655	1664	O
,	1664	1665	O
genotype	1666	1674	O
by	1675	1677	O
environment	1678	1689	O
interaction	1690	1701	O
,	1701	1702	O
and	1703	1706	O
the	1707	1710	O
genetic	1711	1718	O
basis	1719	1724	O
of	1725	1727	O
heterosis	1728	1737	O
.	1737	1738	O

3	0	1	O
-	1	2	O
[	2	3	O
(	3	4	O
Methyl	4	10	O
-	10	11	O
carbamo	11	18	O
-	18	19	O
yl	19	21	O
)	21	22	O
amino	22	27	O
]	27	28	O
-	28	29	O
1H	29	31	O
-	31	32	O
isoindolium	32	43	O
chloride	44	52	O
.	52	53	O

The	54	57	O
title	58	63	O
compound	64	72	O
,	72	73	O
C	74	75	O
(	75	76	O
10	76	78	O
)	78	79	O
H	79	80	O
(	80	81	O
12	81	83	O
)	83	84	O
N	84	85	O
(	85	86	O
3	86	87	O
)	87	88	O
O	88	89	O
(	89	90	O
+	90	91	O
)	91	92	O
.	92	93	O
Cl	93	95	O
(	95	96	O
-	96	97	O
)	97	98	O
,	98	99	O
is	100	102	O
a	103	104	O
derivative	105	115	O
of	116	118	O
o	119	120	O
-	120	121	O
phthaldehyde	121	133	O
and	134	137	O
methyl	138	144	O
-	144	145	O
thio	145	149	O
-	149	150	O
urea	150	154	O
.	154	155	O

The	156	159	O
mol	160	163	O
-	163	164	O
ecules	164	170	O
form	171	175	O
dimers	176	182	O
through	183	190	O
intra	191	196	O
-	196	197	O
and	198	201	O
inter	202	207	O
-	207	208	O
molecular	208	217	O
N	218	219	O
-	219	220	O
H	220	221	O
.	221	222	O
.	222	223	O
.	223	224	O
O	224	225	O
hydrogen	226	234	O
bonds	235	240	O
.	240	241	O

The	242	245	O
dimers	246	252	O
are	253	256	O
further	257	264	O
linked	265	271	O
into	272	276	O
chains	277	283	O
through	284	291	O
one	292	295	O
C	296	297	O
-	297	298	O
H	298	299	O
.	299	300	O
.	300	301	O
.	301	302	O
Cl	302	304	O
and	305	308	O
two	309	312	O
N	313	314	O
-	314	315	O
H	315	316	O
.	316	317	O
.	317	318	O
.	318	319	O
Cl	319	321	O
hydrogen	322	330	O
bonds	331	336	O
.	336	337	O

Oscillatory	0	11	O
alpha	12	17	O
-	17	18	O
band	18	22	O
mechanisms	23	33	O
and	34	37	O
the	38	41	O
deployment	42	52	O
of	53	55	O
spatial	56	63	O
attention	64	73	O
to	74	76	O
anticipated	77	88	O
auditory	89	97	O
and	98	101	O
visual	102	108	O
target	109	115	O
locations	116	125	O
:	125	126	O
supramodal	127	137	O
or	138	140	O
sensory	141	148	O
-	148	149	O
specific	149	157	O
control	158	165	O
mechanisms	166	176	O
?	176	177	O

Oscillatory	178	189	O
alpha	190	195	O
-	195	196	O
band	196	200	O
activity	201	209	O
(	210	211	O
8	211	212	O
-	212	213	O
15	213	215	O
Hz	216	218	O
)	218	219	O
over	220	224	O
parieto	225	232	B-Multi-tissue_structure
-	232	233	I-Multi-tissue_structure
occipital	233	242	I-Multi-tissue_structure
cortex	243	249	I-Multi-tissue_structure
in	250	252	O
humans	253	259	O
plays	260	265	O
an	266	268	O
important	269	278	O
role	279	283	O
in	284	286	O
suppression	287	298	O
of	299	301	O
processing	302	312	O
for	313	316	O
inputs	317	323	O
at	324	326	O
to	327	329	O
-	329	330	O
be	330	332	O
-	332	333	O
ignored	333	340	O
regions	341	348	O
of	349	351	O
space	352	357	O
,	357	358	O
with	359	363	O
increased	364	373	O
alpha	374	379	O
-	379	380	O
band	380	384	O
power	385	390	O
observed	391	399	O
over	400	404	O
cortex	405	411	B-Multi-tissue_structure
contralateral	412	425	O
to	426	428	O
locations	429	438	O
expected	439	447	O
to	448	450	O
contain	451	458	O
distractors	459	470	O
.	470	471	O

It	472	474	O
is	475	477	O
unclear	478	485	O
whether	486	493	O
similar	494	501	O
processes	502	511	O
operate	512	519	O
during	520	526	O
deployment	527	537	O
of	538	540	O
spatial	541	548	O
attention	549	558	O
in	559	561	O
other	562	567	O
sensory	568	575	O
modalities	576	586	O
.	586	587	O

Evidence	588	596	O
from	597	601	O
lesion	602	608	B-Pathological_formation
patients	609	617	O
suggests	618	626	O
that	627	631	O
parietal	632	640	B-Organism_subdivision
regions	641	648	I-Organism_subdivision
house	649	654	O
supramodal	655	665	O
representations	666	681	O
of	682	684	O
space	685	690	O
.	690	691	O

The	692	695	O
parietal	696	704	B-Multi-tissue_structure
lobes	705	710	I-Multi-tissue_structure
are	711	714	O
prominent	715	724	O
generators	725	735	O
of	736	738	O
alpha	739	744	O
oscillations	745	757	O
,	757	758	O
raising	759	766	O
the	767	770	O
possibility	771	782	O
that	783	787	O
alpha	788	793	O
is	794	796	O
a	797	798	O
neural	799	805	B-Multi-tissue_structure
signature	806	815	O
of	816	818	O
supramodal	819	829	O
spatial	830	837	O
attention	838	847	O
.	847	848	O

Furthermore	849	860	O
,	860	861	O
when	862	866	O
spatial	867	874	O
attention	875	884	O
is	885	887	O
deployed	888	896	O
within	897	903	O
vision	904	910	O
,	910	911	O
processing	912	922	O
of	923	925	O
task	926	930	O
-	930	931	O
irrelevant	931	941	O
auditory	942	950	O
inputs	951	957	O
at	958	960	O
attended	961	969	O
locations	970	979	O
is	980	982	O
also	983	987	O
enhanced	988	996	O
,	996	997	O
pointing	998	1006	O
to	1007	1009	O
automatic	1010	1019	O
links	1020	1025	O
between	1026	1033	O
spatial	1034	1041	O
deployments	1042	1053	O
across	1054	1060	O
senses	1061	1067	O
.	1067	1068	O

Here	1069	1073	O
,	1073	1074	O
we	1075	1077	O
asked	1078	1083	O
whether	1084	1091	O
lateralized	1092	1103	O
alpha	1104	1109	O
-	1109	1110	O
band	1110	1114	O
activity	1115	1123	O
is	1124	1126	O
also	1127	1131	O
evident	1132	1139	O
in	1140	1142	O
a	1143	1144	O
purely	1145	1151	O
auditory	1152	1160	O
spatial	1161	1168	O
-	1168	1169	O
cueing	1169	1175	O
task	1176	1180	O
and	1181	1184	O
whether	1185	1192	O
it	1193	1195	O
had	1196	1199	O
the	1200	1203	O
same	1204	1208	O
underlying	1209	1219	O
generator	1220	1229	O
configuration	1230	1243	O
as	1244	1246	O
in	1247	1249	O
a	1250	1251	O
purely	1252	1258	O
visuospatial	1259	1271	O
task	1272	1276	O
.	1276	1277	O

If	1278	1280	O
common	1281	1287	O
to	1288	1290	O
both	1291	1295	O
sensory	1296	1303	O
systems	1304	1311	O
,	1311	1312	O
this	1313	1317	O
would	1318	1323	O
provide	1324	1331	O
strong	1332	1338	O
support	1339	1346	O
for	1347	1350	O
"	1351	1352	O
supramodal	1352	1362	O
"	1362	1363	O
attention	1364	1373	O
theory	1374	1380	O
.	1380	1381	O

Alternately	1382	1393	O
,	1393	1394	O
alpha	1395	1400	O
-	1400	1401	O
band	1401	1405	O
differences	1406	1417	O
between	1418	1425	O
auditory	1426	1434	O
and	1435	1438	O
visual	1439	1445	O
tasks	1446	1451	O
would	1452	1457	O
support	1458	1465	O
a	1466	1467	O
sensory	1468	1475	O
-	1475	1476	O
specific	1476	1484	O
account	1485	1492	O
.	1492	1493	O

Lateralized	1494	1505	O
shifts	1506	1512	O
in	1513	1515	O
alpha	1516	1521	O
-	1521	1522	O
band	1522	1526	O
activity	1527	1535	O
were	1536	1540	O
indeed	1541	1547	O
observed	1548	1556	O
during	1557	1563	O
a	1564	1565	O
purely	1566	1572	O
auditory	1573	1581	O
spatial	1582	1589	O
task	1590	1594	O
.	1594	1595	O

Crucially	1596	1605	O
,	1605	1606	O
there	1607	1612	O
were	1613	1617	O
clear	1618	1623	O
differences	1624	1635	O
in	1636	1638	O
scalp	1639	1644	B-Multi-tissue_structure
topographies	1645	1657	O
of	1658	1660	O
this	1661	1665	O
alpha	1666	1671	O
activity	1672	1680	O
depending	1681	1690	O
on	1691	1693	O
the	1694	1697	O
sensory	1698	1705	O
system	1706	1712	O
within	1713	1719	O
which	1720	1725	O
spatial	1726	1733	O
attention	1734	1743	O
was	1744	1747	O
deployed	1748	1756	O
.	1756	1757	O

Findings	1758	1766	O
suggest	1767	1774	O
that	1775	1779	O
parietally	1780	1790	O
generated	1791	1800	O
alpha	1801	1806	O
-	1806	1807	O
band	1807	1811	O
mechanisms	1812	1822	O
are	1823	1826	O
central	1827	1834	O
to	1835	1837	O
attentional	1838	1849	O
deployments	1850	1861	O
across	1862	1868	O
modalities	1869	1879	O
but	1880	1883	O
that	1884	1888	O
they	1889	1893	O
are	1894	1897	O
invoked	1898	1905	O
in	1906	1908	O
a	1909	1910	O
sensory	1911	1918	O
-	1918	1919	O
specific	1919	1927	O
manner	1928	1934	O
.	1934	1935	O

The	1936	1939	O
data	1940	1944	O
support	1945	1952	O
an	1953	1955	O
"	1956	1957	O
interactivity	1957	1970	O
account	1971	1978	O
,	1978	1979	O
"	1979	1980	O
whereby	1981	1988	O
a	1989	1990	O
supramodal	1991	2001	O
system	2002	2008	O
interacts	2009	2018	O
with	2019	2023	O
sensory	2024	2031	O
-	2031	2032	O
specific	2032	2040	O
control	2041	2048	O
systems	2049	2056	O
during	2057	2063	O
deployment	2064	2074	O
of	2075	2077	O
spatial	2078	2085	O
attention	2086	2095	O
.	2095	2096	O

Absence	0	7	O
of	8	10	O
antisperm	11	20	O
antibodies	21	31	O
in	32	34	O
anejaculatory	35	48	O
men	49	52	O
.	52	53	O

Antisperm	54	63	O
antibodies	64	74	O
were	75	79	O
assessed	80	88	O
in	89	91	O
the	92	95	O
serum	96	101	B-Organism_substance
samples	102	109	I-Organism_substance
of	110	112	O
73	113	115	O
men	116	119	O
unable	120	126	O
to	127	129	O
ejaculate	130	139	O
naturally	140	149	O
and	150	153	O
on	154	156	O
the	157	160	O
sperm	161	166	B-Cell
cells	167	172	I-Cell
of	173	175	O
13	176	178	O
of	179	181	O
these	182	187	O
men	188	191	O
.	191	192	O

None	193	197	O
of	198	200	O
the	201	204	O
serum	205	210	B-Organism_substance
samples	211	218	I-Organism_substance
were	219	223	O
found	224	229	O
to	230	232	O
be	233	235	O
positive	236	244	O
by	245	247	O
sperm	248	253	B-Cell
agglutination	254	267	O
or	268	270	O
sperm	271	276	B-Cell
immobilization	277	291	O
methods	292	299	O
and	300	303	O
antibodies	304	314	O
were	315	319	O
detected	320	328	O
by	329	331	O
an	332	334	O
immunobead	335	345	O
assay	346	351	O
on	352	354	O
the	355	358	O
sperm	359	364	B-Cell
cells	365	370	I-Cell
of	371	373	O
one	374	377	O
of	378	380	O
the	381	384	O
13	385	387	O
men	388	391	O
examined	392	400	O
.	400	401	O
